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Both depression and cardiovascular disease (CVD) affect millions of people worldwide and 
account for considerable mortality. In adults, comorbidity between these conditions is 
common, suggesting that shared pathophysiological mechanisms, such as systemic 
inflammation, may be involved. However, the direction of association between depression 
and CVD risk in young people remains unclear. Gaps also remain in our understanding of 
the role of different immune components in these relationships across the lifespan.  
The purpose of this thesis was two-fold. First, to investigate the association between CVD 
risk (as defined by systolic blood pressure, total cholesterol, low-density lipoprotein, high-
density lipoprotein, high body mass index, and smoking status) and depressive symptoms in 
young people. Second, to test the convergence of evidence for systemic inflammation as a 
shared mechanism for depression and CVD across the lifespan.  
I conducted a systematic review and meta-analysis of longitudinal studies of CVD risk 
factors and subsequent depressive symptoms in young people. Then I used data from two 
contrasting observational studies: the Avon Longitudinal Study of Parents and Children 
(ALSPAC) and the United Kingdom (UK) Biobank to study associations between 
inflammation, depression, and CVD risk in different age groups. ALSPAC is a prospective 
birth cohort of 15,000 individuals born in and around Bristol in 1990/91. In contrast, UK 
Biobank is a long-term UK-based study of over 500,000 individuals aged 40 years old and 
over. I used several measures of systemic inflammation including interleukin-6 (IL-6), C-
reactive protein (CRP), white blood cell count (WCC), and number of childhood infections.  
Through the systematic review and meta-analysis, I highlighted that obesity and cigarette 
smoking are strongly associated with depressive symptoms in individuals up to age 24 
years. Few longitudinal studies of young people have considered the effect of other CVD risk 
factors such as systolic blood pressure, total cholesterol, low-density lipoprotein, or high-
density lipoprotein. I followed PRISMA guidelines when reporting these findings. Using 
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ALSPAC data, I revealed that CVD risk is associated with subsequent depressive symptoms 
but not the other way around. Obesity and cigarette smoking in particular appear to drive this 
association. These findings suggest that targeting smoking and obesity in young people may 
be important for the prevention of both depression and CVD in adults.     
I also used ALSPAC to study the effects of inflammatory markers on health outcomes in 
young people. Specifically, I investigated the associations of childhood infections, IL-6, and 
CRP with depressive symptoms and psychotic experiences. I showed that a higher burden 
of common childhood infections is associated with depressive symptoms and psychotic 
experiences in early and mid-adolescence. In contrast, I discovered that childhood IL-6 and 
CRP were more strongly associated with subsequent CVD risk than depressive symptoms. 
CVD risk in adolescence appeared to mediate the relationship between childhood IL-6 or 
CRP and depressive symptoms in late-adolescence. These results suggest that markers of 
systemic inflammation in early life have differing associations with depression and CVD risk 
in young people.   
I used the UK Biobank to investigate the potential effects of inflammatory markers on 
comorbid and monomorbid depression and CVD outcomes in middle-aged and older adults. 
I used both CRP concentration and WCC as exposures. I discovered that CRP and WCC 
are both associated with depression and ischaemic heart disease (IHD), as well as comorbid 
depression and IHD. I also showed evidence of specific association between WCC and IHD. 
These findings suggest that systemic inflammation is likely to be a shared mechanism for 
depression and IHD, but the risk of each outcome may be underpinned by distinct 
inflammatory pathways.  
Taken together, these results indicate that the bidirectional association between CVD and 
depression is not present until adulthood. While the association between systemic 
inflammation and depression/CVD appears to be robust, pathophysiological mechanisms for 
depression and CVD may differ across the lifespan. 
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SECTION A: BACKGROUND 
 


























1.1 Rationale for Investigating Risk of Depression and 
Cardiovascular Disease (CVD)  
Both depression and cardiovascular disease (CVD) affect millions of people worldwide (1). 
The risk factors for these conditions are complex, but often begin in early life and take time 
to develop (2,3). Once illness is established, depression and CVD can have long-term 
negative effects on quality of life. Despite the significant burden these conditions place on 
the health of individuals, they each receive less funding than neurological diseases, 
infection, or cancers (4). This is particularly problematic in the context of depression, given 
that depression remains poorly understood relative to CVD and other physical illnesses. 
Furthermore, these conditions appear to be related and may be risk factors for each other. 
Work is required to understand the relationship between depression and CVD across the 
lifespan and to establish shared mechanisms that may serve as robust targets for future 
therapeutic interventions.  
This thesis is divided into seven chapters and six sections, including a section for 
references. Section A contains an introduction to the topic (Chapter 1, Page 18) and an 
overview of the analytic work presented in this thesis (Chapter 2, Page 60). In this first 
chapter, I present basic epidemiological information about depression and CVD. I then 
consider the links between depression and CVD across the lifespan, in childhood and 
adulthood. I approached the discussion of these possible relationships systematically, 
according to Paths A to F in Figure 1. I follow this with a summary of the evidence that lends 
support to systemic inflammation as a shared mechanism for depression and CVD before 
moving on to key social and demographic influences in these relationships. The breadth and 
depth of evidence regarding systemic inflammation, depression, and CVD is considerable. I 
then present the analytic work in Section B (Chapter 3, Page 74), Section C (Chapter 4, 
Page 110; Chapter 5, Page 144) and Section D (Chapter 6, Page 187). Section E (Chapter 
7, Page 212) concludes this thesis by discussing the findings and suggesting future 
















Figure 1. Temporal associations between depression and CVD risk (represented by 
Paths A to F) discussed in Chapter 1. 
 
1.1.1 Characteristics and prevalence of depression 
Major depressive disorder (MDD) is a common mental disorder affecting more than 163 
million people globally (1). Episodes of MDD are characterised by a syndrome of emotional, 
behavioural, cognitive and somatic phenomena: persistent low mood, anhedonia, low self-
esteem, sleep disturbance, appetite/weight changes, and concentration difficulties. 
According to the World Health Organisation (WHO), the lifetime prevalence of depression 
ranges from 20% to 25% in women and 7% to 12% in men (5). MDD is a leading cause of 
disability worldwide and can lead to suicide, the second leading cause of death in individuals 
age 15 to 29 years (1). From both the individual and societal perspective, depression is a 
problem of pressing importance.  
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MDD is particularly debilitating due to its recurrent nature, often beginning in adolescence 
(6). The majority of individuals who develop a lifetime episode of depression will go on to 
experience another (7). Each recurrence increases the risk of suicide as well as increasing 
the risk of another episode by approximately 16% (8). In contrast, longer duration of 
recovery is related to reduced risk of recurrence (7). Recurrence rates are similar among 
young people and adults (9). Earlier age of onset predicts longer depressive episodes and 
suicidal behaviour (10), while later age of onset is associated with shorter time to recurrence 
in adolescents (11). These findings are particularly concerning given that most depression 
cases are established in early life (12). Indeed, around 3% of children/adolescents in the US 
reported current depression in 2016 (13). The worldwide prevalence of depression in 
children/adolescents may be similar (14), however the global representativeness of 
prevalence data for depression in this age group is limited (15). Moreover, MDD has been 
validated in children as young as age 3 years, with anhedonia representing a particularly 
important clinical indicator (16). Therefore, MDD can be viewed as a long-term recurrent 
condition affecting individuals across the lifespan. 
MDD is a highly heterogeneous condition. Depressive episodes can differ by severity, 
recurrence, degree of remission, and presence of psychotic features (17,18). The Diagnostic 
and Statistical Manual of Mental Disorders (DSM)-5 includes a number of uncoded specifiers 
to categorise depressive episodes into more specific subtypes (Figure 2) (17). One such 
subtype is MDD with atypical features i.e. symptoms such as increased appetite/weight gain 
and hypersomnia (19). This atypical MDD subtype in particular may be associated with 
dysregulation of biological systems, such as increased inflammation and metabolic changes 
(20). Alteration to these biological processes may explain the comorbidity between 
depression and cardiometabolic conditions (20). Moreover, given the potential differences in 
underlying causes, distinct MDD subtypes may respond differently to antidepressants 
(20,21). As with most long-term physical and mental conditions, it is likely that MDD 














1.1.2 Characteristics and prevalence of CVD  
CVD is the leading cause of death worldwide, causing around a third of all global deaths (1). 
CVD refers to a group of conditions affecting the heart and blood vessels, including 
ischaemic heart disease (IHD) (also called coronary artery disease or coronary heart 
disease), cerebrovascular disease, and peripheral vascular disease. CVD affects more than 
485 million people worldwide (1). The lifetime risk of CVD is 31% in women and 46% in men 
after accounting for physical activity level (22). CVD mortality appears to be increasing in 
women age 35 to 54 years (23). IHD is responsible for around 26% of all global CVD cases, 
making it the most common form of CVD (1). Coordinated international effort is required to 
reduce the high universal prevalence of CVD.  
Atherosclerosis often precedes CVD, although the clinical manifestations of distinct forms of 
CVD are different (24). Atherosclerosis is an inflammatory disease characterised by the 
build-up of fatty plaques in the blood vessels (24). Immune cells play a role in plaque 
formation and activation of inflammation can accelerate progression of the plaques (25). 
Over time, the plaque leads to narrowing and occlusion of the arteries, increasing the risk of 
myocardial infarction (MI) and stroke (24). Both plaque rupture and erosion can lead to 
cardiovascular death as material from inside the plaque becomes exposed to platelets and 
coagulation factors (26). This process of atherothrombosis appears to depend partly on sex. 
Plaque rupture is more frequent in men (27), whereas plaque erosion is more common in 
cases of sudden death in women (28).  
Many risk factors for atherosclerosis and CVD are environmental factors that persist over an 
extended period of time. Smoking, high body mass index (BMI), physical inactivity, poor diet, 
high total cholesterol, high blood pressure, and high blood glucose are well-known risk 
factors for CVD (29). Adverse pregnancy outcomes such as gestational diabetes and pre-
eclampsia are also associated with increased risk of subsequent CVD (23). CVD risk factors 
are highly prevalent in the general population. The estimated lifetime risk of developing 
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hypertension exceeds 90% in high-income countries (30). Over two billion people are 
overweight or obese worldwide (31), and almost 476 million have diabetes (1). In addition, 
36% of men and 7% of women smoke cigarettes (32). Certain CVD risk factors may also 
cross-predict each other across the lifespan. For example, a recent meta-analysis of 21 
longitudinal studies found that childhood obesity was positively associated with adult blood 
pressure and inversely associated with adult high-density lipoprotein (HDL) cholesterol (33). 
Many of the environmental factors that contribute to the pathogenesis of atherosclerosis and 
CVD are modifiable but may require intervention in early life.  
1.1.3 Characteristics and prevalence of comorbid depression and CVD 
Depression and CVD often occur together (34). Depression increases the risk of subsequent 
CVD outcomes and vice versa (34). Pre-existing depression in CVD patients is also related 
to premature cardiovascular mortality (34). The bidirectional association between the two 
conditions suggests shared risk factors and/or pathophysiological mechanisms. Indeed, 
there is an extensive body of literature exploring the epidemiology of comorbid depression 
and CVD, particularly in middle-aged and older adults; the key points are set out below. 
The reported prevalence of comorbid depression and CVD differs between studies and 
contexts. A meta-analysis of 27 studies found that the prevalence of MDD among heart 
failure patients ranged from 9% to 60% (35). The pooled prevalence for MDD in heart failure 
patients was 22% (35), similar to the prevalence of 15% to 27% in IHD patients (36,37). An 
additional 31% to 45% of patients with IHD are estimated to have clinically significant 
depressive symptoms without meeting diagnostic criteria for MDD (37). Subthreshold 
depressive symptoms may explain why other studies have reported considerably higher 
prevalence. In a population-representative sample of over four million US adults with MDD, 
58% of individuals had comorbid CVD (38). Another US-based study found similar results; 
61% of 16,423 older adults in the community met criteria for comorbid MDD and CVD (39). 
Data also indicates that the prevalence of MDD in CVD patients is two to three times higher 
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than in the general population (40). A meta-analysis of epidemiological studies from China 
reported that 51% of hospitalised CVD patients have depression compared with 35% to 46% 
of CVD patients in the community (41). The different prevalence of comorbidity in hospital 
and community samples may reflect demographic differences and distinct study 
methodologies.   
Depression appears to play a role in the onset of CVD (34). The presence of depression has 
been reported to almost double the risk of developing new CVD (42,43). Indeed, MDD has 
been described as the second greatest risk factor for CVD following older age, and as a 
stronger risk factor for CVD than diabetes (43). Depression has also been identified as an 
independent risk factor for various forms of CVD including IHD, angina, heart failure, and MI 
(35,42,44). However, one population representative study found that depression in young 
Swedish men was not associated with IHD or MI during 37 years of follow-up (45). 
Depression may instead contribute indirectly to CVD onset through its association with CVD 
risk factors, such as type II diabetes, hypertension, obesity, low levels of physical activity, 
and smoking (46,47). For example, a cross-sectional study of 20,093 adults age ≥45 years 
reported that individuals with depressive symptoms were 41% more likely to be active 
smokers and 38% more likely to forgo regular intense physical activity (47). In this study, 
depressive symptoms were also associated with worse cardiovascular health even after 
controlling for antidepressant medication use (47). Polygenic sharing between MDD and 
cardiometabolic traits may partly explain the apparent link between depression and CVD 
onset (48). Overall, the evidence indicates that depressive symptoms precede (and may 
contribute to) the development of CVD.  
In addition to CVD onset, adult depression appears to predict morbidity and mortality in CVD 
patients (34). In hospital samples, depression is associated with worse cardiovascular 
outcomes. For example, IHD patients with depression have a two-fold increased risk of 
mortality in the two years following initial assessment, compared to those without depression 
(49). Depression is also associated with more than a two-fold increased risk of cardiac and 
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all-cause mortality among hospitalised MI patients (50,51). Increased cardiovascular 
mortality linked with depression exists for patients with heart failure and unstable angina as 
well as patients with comorbid heart failure and atrial fibrillation (52–54). There is also 
evidence of a dose-response relationship between depression severity and cardiovascular 
outcomes, such that more severe depression in CVD patients is associated with greater risk 
of subsequent morbidity and mortality (34). The link between depression and reduced 
adherence to medical and lifestyle interventions may play a role in the association between 
depression and adverse outcomes in CVD patients (34,55). 
Adult depression also contributes to a reduced quality of life following CVD recovery. 
Depression in patients with MI has been linked with poorer quality of life in both the short 
and long term (56). Depression in patients with heart failure appears to be more strongly 
related to quality of life than social and demographic factors, severity of heart failure, or other 
comorbidities (57). In addition, more severe depressive symptoms in patients with IHD 
predict poorer lifestyle behaviours five years later, including less physical activity, lower 
medication adherence, higher BMI, worse sleep quality, and smoking (58). These lifestyle 
behaviours in turn may increase risk of adverse cardiovascular outcomes. Thus, depression 
may have a negative impact on multiple aspects of the course of cardiovascular illness 
including quality of life and morbidity. 
CVD risk factors are associated with later depression in adulthood. A meta-analysis of 26 
longitudinal studies in adults age ≥50 years reported that CVD and CVD risk factor 
composite score are both independently associated with subsequent depression (59). There 
was also a weak association between smoking and depression, but no evidence of 
associations between Framingham Score Risk Score, hypertension or dyslipidaemia with 
subsequent depression in adulthood (59). Conversely, good cardiovascular health is 
protective against depression in adulthood. The American Heart Association (AHA) has 
previously defined ideal cardiovascular health in adults according to smoking status, diet, 
physical activity, BMI, blood pressure, blood glucose, and total cholesterol (Figure 3) (29). 
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Having a higher number of AHA ideal cardiovascular health metrics is associated with a 
reduction in the odds of depressive symptoms (60). Participants meeting five to seven of the 
ideal cardiovascular health metrics have 36% decreased odds of depressive symptoms 
compared with those meeting zero to two ideal components (60). Smoking, high BMI, low 
physical activity, and poor diet were all inversely associated with the odds of depressive 
symptoms (60). Other studies have also reported that smokers have substantially higher 
lifetime prevalence of MDD than non-smokers (61,62). The evidence therefore suggests that 




Figure 3. Ideal cardiovascular health metrics, according to the AHA.  
 
The link between CVD and depression during adulthood may be due to shared risk factors 
such as systemic inflammation, which I discuss in detail in Section 1.3 (Page 37). 
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Alternatively, atherosclerosis may mediate the relationship between inflammation and 
depression. This alternative hypothesis is plausible since atherosclerosis is strongly 
correlated with inflammation (24,25,63). Similarly, there is a growing body of evidence linking 




1.2 Relationship between Depression and CVD across the Lifespan  
David Barker’s developmental origins of health and disease (DOHAD) hypothesis links the 
environmental conditions of early life with the risk of disease later in childhood and adulthood 
(2). The hypothesis proposes that fetal adaptations to intrauterine and maternal conditions 
during development shape the structure and function of organs in the body. Epigenetic 
processes are involved in the differentiation of cells during the early stages of development. 
Certain types of adverse exposures may alter long-term outcomes via these epigenetic 
mechanisms (64). For example, fetal exposure to tobacco smoke, antidepressant 
medication, and folic acid deficits have been independently associated with fetal 
maladaptation (64). The point in development at which exposure occurs will ultimately 
determine the prevalence of maladaptive alterations in the cells and tissues of the body.  
Consistent with the DOHAD hypothesis is the fact that measures of depression and CVD are 
generally stable across the lifespan. For example, depression in childhood is strongly 
correlated with depression in adulthood (6). As previously mentioned in Section 1.1.3 (Page 
24), depression and CVD may also cross-predict each other in a bidirectional fashion, 
indicating potential shared mechanisms. Understanding these conditions from the lifespan 
perspective may support the development of early interventions and preventative measures. 
Figure 1 summarises the temporal associations between depression and CVD across the 
lifespan. Paths A to F (Figure 1) represent these associations and are discussed in 
consecutive order in the subsections below. 
1.2.1 Links between depression in childhood/adolescence and depression in 
adulthood  
Path A in Figure 1 represents the association between depression in childhood/adolescence 
and subsequent depression in adulthood. Depression occurring in childhood/adolescence 
can follow homotypic continuity (i.e. similar symptoms over time) or heterotypic continuity 
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(i.e. change in symptoms over time) into adult life. Here, I discuss depression continuity as 
well as key differences in depression among different age groups.  
Homotypic continuity of depressive symptoms is relatively common; an estimated 70% of 
children/adolescents with depression will experience recurrence of depressive symptoms 
within five years of a depressive episode (9,65). Evidence from clinical samples indicates 
that girls are more likely to have earlier recurrence of depression while boys are more likely 
to have persistent severe depression (66). MDD in childhood/adolescence increases the risk 
of MDD recurrence in adulthood as well as poor psychosocial functioning (66–68). Brain 
changes, particularly in the amygdala and hippocampus, may predispose to and perpetuate 
recurrent depression across the lifespan (69). Data from a UK-based community sample of 
adolescents reported that 35% experienced recurrent depressive episodes and a further 
22% experienced persistent depression into adulthood (66). However, clinical samples of 
children/adolescents have reported higher levels of MDD recurrence in adulthood ranging 
from 49% to 69% (67,70,71). Given that depression begins early in life and can recur/persist, 
prevention and effective treatment of depression in young people remains imperative.  
There is also evidence to suggest heterotypic continuity of depression across the lifespan. 
Psychiatric disorders in early life may influence the subsequent onset or recurrence of 
depressive symptoms. For example, anxiety in childhood has been shown to predict 
depression in adolescence (72). In addition, a US-based longitudinal study of 1,420 
participants found that the relationship between depression in adolescence and young adults 
was entirely explained by comorbid adolescent oppositional defiant disorder, anxiety, and 
substance use disorders (73). These findings suggest that the relationship between child 
and adult depression is complex. Despite the importance of depressive episodes in early life, 
children and adolescents remain relatively understudied in the context of depression 
compared with adults.  
There are a number of important differences between child/adolescent depression and adult 
depression. For example, biological and psychosocial risk factors may vary depending on 
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age of onset (74). Early childhood risk factors (e.g. neurodevelopmental problems and early 
life adversity) distinguish child/adolescent-onset from adult-onset depression, such that 
adult-onset depression is associated with low levels of childhood risk factors (74). In 
addition, children/adolescents and adults may present differently with depression. 
Children/adolescents with depression do not present with the high levels of circulating 
cortisol that are common in adults with depression, possibly due to the positive association 
between age and cortisol secretion (75). Children with depression also rarely present with 
sleep disturbances that are common in adolescents and adults with depression (75). 
Moreover, the nature of dysregulation of the serotonergic system and immune system in 
depression appears to vary across the lifespan (75). These distinctions may mean that 
depression in childhood/adolescence often goes unrecognised (and untreated) due to 
symptom variation from adult criteria (76).  
Finally, there are differences in the efficacy of antidepressant treatments across the lifespan. 
For example, young people with depression do not respond to tricyclic antidepressants; this 
medication works in adults (75), though tricyclic drugs have largely been superseded by 
selective serotonin reuptake inhibitor drugs. Fluoxetine (alone or in combination with 
cognitive behavioural therapy) currently appears to be the best option for the treatment of 
MDD in children/adolescents (77). However, response to fluoxetine among adolescents with 
depression is heterogeneous and dependent on clinical profile (78), suggesting the need for 
additional effective treatment options for depression in young people. This is particularly 
pertinent given that young people are at increased risk of suicidal behaviours and mania 
following antidepressant treatment compared with adults (65,79). Thus, continued focus on 
the differences between child/adolescent depression and adult depression is required. 




Path B in Figure 1 represents the association between CVD risk factors in 
childhood/adolescence and subsequent CVD in adulthood. CVD outcomes (excluding 
congenital heart diseases) tend to develop gradually across the lifespan, first appearing in 
later adulthood. The presence of CVD risk factors in early life is pertinent to current 
cardiovascular health and future CVD in adulthood. I have given a general description of key 
CVD risk factors in Section 1.1.2 (Page 23). 
CVD risk factors often appear in childhood/adolescence and continue into adulthood. 
Overweight/obesity, a key risk factor for CVD, is increasingly common in children and 
adolescents (80). Obesity tracks from childhood to adulthood (81). Childhood 
overweight/obesity is associated with higher subsequent CVD risk in adolescence (82). 
Parental history of CVD may influence the development of adverse CVD risk profiles in 
young people (82). For example, offspring of parents with early-onset IHD exhibited 
childhood overweight/obesity and developed higher CVD risk at a faster rate than their peers 
(83). Smoking is another highly prevalent CVD risk factor that begins early in life. In a study 
of 25,093 US participants, individuals who began smoking regularly before age 18 years 
were significantly less likely to intend or attempt to quit than those who began smoking at an 
older age (84). This has important implications for CVD risk in adulthood given that 50% of 
smokers in the US start before age 18 years (84). In addition, childhood blood pressure 
predicts adult levels, particularly for systolic blood pressure (SBP) (85). This finding suggests 
that hypertension is established early in life. Therefore, early identification and management 
of CVD risk factors may reduce CVD outcomes later in adulthood. 
1.2.3 Links between depression in childhood/adolescence and CVD in 
adulthood  
Path C in Figure 1 represents the association between depression in childhood/adolescence 
and CVD outcomes in adulthood. Depression in early life may predict both CVD risk factors 
and CVD outcomes in later life. The effect of child/adolescent depression on adult CVD 
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outcomes is relatively understudied compared with the effect of adult depression. I discuss 
the latter association in Section 1.1.3 (Page 24). In contrast, a number of studies have 
demonstrated links between child/adolescent depression and adult CVD risk factors, 
particularly obesity and smoking.  
Depression in childhood and adolescence has been linked with CVD risk factors in adults. 
For example, depression in early life is implicated in adult obesity. A meta-analysis of six 
studies found that depression in adolescents was associated with a 70% increased risk of 
obesity in adult life (86). Both depressive symptoms and MDD diagnosis during childhood 
are associated with obesity in adulthood (86). The overall duration of depressive symptoms 
from childhood to adulthood may be particularly relevant to the strength of the relationship 
between depression and subsequent BMI (87). Furthermore, depression in early life is 
related to subsequent smoking behaviour. In a longitudinal study of 2,393 US students, 
depression in adolescence contributes to smoking uptake in early-adulthood and smoking 
modulates depressive symptoms (88). This reciprocal relationship may reinforce smoking 
behaviour during adulthood (88), possibly as a form of self-medication for depressive 
symptoms. Early adolescence appears to be the most important period in establishing the 
reciprocal association between depression and smoking, although associations are 
maintained into adulthood (89). Observational studies of MDD in early life and subsequent 
CVD in adulthood are relatively rare. However, large genetic studies have reported links 
between MDD polygenic risk score and IHD in adults (90). Depression in early life can have 
a range of long-term consequences on physical health in adulthood. 
1.2.4 Links between CVD risk in childhood/adolescence and depression in 
adulthood 
Path D in Figure 1 represents the association between CVD risk in childhood/adolescence 
and depression in adulthood. Depression in early life may predict both CVD risk factors and 
CVD outcomes in later life. The effect of child/adolescent depression on adult CVD 
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outcomes is relatively understudied compared with the effect of adult depression. I discuss 
the latter association in Section 1.1.3 (Page 24). In the context of adult depression, obesity is 
a particularly well-studied early life CVD risk factors. As such, I focus on the effect of 
childhood obesity on subsequent adult depression below.   
Early life obesity is the most studied CVD risk factor with respect to lifetime risk of 
depression. A meta-analysis of six studies found that obesity in adolescents is associated 
with a 40% increased risk of depression in adult life (86). Another study has also reported 
links between overweight/obesity in childhood and increased odds of lifetime MDD (91). 
However, this study found no clear relationship between child/adolescent weight status and 
depressive symptoms in late adulthood (91), possibly due to small sample size. Similarly, a 
study using ALSPAC data showed that high BMI during childhood was not associated with 
depressive symptoms in late adolescence (92). It is possible that obesity is only relevant to 
risk of MDD in women. Compared to women of healthy weight, those who were overweight 
in adolescence are significantly more likely to experience depressive symptoms in late 
adulthood (93). The link between early life weight status and adult depressive symptoms is 
most pronounced for women who grew up in households of low socioeconomic position 
(SEP) (93). In contrast, no relationship was found between weight status and later 
depressive symptoms in men (93). The evidence suggests that the effect of child/adolescent 
obesity on adult depression is dependent on social and demographic factors. 
The effect of other CVD risk factors in early life on depression in adulthood are less well-
studied. Regarding cigarette smoking, there is some evidence that smoking in adolescence 
reduces depressive symptoms in early-adulthood, supporting the self-medication hypothesis 
(88). In contrast, a recent study using ALSPAC data revealed that there was no association 
between measures of insulin resistance during childhood and depressive symptoms in late 
adolescence (92). Studies of child/adolescent SBP or total cholesterol and subsequent risk 
of later depression are scarce but may offer insights into the links between depression and 




1.2.5 Links between depression and CVD in adulthood 
Path E in Figure 1 represents the association between depression and CVD in adulthood. I 
have provided an in-depth discussion of this relationship in Section 1.1.3 (Page 24). To 
summarise, pre-existing depression is related to CVD onset and cardiovascular mortality as 
well as reduced quality of life following recovery from CVD. Pre-existing CVD risk factors are 
also associated with depression onset. Finally, comorbid depression and CVD is relatively 
common, although the prevalence varies depending on the characteristics of the sample.  
1.2.6 Links between depression and CVD risk in childhood/adolescence  
Path F in Figure 1 represents the association between depression and CVD risk in 
childhood/adolescence. Depression and CVD risk factors in early life may cross-predict each 
other and contribute to future adverse health outcomes. Studies of CVD risk and depression 
in early life have generally focused on individual risk factors; the independent effects of 
obesity and smoking on depression (Chapter 3, Page 74) and vice versa are particularly 
well-studied. As such, I focus on the evidence for reciprocal links between depression and 
obesity/smoking below.   
Bidirectional relationships may exist between depression and obesity/smoking in early life. 
Evidence is somewhat mixed for reciprocal links between obesity and depression. A meta-
analysis of 22 studies representing 143,603 children reported that depression is present in 
10% of children with obesity (94). In this study, obesity was associated with higher risk of 
depression during childhood in females, but not in males (94). Adolescent-onset MDD has 
also been shown to predict obesity later in adolescence (95,96). However, other 
epidemiological studies in adolescents have observed no associations between obesity and 
subsequent depression (95,97,98) or between depression and later obesity (99–101). The 
relationship between smoking and depression in early life appears to be clearer. In a meta-
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analysis of 15 longitudinal studies of adolescents, there was evidence that depression 
predicts smoking, and that smoking predicts depression (102). In this meta-analysis, the 
studies that tested competing models directly showed that depression predicting smoking 
was the stronger effect (102). Exposure to second-hand smoking also appears to increase 
the risk of depression during adolescence (103). To confirm the potential links between 




1.3 Systemic Inflammation as a Shared Mechanism for Depression 
and CVD 
Inflammatory processes and their causes are diverse and complex (104). The physiological 
role of inflammation is to maintain homeostasis and promote tissue repair and recovery. 
Inflammation is first initiated on a cellular level and can expand to involve different 
inflammatory pathways and organs, resulting in systemic acute inflammation (105). Certain 
stimuli and unresolved inflammatory responses can promote a state of low-grade, sterile, 
systemic chronic inflammation, which is associated with a number of adverse health 
outcomes (106). From this point onwards, I will use the term systemic inflammation to refer 
to low-grade, sterile systemic chronic inflammation only.  
1.3.1 Acute inflammatory processes usually lead to resolution of inflammation  
Acute inflammation is an adaptive local response to noxious stimuli, including infection or 
tissue injury (107). Acute inflammation is characterised by the cardinal signs of inflammation 
i.e. redness, swelling, heat, and pain (104). A typical innate immune response consists of 
four components: inducers, sensors, mediators, and target tissues. Inflammatory inducers 
are classified as exogenous inducers (pathogen-associated molecular patterns, virulence 
factors, non-microbial inducers) and endogenous inducers (danger-associated molecular 
patterns (DAMPs)) (104). Inflammatory sensors, such as different pattern recognition 
receptors on macrophages and dendritic cells, recognise the inflammatory inducers 
(104,108). The sensors stimulate inflammatory mediators including vasoactive amines and 
peptides, fragments of complement components, lipid mediators, proteolytic enzymes, 
chemokines, and cytokines (e.g. interleukin (IL)-1, IL-6, tumour necrosis factor (TNF)-alpha) 
(104). Inflammatory mediators then act on target tissues, including local blood vessels, to 
induce vasodilation, extravasation of immune cells, and leakage of plasma into the infected 
tissue (104). IL-1, IL-6, and TNF-alpha can also have systemic effects when secreted in 
sufficient amounts. They induce hepatocytes to produce acute phase proteins, including C-
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reactive protein (CRP), and coagulation factors (109). The immune cells that are initially 
recruited to the tissue, such as neutrophils, release enzymes that fight off infectious 
organisms and clear dead cells. This process is aided by plasma components such as 
antibodies and complement (104). Acute inflammatory events can also result in local 
transient damage such as tissue oedema, accumulation of reactive oxygen species, and 
intravascular thrombosis (107,108). The acute inflammatory response is usually terminated 
once the triggering insult is eliminated, the infection is cleared, and the damaged tissue is 
repaired (104). Termination of the inflammatory response and transition to the homeostatic 
state is an active and highly regulated process known as the resolution of inflammation 
(104). Resolution appears to act as a bridge between innate and adaptive immunity 
pathways (110). 
1.3.2 Systemic inflammation can lead to damage and negative health 
consequences 
Although acute inflammation is critical to survival following injury or infection, systemic 
inflammation can cause damage. A range of factors can promote systemic inflammation 
including chronic infections, physical inactivity, obesity, intestinal dysbiosis, diet, social 
isolation, psychological stress, disturbed sleep and disrupted circadian rhythm, and 
exposure to xenobiotics (106). Systemic inflammation is characterised by low-grade chronic 
inflammation occurring throughout the body (104), reflected by increased concentrations of 
circulating inflammatory markers in the peripheral blood such as cytokines and acute phase 
proteins (111). The chronic inflammatory processes underlying systemic inflammation 
generally develop when resolution of inflammation cannot be achieved (107,108). Resolution 
of inflammation can be impeded if an initial acute inflammatory response is not sufficient to 
eliminate noxious stimuli and/or if noxious stimuli are present for a sustained period of time; 
the result is persistent low levels of cell stress or dysfunction and subsequent low-grade 
chronic inflammatory responses (104,107,108). It is possible that systemic inflammation 
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reflects incomplete resolution of the initial acute response that does not fully engage an 
appropriate adaptive immune response that would otherwise lead to full resolution (110). 
The low-grade and chronic nature of systemic inflammation ultimately leads to collateral 
damage to tissues and organs over time (112,113).    
Systemic inflammation often increases with age (114). Inflammageing, the term used to 
describe this age-related inflammatory state, may be partly due to cellular senescence (115). 
Cellular senescence is characterised by an arrest of cell proliferation and the development of 
a senescence-associated secretory phenotype (115). This phenotype involves increased 
secretion of pro-inflammatory cytokines, chemokines, and other pro-inflammatory molecules 
from cells (115). Senescent cells expressing this phenotype can promote various chronic 
health conditions and diseases (106). Inflammageing can lead to chronic low-grade 
activation of various immune signalling pathways, resulting in a weakened acute 
inflammatory response to various noxious stimuli in older adults (106); this explains why 
older adults with systemic inflammation are also more susceptible to viral infections and less 
responsive to vaccines (106). The link between age and systemic inflammation may partly 
explain why many non-communicable diseases are age-related. 
Other than ageing, stress appears to be important in the development of systemic 
inflammation (106). Exposure to psychological stress early in life can result in heightened 
neural responses to perceived threat, which can increase inflammatory activity (116), and 
lead to systemic inflammation throughout the lifespan (117,118). Noradrenaline and other 
catecholamines are released in response to stress by the activated sympathetic nervous 
system and stimulate the release of myeloid cells that activate inflammatory signalling 
pathways following an encounter with stress-induced DAMPs (119). Evidence demonstrates 
that psychological stress can lead to an increase in the circulating concentrations of IL-6 and 
other cytokines (120). In addition, epigenetic modifications induced by parental factors 
during conception and maternal exposures during pregnancy (e.g. infection, diet, 
psychological stress, xenobiotics) may result in elevated risk of systemic inflammation during 
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childhood and adulthood in the offspring (106). These findings are relevant to the concept of 
allostatic load in which the cumulative burden of frequent/repeated exposure to stress can 
result in adverse health consequences (121,122). 
Systemic inflammation is associated with increased risk of various diseases in adulthood, 
even following in utero or childhood exposure (106,110,112,119). Systemic inflammation can 
lead to changes such as breakdown of immune tolerance and impaired immune function, 
which can affect normal cellular physiology and contribute to the development of health 
conditions and disease (106). These alterations to the immune system can also increase 
susceptibility to infections and tumours as well as poor response to vaccines (106). 
Furthermore, long-term activation of the immune system is highly energy intensive and is 
accompanied by sickness behaviour and anorexia, which may be the result of energy 
shortages (123–125). Sickness behaviour and anorexia in turn can prevent adequate food 
intake and lead to rapid breakdown of energy reserves (123,124). Systemic inflammation 
can also induce blood-brain barrier changes that may contribute to sickness behaviour and 
anorexia through altered transport to the brain of prostaglandins, insulin, and other factors 
(109,126). In extreme cases, such as systemic inflammatory response syndrome and sepsis, 
systemic inflammation can result in multiple organ failure and death (107). Systemic 
inflammation can lead to physiological changes that predispose to various diseases across 
the lifespan.  
As described above, the clinical consequences of damage caused by systemic inflammation 
can be severe (106). More specifically, evidence suggests that systemic inflammation is 
associated with increased risk of both depression (119) and CVD (112). It is possible that 
activation of systemic inflammatory processes may be a common link between depression 
and CVD. Systemic inflammation may also contribute to the high level of comorbidity 
between these conditions (Section 1.1.3, Page 24) (63), although it is unclear whether 
systemic inflammation is a risk factor or mediator for comorbid depression and CVD 
(63,127). Furthermore, systemic inflammation in individuals with depression and/or CVD 
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may be stress-induced (63), indicating a role for environmental factors in the pathogenesis of 
illness. Understanding how systemic inflammation may contribute to depression and CVD 
could result in a more nuanced understanding of these conditions as well as new targets for 
therapeutic interventions.  
1.3.3 Markers of systemic inflammation  
There are currently no standard biomarkers for indicating the presence of systemic 
inflammation (106), so biomarkers for acute inflammation are often used instead. Such 
biomarkers include those based on acute phase proteins (e.g. CRP), cytokines (e.g. IL-6), 
and immune cell counts. Although no biomarkers exist that can distinguish systemic 
inflammation from other inflammatory conditions, biomarker still offer useful information 
about the current inflammatory state of the individual. In addition, the presence of 
recurrent/persistent infection or autoimmune disease, key triggers of systemic inflammation, 



















Both CRP and IL-6 are widely used to assess the presence and severity of systemic 
inflammation (128). These measures are non-specific markers of systematic inflammation 
since CRP and IL-6 concentrations can be elevated in various physiological states 
(128,129). CRP concentration begins to increase around two hours after an acute insult (as 
it is downstream of IL-6), reaching its peak at 48 hours (130). CRP is synthesised primarily in 
hepatocytes following IL-6 stimulation as well as in smooth muscle cells, macrophages, 
endothelial cells, lymphocytes, and adipocytes (131). CRP is produced as a pentameric 
protein, which has anti-inflammatory effects (131). At sites of inflammation and infection, 
pentameric CRP can irreversibly dissociate into five separate CRP monomers, which have a 
pro-inflammatory role in the tissue (131). Unfortunately, there are issues surrounding CRP 
measurement. Studies that address the stability of CRP measurements within individuals 
over time are conflicting, yet there is some suggestion that CRP exhibits intra-individual 
variability (132). CRP levels can also be affected by physiological states such as 
infection/fever (129), obesity (133), and exercise (134). CRP concentration at a single time 
point may therefore represent a state measure rather than a stable trait measure. As such, it 
may be problematic to rely solely on CRP values for risk prediction and therapeutic decision 
making in individual subjects (132). 
Upstream of CRP, IL-1-beta is a potent inducer of IL-6 gene expression in various cell types 
(135). The IL-6 cytokine can then act through two major pathways: classic signalling and 
trans-signalling (Section 7.3.2, Page 225) (136,137). In classic signalling, IL-6 binds to the 
membrane-bound IL-6 receptor expressed on limited cell types, mainly hepatocytes and 
certain WBCs. Classic signalling has homeostatic functions such as cell regeneration, 
haematopoiesis, and release of CRP and other acute phase proteins (136). In trans-
signalling, IL-6 binds to a soluble IL-6 receptor (sIL-6R) in circulation (136). The IL-6:sIL-6R 
complex is capable of inducing signalling on every cell type and can be inhibited by 
circulating soluble glycoprotein-130 (136,138). The IL-6 trans-signalling pathway promotes a 
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pro-inflammatory response (136,138,139) and may be an important therapeutic target for 
health conditions associated with inflammation. Thus, systemic inflammation may underlie 
elevated CRP and IL-6 concentrations although elevated levels do not necessarily indicate 
an inflammatory state.   
There are a number of other non-specific markers for inflammation based on the levels of 
different white blood cells (WBC) in the blood. WBC, also called leucocytes, play an 
important role in the immune response. Neutrophils are the predominant WBC subset 
recruited to inflamed tissue by the initial innate immune response (140). Neutrophils are 
reactive to a wide range of potentially health-damaging stimuli and act to drive inflammation 
and clear pathogens (140). Other WBC subsets such as lymphocytes are involved in the 
slower adaptive immune response, which is responsible for long-lasting protection against 
recognised pathogens (141). Therefore, the neutrophil to lymphocyte ratio (NLR) can be 
used to assess the inflammatory state of an individual. The range for NLR in healthy non-
geriatric adults may be between 0.78 and 3.58, with higher NLR values indicating higher 
levels of inflammation (142). In addition, WBC count (WCC) is routinely checked in clinical 
practice and may be used as a marker of inflammation. The normal WCC range is 5x109 to 
10x109 cells/L (143). Inflammatory processes are indicated by a higher than normal WCC, 
as well as a lower count in certain cases (144). Therefore, counts of distinct WBC cell types 
may be useful markers for inflammation. 
Here, I will discuss the associations of systemic inflammation with depression and CVD in 
terms of the inflammatory markers shown in Figure 4 (i.e. autoimmune diseases, infections, 
WCC, cytokines, and acute phase proteins).  
1.3.4 Links between systemic inflammation and depression  
The link between depression and autoimmune diseases is well-known. A longitudinal study 
of almost four million people from Denmark found that hospital contact due to autoimmune 
disease increased the risk of subsequent mood disorder by 45% (145). The prevalence of 
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MDD is substantially higher in patients with an autoimmune disease than in the general 
population. Specifically, the prevalence of MDD is 24% in systemic lupus erythematosus 
patients (146), 21% in multiple sclerosis patients (147), 19% in psoriasis patients (148), and 
ranges from 11% to 17% in rheumatoid arthritis patients (149,150). These autoimmune 
disorders may predict onset of MDD. For example, there is evidence that rheumatoid arthritis 
is associated with risk of first-onset depression (151), although it is unclear whether this 
relationship is bidirectional (151,152). Moreover, higher circulating TNF-alpha concentrations 
in systemic lupus erythematosus patients have been associated with MDD, severity of 
depressive symptoms, and poorer health-related quality of life (153,154). These findings 
suggest a potential role for systemic inflammation in the development of depression. 
In addition to autoimmune diseases, infection is associated with depression across the 
lifespan. History of hospitalisation for infection has been shown to increase the risk of later 
mood disorder by 62% (145). This link between infection and depression appears early in 
life, with severe infection during childhood predicting increased odds of MDD (155). 
Moreover, a longitudinal study of nearly two million children from Sweden found that fetal 
exposure to maternal infection while hospitalised increased the risk of depression diagnosis 
in adulthood (156). Another longitudinal study found that maternal experiences of daily 
stress during pregnancy exacerbated the association between exposure to maternal 
infection and subsequent depressive symptoms in the adolescent offspring (157). Severe 
infection or exposure to infection during fetal neurodevelopment may result in subtle damage 
to the brain, contributing to the development of depression later in life. However, the specific 
infectious agent may be less relevant to the development of depression. A meta-analysis of 
16 microbial infectious agents in depressed patients and non-depressed controls found that 
only five (31%) were associated with depression (158). It is possible that physiological 
changes caused by systemic inflammation (Section 1.3.2, Page 38) are responsible for the 
link between infection and depression. 
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The WCC also appears to be related to depression in adulthood. A population-based study 
of 3,352 adults with depression found that 22% had abnormal WCC, the majority of whom 
had high WCC (>10x109 cells/L) (159). Data indicates that elevated WCC may be particularly 
relevant to depression severity in men (160). Compared with controls, patients with 
depression have elevated counts of neutrophils and monocytes as well as reduced counts of 
natural killer cells (161–163). It is possible that the NLR is associated more robustly with 
depression than WBC subset counts (164). However, the relationship between T lymphocyte 
counts in depression is less clear. There is evidence to support both an increase (161,162) 
and decrease (163) in the levels of T lymphocytes. In addition, one study reported that 
increased memory CD8+ T lymphocytes and decreased natural killer cells were related to 
sleep disturbance in depression (162). Overall, depression is associated with WCC changes 
including altered levels of specific WBC subtypes. 
A number of pro-inflammatory cytokines have been linked to the development of depressive 
symptoms. Compared with healthy controls, raised peripheral levels of IL-6, TNF-alpha, and 
other cytokines have been observed in MDD patients (161,165). Selective serotonin 
reuptake inhibitors may alleviate depressive symptoms partly by decreasing pro-
inflammatory cytokine production (e.g. TNF-alpha and IL-1) and increasing anti-inflammatory 
cytokine production (e.g. IL-10) (166). In addition, pro-inflammatory cytokines have been 
shown to induce depressive  symptoms in previously mentally healthy participants (166). For 
example, immunotherapy with interferon-alpha can lead to depressive symptoms (46). The 
role of IL-6 in depression is particularly well-studied. A bidirectional relationship between IL-6 
and depression has been proposed, such that elevated IL-6 is associated with later 
depression and vice versa (167,168). Genetically-determined higher IL-6 concentration in 
childhood is also associated with increased risk of depressive symptoms in early adulthood 
in a linear dose-response fashion (169), suggesting that cytokines play a causal role in 
depression across the lifespan and that the association is unlikely to be due to residual 
confounding. Moreover, IL-6 signalling pathways have been implicated in MDD (169). 
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Cytokines may be involved in the development of depression by contributing to the 
dysregulation of glutamate neurotransmission, monoaminergic systems, and the 
hypothalamic-pituitary-adrenal (HPA) axis as well as changes to growth factors and 
neuropeptides, and decreased neurogenesis (170). As such, pro-inflammatory cytokines 
may influence genetic or environmental factors that contribute to the onset of depression.  
The acute phase protein, CRP, has been widely studied in the context of depression. CRP is 
elevated in around 27% of patients with MDD (171). It is particularly elevated in treatment-
resistant depression (172), suggesting a link between CRP and depressive symptom 
severity. Raised CRP concentration may be particularly important for specific symptoms of 
depression such as concentration difficulties, sleep disturbance, and psychomotor changes 
(172). CRP and depression are also related in early life. A cross-sectional study of 563 
adolescent girls from Iran found significant association between serum high sensitivity CRP 
and depression, even after adjusting for confounders such as SEP, BMI, tobacco exposure, 
and recent infections (173). However, the direction of association between CRP and 
depression in early life remains unclear. A meta-analysis of 22 studies containing 20,791 
participants age <18 years found evidence of association between CRP and future MDD but 
not the other way around (167). Other studies have reported the opposite; a US population-
based study of 1,420 children found that depression was associated with later CRP levels 
but CRP was not related to later depression (174). The discrepancy between these results 
may be explained by genetic or environmental factors that contribute to the link between 
CRP and depression.  
Anti-inflammatory drugs may offer new treatment options for MDD patients with signs of 
systemic inflammation. There are now a number of randomised controlled trials testing 
whether anti-inflammatory drugs as adjuvant treatment can improve outcomes in individuals 
with depression and raised inflammatory markers. For example, MDD patients with raised 
CRP may be responsive to infliximab, which inhibits TNF-alpha from stimulating CRP 
production (175). Statins and non-steriodal anti-inflammatory drugs may also be valuable for 
47 
 
treating depression (176–178). Moreover, tocilizumab, an anti-inflammatory drug that inhibits 
IL-6 signalling, is currently under investigation for its effect on depressive symptoms in 
depressed adults (179). These findings are promising, however physical comorbidities (e.g. 
CVD) can complicate the use of anti-inflammatory drugs with related side effects (e.g. 
cardiovascular morbidity/mortality) (180). 
1.3.5 Links between systemic inflammation and CVD  
Autoimmune diseases are associated with subsequent CVD outcomes. Type I diabetes, 
characterised by autoimmune destruction of pancreatic beta cells, is a well-known risk factor 
for CVD. Compared to their peers, individuals with type I diabetes are at substantially greater 
risk of IHD, MI, stroke, heart failure, atrial fibrillation, and cardiovascular mortality (181). By 
age 20 years, life expectancy of individuals with type I diabetes is reduced by around 12 
years, with approximately 33% of the excess risk being attributable to IHD (182). Moreover, 
rheumatoid arthritis patients have a substantially higher risk of CVD and cardiac mortality 
than the general population (183,184). CVD risk factors such as insulin resistance, 
dyslipidaemia, and hypertension are also common is rheumatoid arthritis patients (106). 
There are shared inflammatory pathways between active rheumatoid arthritis and unstable 
plaque formation as well as links between inflammation and subclinical myocardial injury 
(185). These findings suggest that the excess cardiovascular risk in autoimmune diseases 
may be attributable to systemic inflammation. 
A number of infections have been linked with CVD later in life. For example, HIV infection is 
an independent risk factor for ischaemic stroke, MI, and heart failure (186–188). HIV 
infection results in systemic inflammation and impairment of the immune system (189), 
which may contribute to CVD risk through altered monocyte function and subsequent 
progression of atherosclerotic plaque formation (190). Prolonged use of antiretroviral therapy 
among individuals with HIV may also increase risk of CVD through dyslipidaemia (191). 
Coinfection with HIV and hepatitis C virus is associated with increased risk of CVD 
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compared to individuals with HIV infection alone (192), perhaps suggesting a dose-response 
relationship between number of infections and risk of CVD outcomes. A number of clinical 
studies have reported a two-fold increase in risk of CVD within the first month of respiratory 
infection (193). For example, hospitalisation for pneumonia increases both the short-term 
and long-term risk of CVD (194). The evidence from studies of infection suggests a role for 
systemic inflammation in the development of adverse cardiovascular outcomes.  
WBC are key to the formation and maintenance of atherosclerotic plaques, particularly 
monocyte-derived macrophages. Macrophages initiate fatty streaks at the plaque site in the 
blood vessel and release lytic enzymes that can leave the fibrous plaque prone to rupture or 
erosion. Indeed, more than half of all cells at the immediate site of plaque rupture are 
macrophages (195,196). Other WBC subtypes may also be associated with CVD outcomes. 
Regulatory T lymphocytes can have an inhibitory effect on atherosclerosis (197) whereas 
neutrophils can contribute to damage of blood vessel walls and destabilisation of plaques 
(198). Therefore, a high NLR may be a useful predictor of atherosclerosis and CVD 
outcomes (199). High neutrophil count (>7.5x109 cells/L) has been associated with an 
increase in cardiovascular mortality (200). Conversely, reduction of circulating neutrophil 
counts using canakinumab, a monoclonal antibody that targets IL-1-beta, has been shown to 
be effective at preventing CVD (201). In addition, total WCC has been reported to be a 
robust risk factor for fatal and non-fatal CVD (198), although it is unclear if WCC may simply 
reflect poor health. As with depression, CVD is associated with WCC changes including 
altered levels of specific WBC subtypes. 
Pro-inflammatory cytokines have been implicated in atherosclerosis and CVD. 
Atherosclerosis is an inflammatory state; endothelial damage elicits the release of cytokines 
which induce a sequence of events leading to plaque formation and vascular occlusion (63). 
IL-1-beta is a pro-inflammatory cytokine produced by macrophages and endothelial cells at 
the plaque site (202,203). IL-1-beta can induce its own gene expression resulting in elevated 
IL-1-beta levels and maintenance of the inflammatory response at this site (203). Inhibition of 
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IL-1-beta appears to improve cardiovascular outcomes (203). IL-1-beta also stimulates the 
production of IL-6, which plays a key role in atherothrombosis (203). Observational studies 
have reported links between IL-6 and later CVD risk in childhood and adulthood (204,205). 
In addition, genetic studies support causality of IL-6 in IHD (206,207). TNF-alpha and a 
number of other pro-inflammatory cytokines are released by WBC in the atherosclerotic 
plaque which further support the maintenance of the plaque and may contribute to later CVD 
outcomes (202,208). 
Similar to depression, CRP has been widely studied in the context of CVD. Elevated high 
sensitivity CRP concentration (>3 mg/L) has been linked with an increase in cardiovascular 
events and cardiovascular mortality in both women and men (200,209). Similarly, in a meta-
analysis of 54 longitudinal studies containing 160,309 individuals, elevated circulating CRP 
was independently related to increased risk of IHD, stroke, and cardiovascular mortality 
(210). CRP concentration appears to predict CVD occurring many years in the future. For 
example, a study of 8,006 middle-aged men of Japanese ancestry reported that raised CRP 
was associated with cardiovascular events up to 15 years later (211). CRP has also been 
associated with adverse cardiovascular events among apparently healthy post-menopausal 
women (204). Finally, CRP may also be related to key CVD risk factors in children, such as 
BMI (205). Therefore, there is robust evidence to support a link between CRP and adverse 





1.4 Social and Demographic Influences on Systemic Inflammation 
and Depression/CVD Outcomes 
 
In the previous section (Page 43), I presented evidence for associations of inflammatory 
markers with depression and CVD outcomes. It is highly likely that these relationships are 
influenced by a range of genetic and environmental factors. Specifically, disparities in health 
status and disease burden are often related to factors such as age, sex, ethnicity, and SEP, 
partly due to social inequalities. The link between social inequalities and differences in health 
outcomes is strong and persistent (212). Therefore, sociodemographic factors can affect 
healthcare access and quality, disease-related outcomes, and the prevalence of adverse 
health outcomes (212). Moreover, sociodemographic factors are also often interrelated, 
exacerbating existing disparities in health. The relevance of sociodemographic factors to 
health outcomes means that they are often included as key confounders in epidemiological 
studies. Here, I will discuss the influence of age, sex, ethnicity, and SEP in relation to levels 









Figure 5. Social and demographic influences on systemic inflammation, depression, 
and CVD outcomes. 
51 
 
1.4.1 The role of age in systemic inflammation 
Systemic inflammation is strongly associated with older age (114). As discussed in Section 
1.3.2 (Page 38), the term inflammageing has been coined to describe age-related systemic 
inflammation, which is linked with morbidity and mortality (213). Older adults have higher 
circulating levels of cytokines (e.g. IL-6, IL-1, TNF-alpha), chemokines, and acute phase 
proteins (e.g. CRP) than younger people, as well as greater expression of genes involved in 
inflammation (112,114).. Ageing has long been associated with a number of changes that 
lead to immune system dysfunction, including cytokine dysregulation, overproduction of 
reactive oxygen species, slowing of autophagic processes that clear cellular waste from 
cells, and cellular senescence (213). In contrast, systemic inflammation in young people is 
rare in the absence of environmental or behavioural factors.  
1.4.2 The role of age in depression and CVD outcomes  
The relationship between age and the prevalence of depression is somewhat unclear. The 
lifetime prevalence of MDD varies widely across countries (214,215). In low- and middle-
income countries (LMICs), the 12 month prevalence of MDD generally does not differ by age 
group (216). In high-income countries, studies have reported that the MDD 12 month 
prevalence decreases with age (215,216). Other research has concluded that depressive 
symptoms in high-income countries may follow a U-shaped pattern across adulthood, such 
that younger and older adults have elevated depressive symptoms compared to middle-aged 
adults (217). Moreover, younger women in high-income countries are more likely to have 
persistently high peripartum depressive symptoms in the years after birth than older women 
(218), perhaps due to additional confounding factors such as SEP and stress. Although the 
exact trajectory across the lifespan remains obscure, the association between age and MDD 
appears to be stronger in high-income countries than LMICs (219). In addition, genetic 
studies suggest that early-onset MDD is more strongly related to alleles conferring risk of 
bipolar disorder and schizophrenia compared to late-onset MDD (220). This may explain 
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partly the differences in depressive symptom profiles recorded between children/adolescents 
and adults with depression (221). The inconsistent findings described above suggest that the 
effect of age on depression may be indirect and related to other genetic and environmental 
factors.  
In contrast to depression, there is a well-established dose-dependent relationship between 
older age and CVD prevalence (43). Increased age is associated with cardiovascular 
mortality (200). Heart attack and fatal IHD cases increases with age in both women and men 
(222). Data from the US national mortality data indicates that the prevalence of premature 
CVD mortality is 43 per 100,000 among younger adults (age 25 to 49 years) compared with 
a prevalence of 258 per 100,000 among middle-aged adults (age 50 to 64 years) (223). The 
increased risk of CVD with older age may results from the culmination of risk factors across 
the lifespan along with typical ageing processes that alter heart function. Since CVD is still 
relatively rare in young people, comorbidity between depression and CVD is more common 
among older people. An observational study from Taiwan reported that MI patients age ≥65 
years had a substantially higher incidence of MDD compared to equivalent MI patients age 
<45 years (224). Therefore, there is evidence that the relationship between CVD and 
depression depends on age. 
1.4.3 The role of sex in systemic inflammation 
Sex has a somewhat complex influence on inflammatory processes. Infections are more 
common in males and acute inflammatory conditions in males are associated with higher risk 
of morbidity and mortality than in females (225). However, autoimmune disorders are more 
common in women and females have worse prognosis and higher mortality than males in 
chronic inflammatory processes (225). These findings suggest that female gender is 
associated with systemic inflammation, perhaps due to females having a more robust 
inflammatory response and higher immune reactivity than males (226). For example, a study 
of 2,749 participants from the US found that women have higher CRP concentrations than 
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men even after adjusting for oral oestrogen use, BMI, and other confounders (227). The 
robust inflammatory response in females is beneficial during infection but may contribute to 
greater severity of inflammatory diseases in females compared to males (226). Oestrogens 
are also known to modulate the immune response, including cytokine production and 
receptor expression (225). However, the role of oestrogens does fully explain the universal 
sex differences in inflammation found across the lifespan (225). The association of female 
gender and systemic inflammation is likely the result of interaction between genetic and 
environmental factors.   
1.4.4 The role of sex in depression and CVD outcomes 
Globally, depression is more common in women. Around 5% of women worldwide have 
depression compared to less than 4% of men (228). The prevalence of depression increases 
significantly from childhood to adolescence in both males and females, although the relative 
proportion of females reporting depressive symptoms is higher (229). Indeed, by young 
adolescence the reported prevalence of depression in females in approximately double that 
in males (229). Higher lifetime risk of depression among women is only present between 
puberty and menopause (230,231). This sex difference has been attributed in part to the 
burden of stressful reproductive events as well as the effects of hormones (230). Changes to 
hormone levels may increase risk of depression in women and men. Both hormone excess 
and hormone deficiency have been linked with increased risk of depression in women (232–
234), whereas androgen deficiency has been associated with increased risk of depression in 
men (235). Interestingly, the risk of depression increases in boys as well as girls at the time 
of puberty (231), although no relationship between depression and testosterone levels has 
been established in adolescent males (236). Despite these findings, women with a history of 
depression do not differ from men with a history of depression in terms of persistence or 
recurrence of symptoms (231). As such, it appears that biological and social factors 
contribute only to the higher risk of initial depression onset among women.  
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On the other hand, sex differences in CVD prevalence and adverse outcomes are less clear. 
The typical risk factors for CVD are the same in women and men (222). Similarly, IHD is the 
largest contributor to cardiovascular morbidity and mortality, regardless of sex (222). 
However, male gender is associated with age-adjusted IHD mortality, a higher lifetime risk of 
CVD at age 40 years, and a higher prevalence of heart failure (200,222). In contrast, women 
have higher 30 day cardiovascular mortality compared with men (237,238), as well as a 
higher prevalence of stroke (222). The prevalence of CVD risk factors also display sex 
differences. Smoking, overweight/obesity, and low HDL cholesterol are more prevalent in 
men (239,240), whereas diabetes, high total cholesterol, and physical inactivity are more 
prevalent in women (239). Furthermore, there is ongoing debate about gender bias in the 
management of CVD (241), which may contribute to sex differences in CVD outcomes. For 
example, women previously experienced greater morbidity and mortality following coronary 
artery bypass grafting (242), but increasing use of off-pump techniques which 
disproportionately benefit women has narrowed the disparity in outcomes following surgery 
(243). Thus, it is not clear whether sex differences in CVD outcomes reflect differences in 
preventative care or underlying genetic vulnerability.   
The literature suggests that the prevalence of comorbid depression and CVD is higher in 
women, although there is some evidence on the contrary. Women are more likely to have 
depression in the context of CVD (244,245). A study of 7,641 young adults from the US 
found that depression and attempted suicide was associated with increased risk of CVD 
mortality in both women and men, but to a substantially greater extent in women (246). 
Depressive symptoms in patients with IHD also appear to be most relevant in young women 
in terms of risk of mortality (247). Moreover, the relationship between depressive symptoms 
and a lack of functional improvement in cardiac patients following coronary artery bypass 
graft surgery is particularly pronounced among women (248). Finally, in a US study, when 
controlling for demographic and lifestyle risk factors, results indicated that the risk of any 
CVD associated with MDD was found almost exclusively among women age ≥45 years (43). 
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However, some studies have found that the age-adjusted prevalence of heart disease in 
patients with depression is similar among women and men (249), while other studies have 
reported that the prevalence of comorbid depression and CVD is twice as high in men 
compared to women (39). These differences may be due to heterogeneity within the study 
populations, depression/CVD measurements, or methodology.  
1.4.5 The role of ethnicity in systemic inflammation 
Studies considering the effect of ethnicity on systemic inflammation are largely restricted to 
comparison of CRP levels among the US population. In a systematic review of mainly US-
based studies, 14 out of 15 relevant studies found that individuals of European origin had 
the lowest CRP levels while African American, Hispanic, and South Asian individuals had the 
highest CRP levels (250). In UK-based studies, individuals of South Asian origin have also 
been found to have elevated CRP relative to those of European origin (251,252). Some US 
studies have found Hispanic individuals have lower CRP concentrations than African 
Americans (253,254), while others have reported the opposite (255). In addition, US studies 
have demonstrated that CRP concentration is lower in East Asian individuals than European, 
African American or Hispanic individuals (256,257). A Canadian study also reported that 
East Asian participants have lower CRP concentration than European, South Asian, or 
Aboriginal participants (258). Moreover, Aboriginal and South Asian participants had 
increased WCC compared with Europeans (258). Despite these findings that suggest 
ethnicity influences inflammation, many US studies report no differences in CRP levels 
among participants of various ethnic origins (254,255,259). The discrepancy in findings 
regarding ethnicity and inflammation may be related to factors such as SEP, adiposity, and 
geographical location (257,258). Indeed, one US study observed that ethnic differences 
disappeared after accounting for confounders (259). It is unclear whether factors such as 
SEP explain the relationship between ethnicity and inflammation or whether the true effect of 
ethnicity is underestimated due to unintentional adjustment for mediating factors.   
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1.4.6 The role of ethnicity in depression and CVD outcomes 
There appear to be disparities in depression and CVD outcomes according to ethnic group. 
In the UK, depression appears to be more prevalent among Black women than either White 
women or Asian women (260). The opposite was true for men in this study; depression 
prevalence was highest in Asian men and lowest in Black men (260). In the US, the severity 
of depressive symptoms in community-based older adults is higher in Hispanic and African 
Americans compared with European Americans (261). Disparities in depression care may 
partly explain ethnicity-related differences in the prevalence of depression. For example, 
African Americans with MDD diagnoses are 55% less likely to receive appropriate treatment 
for their symptoms compared with European Americans (262). Regarding CVD, African 
Americans have the highest age-adjusted cardiovascular mortality rates, followed by 
American Indian/Alaska Native, European, and Hispanic individuals (223). African American 
individuals are also more likely to have comorbid depression and CVD than European 
Americans (39). Among women, African Americans have the highest prevalence of CVD and 
the highest age-adjusted IHD death rate (239). In contrast, Asian American women have the 
lowest prevalence of IHD compared to other ethnic groups (239). These findings provide 
evidence that the prevalence of both depression and CVD are influenced by ethnicity.  
1.4.7 The role of SEP in systemic inflammation 
SEP, often characterised as income, education, or occupation, plays an important role in 
systemic inflammation. Low SEP, broadly defined, has been consistently associated with 
higher levels of systemic inflammation (250,263,264), although estimates of association 
between SEP and inflammatory markers vary widely across studies (263). A meta-analysis 
of 43 studies containing 111,156 participants reported that low SEP was associated with 
both elevated circulating CRP and IL-6 levels (263). In subgroup analyses, both low income 
and low education levels were independently related to higher CRP and IL-6 levels (263). 
The age at measurement of SEP and inflammatory markers did not alter the magnitude of 
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association between SEP and CRP/IL-6 (263), suggesting that SEP influences levels of 
systemic inflammation across the lifespan. Indeed, the association between lower education 
levels and elevated CRP is present even in older adults (259). Another recent meta-analysis 
containing 43,629 participants from 15 studies found that children/adolescents from the least 
advantaged families had 25% higher adult CRP levels compared with those from the most 
advantaged families (264). The association between low SEP in childhood and elevated 
CRP in adulthood in this study was attenuated by the inclusion of adult BMI, indicating that 
BMI has a strong mediating role (264). In addition to BMI, cigarette smoking may mediate 
the relationship between SEP and CRP. Studies that control for BMI and/or cigarette 
smoking have smaller associations between SEP and CRP than studies that do not control 
for these factors (263). However, there is no evidence that the relationship between SEP 
and IL-6 is influenced by BMI or cigarette smoking (263).  
1.4.8 The role of SEP in depression and CVD outcomes 
SEP appears to be related to the risk of depression. In high-income countries, low income is 
associated with a two-fold increase in odds of MDD compared to high income, whereas 
income does not appear to be related to MDD in LMICs (219). Childhood/adolescent 
depression also predicts reduced income in adulthood, indicating a reciprocal relationship 
between income and depression (265). In addition, the prevalence of depression in high-
income countries is higher among individuals who are unemployed compared to those who 
are employed full-time or part-time (260). Moreover, the prevalence of peripartum 
depression varies depending on the SEP of the study population; a prevalence of 7% to 20% 
has been reported for maternal depression in high-income countries, whereas prevalence 
greater than 20% has been reported for LMICs (266). Low income, financial difficulties, low 
education levels, and unemployment have also been independently associated with 
peripartum depression in women, although there are some contradictory results (266). 
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Despite some differences in the evidence from different countries, SEP seems to play a role 
in the onset of depression.  
Low SEP is associated with increased risk of CVD and cardiovascular mortality in high-
income countries (267). Unemployment and low material amenities are both independently 
associated with increased risk of CVD mortality among adults from Russia, Poland, and the 
Czech Republic (268). Low levels of education are associated with adverse cardiovascular 
events worldwide (269). This finding is particularly marked in low-income countries, perhaps 
due the quality of medical care playing an important role in adverse CVD outcomes (269). 
CVD risk factors in childhood such as obesity are also more common among individuals of 
lower SEP (270). It is unclear whether income plays a role in CVD outcomes (82,269). 
Indeed, one study in Scotland found that higher deprivation levels were not associated with 
cardiovascular mortality (200). Finally, SEP appears to be associated with comorbid 
depression and CVD. Among CVD patients from a UK population representative sample, the 
prevalence of depression was 38% in the most deprived socioeconomic group compared 
with 26% in the least deprived group (271). Taken together the evidence suggests that SEP 




1.5 Overview of Structure and Justification of Thesis  
In this chapter, I have presented the three concepts that are pertinent to this thesis. First, I 
discussed the associations between depression and CVD across the lifespan. Second, I 
addressed the evidence for systemic inflammation as a shared mechanism for depression 
and CVD. Finally, I highlighted the role of various social and demographic factors on 
systemic inflammation, depression, and CVD. In Chapter 2 (Page 60), I present the aims, 
objectives and methods for the current analytic work, including descriptions of the relevant 
datasets. Chapter 3 (Page 74), Chapter 4 (Page 110), Chapter 5 (Page 144), and Chapter 6 
(Page 187) contain the analyses, themselves introduced by a visual summary (Figure 6, 
Figure 23, Figure 28, Figure 31). Chapter 7 (Page 212) concludes the thesis with a general 
discussion of the findings and suggestions for further work.  
This first chapter has revealed a number of gaps in the literature regarding these three 
concepts. Most importantly, young people remain understudied in the context of depression 
and CVD risk relative to adults. The precise nature of the role of systemic inflammation in 
depression and CVD along with the utility of different inflammatory markers also remain 
unclear. The remainder of this thesis attempts to address some aspects of these gaps. My 
hypotheses for the analytic work in this thesis are two-fold: (i) CVD risk and depressive 
symptoms are bidirectionally associated in young people; and (ii) systemic inflammation is a 
robust shared mechanism for CVD and depression across the lifespan. The specific 
hypotheses I test in order to address these overall hypotheses are set out in each of the four 
analytic chapters.    
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Chapter 2: Aims and Objectives of the Thesis and 




2.1 Aims  
As shown in Chapter 1, both depression and CVD are highly prevalent in the general 
population (Section 1.1, Page 19) and systemic inflammation may represent a shared 
mechanism (Section 1.3, Page 37). However, an in-depth exploration of the nuances in 
these relationships (Figure 1) is currently lacking. The aim of this thesis is to explore the 
associations between systemic inflammation, depression and CVD across the lifespan. More 
specifically, this thesis covers different inflammatory markers, associations of depression 
and CVD in childhood/adulthood, and the role of confounding demographic factors in these 
relationships. I have defined the age groups below (Section 2.3, Page 63). The purpose of 
this thesis is to shed light on the complex links between depression and CVD and to 





The objectives of this thesis are as follows: 
1) Determine the direction of association between depression and CVD risk in young 
people. 
2) Test the convergence of evidence for systemic inflammation as a shared mechanism for 
depression and CVD across the lifespan by: 
a) Investigating the association of various inflammatory markers with depression and 
CVD risk outcomes in young people. 
b) Investigating the association of various inflammatory markers with depression, CVD, 
and comorbid depression and CVD outcomes in adults. 
c) Investigating the specificity of association of various inflammatory markers with 
depression and CVD outcomes in adults. 
3) Determine the effect that demographic factors have on the associations between 
systemic inflammation, depression and CVD across the lifespan. 
The specific hypotheses tested in order to meet these objectives are set out in the 
subsequent chapters. Type I error (i.e. the mistaken rejection of the null hypothesis) and 
type II error (i.e. the mistaken acceptance of the null hypothesis) must be taken into account 




2.3 General methods 
To address the objectives of this thesis, I performed a systematic review (Objective 1) and 
used two different datasets for analysis: (i) the Avon Longitudinal Study of Parents and 
Children (ALSPAC; Objective 2a and 3); and (ii) the UK Biobank (Objective 2b and 2c). A 
key part of the thesis is to determine the robustness of the link between inflammation, 
depression, and CVD (risk) by investigating associations across the lifespan. 
The age groups I refer to in throughout this thesis are defined as follows: children (age 0 to 
10 years), adolescents (age 10 to 19 years), young people (age 10 to 24 years), adults (age 
≥25 years), and middle-aged and older adults (age ≥40 years).  
In the systematic review, associations were assessed in children and young people. Using 
the selected UK-based datasets, associations were assessed in children, adolescents, and 
middle-aged and older adults. ALSPAC was used for analysis in children/adolescents and 
the UK Biobank was used for analysis in adults. The specificity of association of systemic 
inflammation with comorbid depression and CVD (vs monomorbid depression or CVD) was 
also tested in middle-aged and older adults. Analyses were presented with and without 
adjustment for confounders to assess the effect of demographic factors on associations 
between systemic inflammation, depression, and CVD.   
Various statistical methods were used including meta-analysis, regression, structural 
equation modelling, and imputation. I examined a range of inflammatory markers to assess 
convergence of the evidence for systemic inflammation as a shared mechanism for 
depression and CVD. The inflammatory markers used in this research include a high burden 
of infection, cell counts (i.e. WCC), and a high acute phase protein (i.e. CRP) or cytokine 
concentration (i.e. IL-6). I considered the demographic factors discussed in Section 1.4 
(Page 50), namely age, sex, ethnicity, and SEP, as either key confounders or risk factors in 




2.4 Description of the ALSPAC birth cohort  
ALSPAC, also known as “Children of the 90s”, is a general population-based birth cohort in 
the former county of Avon in England. ALSPAC was established as part of an initiative by 
the WHO to carry out prospective birth cohorts across Europe with the purpose of studying 
modifiable influences on child health and development (272). Professor Jean Golding from 
the University of Bristol designed the methodology for ALSPAC (273). Core funding for 
ALSPAC is currently provided by the UK Medical Research Council, Wellcome Trust, and 
the University of Bristol. 
The former county of Avon was located in the South West of England, comprising three UK 
National Health Service (NHS) administrative districts (272). In 1991, the total population in 
the ALSPAC catchment area was approximately 0.9 million. Avon covered both urban and 
rural areas, and the population was broadly representative of the rest of the UK. However, 
the study has a shortfall in mothers of ethnic minority origins and in less affluent families. 
Furthermore, there has been considerable attrition in follow-up (see Table 1, Table 6, and 
the text, thereafter), though the study remains a remarkable resource for research and policy 
planning. 
Pregnant women residing in the former county of Avon with expected delivery dates between 
1 April 1991 and 31 December 1992 were eligible to participate in ALSPAC. Pregnant 
women who migrated into the catchment area up to the point of delivery were also eligible to 
take part in the study. Pregnant women moving out of the catchment area prior to delivery 
were excluded if they had not completed the questionnaire scheduled for the third trimester 
of pregnancy (272). ALSPAC comprises data from the parents as well as the children and 
covers a wide range of phenotypic and environmental measures and biological samples. 
The initial ALSPAC cohort consisted of 14,541 pregnancies which resulted in 14,062 live 
births. Of the live births, 13,988 infants were still alive at 12 months (272,274). Subsequent 
attempts to trace eligible participants who were initially missed has increased the size of the 
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ALSPAC cohort to 15,454 pregnancies with 14,901 infants alive at 12 months. Follow-up of 
the cohort until age 18 years has included 59 questionnaires, which began during 
pregnancy. From birth to age 7 years, the mothers answered questions about their children. 
From age 7 years onwards, the children attended an annual assessment clinic, during which 
they participate in a range of face-to-face interviews and physical tests. 
2.4.1 Ethical approval and consent 
Ethical approval for ALSPAC was obtained from the Local Research Ethics Committees for 
the three health authorities (Southmead, Frenchay, and Bristol and Weston) that formed the 
study’s catchment area. Ethical approval for individual research studies conducted using 
ALSPAC data are covered under this ethical approval. The parents of participating children 
provided written informed consent for the use of questionnaire and clinic data in research 
studies approved by the ALSPAC executive committee without requiring separate consent 
for each study. No financial compensation was given to participants.  
Detailed information about ALSPAC can be found on the study website 
(http://www.bristol.ac.uk/alspac). A fully searchable data dictionary is also available for 
information on all available ALSPAC data (http://www.bris.ac.uk/alspac/researchers/our-
data).  
2.4.2 Assessment of outcomes 
Depressive symptoms and composite CVD risk score were the main outcomes in the studies 
using data from the ALSPAC cohort. Depressive symptoms were assessed by the Short 
Mood and Feelings Questionnaire (SMFQ) at age 10, 13, 14, 17, 18, and 19 years old. 
Depressive symptoms were also assessed by the Clinical Interview Schedule Revised 
(CISR) at age 18 years. I created the CVD risk score using age, ethnicity, maternal SEP, 
maternal smoking, own smoking, physical activity, BMI, SBP, LDL, HDL, and triglycerides. 
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Detailed information on these outcome measures as well as the other variables used in 














Type of variable Measurement Time of recording Use in my analysis  
Parental history of severe depression  7,664 Parent-based Self-report  12 weeks gest Confounder 
Maternal smoking  10,598 Parent-based Self-report  12 & 32 weeks gest Exposure, Outcome 
Maternal SEP 9,183 Parent-based Self-report 32 weeks gest Confounder, Exposure, Outcome 
Maternal education  11,138 Parent-based Self-report 32 weeks gest Confounder 
Family history of CVD 4,742 Parent-based Self-report Age 18 Confounder 
Sex 11,786 Child-based Self-report (by mother) Birth Confounder 
Birthweight  11,613 Child-based Hospital record Birth  Confounder 
Ethnicity  11,080 Child-based Self-report Birth  Confounder, Outcome 
Number of infections  11,786 Child-based Self-report (by mother)  Age 1.5 to 7.5 Exposure 
Total difficulties score (SDQ)  8,188 Child-based Self-report (by mother) Age 7 Confounder 
IL-6  4,626 Child-based Biological  Age 9 Exposure 
CRP 4,636 Child-based Biological Age 9 Exposure 
BMI  4,923 Child-based Clinic Age 15 Exposure, Outcome 
Smoking  4,757 Child-based Self-report Age 15 Exposure, Outcome 
LDL   3,184 Child-based Biological Age 15 Exposure, Outcome 
HDL 3,184 Child-based Biological Age 15 Exposure, Outcome 
Triglycerides  3,184 Child-based Biological Age 15 Exposure, Outcome 
SBP 4,831 Child-based Biological Age 15 Exposure, Outcome 
Physical activity  4,992 Child-based Self-report Age 15 Exposure, Outcome 
Age 5,007 Child-based Self-report Age 15 Confounder, Exposure, Outcome 
Depressive symptoms (CISR)  4,117 Child-based Structured interview Age 18 Outcome 
Depressive symptoms (SMFQ)  6,685 to 3,101 Child-based Self-report Age 10 to 19 Outcome 
a BMI: body mass index; CISR: Clinical Interview Schedule Revised; CRP: C-reactive protein; HDL: high-density lipoprotein; CVD: cardiovascular disease; IL-6: interleukin-




2.4.3 Overview of analytic strategy  
All studies based on ALSPAC data in the following chapters are longitudinal by design. They 
link a putative risk factor (i.e. the exposure) with the outcome of either depressive symptoms 
or CVD risk. In most cases the risk factors were continuous measures, thus I measured the 
change in the outcome as a function of the change in exposure. The continuous exposures 
were standardised to allow comparison between different exposures. This has been 
represented as a beta estimate. For categorical exposures, the beta estimates represent the 
change in outcome for the presence of the risk factor compared with its reference group. The 
possible contribution from factors other than the exposure of interest (i.e. confounders; 
alternative explanations for an apparent association) were accounted for in regression 
analysis. 
I used multiple imputation to deal with missing values for specific confounders and exposure 
variables. Missing data can reduce the statistical power of a study and produce biased 
estimates (275). One of the assumptions of multiple imputation is that data are missing at 
random. A strength of multiple imputation is that, unlike complete case analysis, it 
incorporates the uncertainty associated with missing data. In this method, missing data are 
replaced with predicted values using the existing data from other variables. This process 
repeats a set number of times to create multiple imputed datasets, which can be analysed 
using standard statistical methods and the results combined using Rubin’s rules.  
Specifically, I used the fully conditional Markov Chain Monte Carlo (MCMC) method for 
multiple imputation. This method specifies a multivariate imputation model on a variable-by-
variable basis by a set of conditional densities, one for each incomplete variable (276). An 
appropriate regression model can be selected for each variable. For example, linear 
regression for continuous variables and logistic regression for categorical variables 
(277,278). This process is repeated for each variable per iteration. 
69 
 
I used mediation analysis to test the indirect effect of an exposure on an outcome through an 
intermediate variable. Baron and Kenny were the first to describe a method for mediation 
analysis in which a series of regression equations were used to assess associations 
between: (i) exposure and outcome; (ii) exposure and mediator; and (iii) mediator and 
outcome (279). Significant associations are required in all of these steps to proceed with 
mediation modelling. This strategy has low statistical power due to multiple hypothesis tests 
and is no longer recommended for mediation analysis (280,281).  
The pathway analysis framework based on structural equation modelling is a more 
appropriate method for mediation analysis (282). Simple association between the exposure 
and outcome is not a precondition (281), since inference about mediation is focused on the 
indirect effect of the exposure on the outcome. Using structural equation modelling, 
relationships are tested in a single analysis such that the structural equations for the direct 
and indirect effects are linked together and inference about them is simultaneous (282). The 
direct effect describes the exposure to outcome pathway controlling for the mediator 
whereas the indirect effect describes the exposure to outcome pathway through the 
mediator. The total effect is the sum of the direct and indirect effects of the exposure on the 
outcome (282). Inference about mediation effects is based on maximum likelihood and non-
parametric bootstrapping (283). In the case of complete mediation, the pathway between 
exposure and outcome is eliminated by the intermediate variable. In the case of partial 
mediation, the pathway between exposure and outcome is attenuated.  
Although mediation analysis can be useful for testing putative causal pathways for complex 
conditions, such as depression, it has its limitations. Associations that are considered part of 
the mediation model could themselves be affected by other confounders. This issue must be 
considered while interpreting the results of mediation analysis. Nevertheless, the issue of 
residual confounding is relevant to all observational investigations and is not exclusive to 
mediation analysis. Further description of specific statistical analyses are presented in the 
methods section of the relevant chapters.  
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2.5 Description of the UK Biobank sample 
The UK Biobank is a UK-based open-access prospective study. The UK Biobank was 
established to allow detailed investigations of the genetic and non-genetic determinants of 
the diseases of middle and old age (284,285). The Science Committee for UK Biobank 
developed the protocol for the study. Core funding for the UK Biobank is currently provided 
by the Wellcome Trust, UK Medical Research Council, Cancer Research UK, and the 
National Institute for Health Research.  
Over half a million participants age 40 to 69 years were recruited into the study. The 
participants were recruited from 22 assessment centres across the UK between 2006 and 
2010 (286). The assessment centre sites were selected based on proximity to a sufficient 
population of eligible individuals and good transport links (285). The assessment centres 
covered various settings to provide urban-rural mix and socioeconomic and ethnic 
heterogeneity (286). In 2006, the total population of the UK was around 60.5 million. 
The UK Biobank contains results of clinical examinations, assays of biological samples, self-
reported health behaviour, genome-wide genotyping, and is supplemented by linkage with 
routinely available national datasets such as NHS records. At the baseline assessment, 
participants completed a self-report touch-screen questionnaire, a short computer-assisted 
interview, physical and functional measures, as well as collection of blood, urine, and saliva 
samples, which allow a variety of assay types (285). Follow-up is primarily conducted 
through linkage to electronic health-related records, although online questionnaires have 
also been performed. For example, an online mental health self-report questionnaire was 
issued in 2016. 
2.5.1 Ethical approval and consent 
The UK Biobank received full ethical approval from the NHS National Research Ethics 
Service (reference 11/NW/0382). Written informed consent was obtained from participants at 
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recruitment. The analyses presented in this thesis were conducted under approved UK 
Biobank project no. 26999.  
Details of the UK Biobank resource can be found on the study website 
(https://www.ukbiobank.ac.uk/). A searchable showcase of UK Biobank data is also available 
which contains essential information, listings of database content, and access to data 
(https://biobank.ndph.ox.ac.uk/showcase/).  
2.5.2 Summary of information used  
Lifetime depression and lifetime IHD were the outcomes used in UK Biobank analysis. 
Depression was defined according to self-report whereas IHD was defined according to 
International Classification of Diseases (ICD)-10 criteria. Details of the other variables used 
(Table 2) in analysis are given in the relevant chapter. The data used in this particular UK 
Biobank study were all collected at the same time during recruitment in 2006 to 2010.  








Use in my analysis 
CRP 468,553 Biological 2006 – 2010  Exposure 
WCC 478,152 Biological  2006 – 2010  Exposure 
IHD (diagnosis) 410,252 Clinic 2006 – 2010  Outcome 
Depression (diagnosis) 410,252 Clinic 2006 – 2010  Outcome 
Depression (self-report)  122,972 Self-report 2006 – 2010  Outcome 
Age  502,488 Self-report 2006 – 2010  Confounder 
Sex 502,488 Self-report 2006 – 2010  Confounder 
Ethnicity  499,712 Self-report 2006 – 2010  Confounder 
TDI 501,865 Self-report 2006 – 2010  Confounder 
BMI 499,384 Clinic 2006 – 2010  Confounder 
Smoking 499,540 Self-report 2006 – 2010  Confounder 
Alcohol use 500,987 Self-report 2006 – 2010  Confounder 
Physical activity  462,494 Self-report 2006 – 2010  Confounder 
Mood disorders 410,252 Clinic 2006 – 2010  Confounder 
Metabolic disorders 410,252 Clinic 2006 – 2010  Confounder 
Chronic inflammatory 
conditions 
410,252 Clinic 2006 – 2010  Confounder 
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Acute infections 410,252 Clinic 2006 – 2010  Confounder 
a BMI: body mass index; CRP: C-reactive protein; ICD-10: International Classification of Diseases-10; IHD: 
ischaemic heart disease; TDI: Townsend deprivation index; WCC: white blood cell count. 
  
2.5.3 Overview of analytic strategy  
The study based on UK Biobank data in Chapter 6 (Page 187) is essentially cross-sectional 
by design due to all of the data I used being collected at the same time. The study links an 
exposure with the outcome of depression, IHD, or comorbid depression and IHD. The two 
exposures of interest were continuous measures whereas the outcomes were binary 
measures. As such, I have measured the presence/absence of the outcome as a function of 
the change in exposure. The exposures were standardised to allow comparison between 
different exposures. This has been represented as an OR. Effects of possible contribution 
from confounders were accounted for in regression analysis.  
To assess the specificity of association between exposure and outcomes, I used bivariate 
probit regression. This is a valid method for modelling two binary outcome variables jointly 
as a function of an exposure.  
I assessed the effect of selection bias using inverse probability weighted regression. Using 
this regression method is appropriate when individuals vary in their probability of having 
missing information, such as missing outcome data. Missing outcome data is unlikely to 
happen completely at random leading to biased effect estimates (287). As such, weights to 
account for this bias can be estimated from a logistic regression model for predicting non-
response. However, the validity of the weights depend on a correctly specified model that 
includes all relevant exposures associated with non-response (287). This weighting method 
up-weights participants with missing outcome data and down-weights participants with 
complete outcome data. In this way, weighted analyses estimate results as if the full UK 
Biobank dataset were used in analyses. 
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SECTION B: SYSTEMATIC REVIEW 
 
Chapter 3: A Systematic Review and Meta-analysis of 
Longitudinal Cohort Evidence for Association between 

























Depression is a common and serious mental illness with a lifetime risk of 10% to 20% (288). 
The majority of depression cases are established by age 24 years old (12); this condition is 
the leading cause of disability among children and young people (14). Following an initial 
depressive episode, the risk of recurrence is 60% (289). Therefore, early-onset depression is 
associated with a longer risk period for relapse as well as poor long-term outcomes 
(289,290). A better understanding of the aetiology of depression in young people is required 
to develop effective strategies for prevention and treatment (291).  
CVD is a leading cause of health-related disability worldwide (292). There is evidence for 
bidirectional associations between CVD and depression in adults (293,294). A substantial 
body of literature suggests that depression is a key risk factor for CVD in adults and that it 
may predict poor outcomes following a cardiac event (293–298). CVD is also subsequently 
associated with depression in adults (34,298–300). However, studies of CVD risk and 
subsequent depression in young people are relatively less common. A clearer understanding 
of the association between CVD risk factors and depression in young people is required. 
Early detection and management of CVD risk factors may reduce risks for both CVD and 
depression subsequently during the life-course.   
The WHO defines age 24 years as the upper age limit for the term young people (301). 
Existing studies of CVD risk and depression in young people have often focused on 
individual risk factors such as BMI or smoking. In the past decade, a number of systematic 
reviews have highlighted a longitudinal association between obesity in young people and 
depression across the lifespan (86,94,302,303). However, none of these studies specifically 
examined depression risk in young people. A recent systematic review of individuals age 14 
to 35 years old reported that childhood obesity is associated with approximately 50% 
increased risk of depression (94). Another review reported that smoking in early life is 
associated with 73% increased risk of depression in young people (102). According to the 
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Framingham study, a gender-specific algorithm used to estimate an individual’s 10 year 
cardiovascular risk, other established CVD risk factors for adults include SBP, total 
cholesterol, and HDL, in addition to smoking and BMI (304,305). These CVD risk factors are 
all potentially modifiable and may be important in the aetiology and prevention of depression. 
CVD risk factors are increasingly being examined in young people; thus, a systematic review 
is required to summarise these findings. 
I conducted a systematic review and meta-analysis of existing studies to quantify the 
longitudinal association of five key CVD risk factors (BMI, smoking, SBP, total cholesterol, 
and HDL) and depression in young people (age ≤24 years). These CVD risk factors were 
chosen for a number of reasons: (i) they are part of the Framingham Cardiovascular Risk 
Score for adults; (ii) they are potentially modifiable; and (iii) they remain relevant in the 
context of young people. The outcome was depression (binary or continuous) assessed 
using a validated tool. I also performed a number of sensitivity analyses, for example by 






3.3 Hypotheses   
 
1. High BMI is associated with depression in young people.  
2. Cigarette smoking is associated with depression in young people. 
3. High SBP is associated with depression in young people. 
4. High total cholesterol is associated with depression in young people. 
5. Low HDL is associated with depression in young people. 





3.4.1 Search strategy  
This study has been performed according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines. Details of the protocol were prospectively 
registered on PROSPERO (see: 
https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42020172460). 
MEDLINE, EMBASE, and PsycINFO databases were searched to identify all relevant 
studies of the association between CVD risk factors and depression from database inception 
to 1 January 2020. The following keywords were used: “(cohort OR longitudinal OR 
prospective OR retrospective OR follow up stud*) AND depress* AND (adolescen* OR 
young person OR young people OR child* OR infant OR early adult OR youth* OR teen*) 
AND ((cardiovascular AND risk) OR total cholesterol OR high density lipoprotein OR hdl OR 
smok* OR bmi OR body mass index OR adiposity OR waist circumference OR body fat 
distribution OR skinfold thickness OR lipid accumulation product OR systolic blood pressure 
OR systolic bp OR sbp) ”. The full MEDLINE search strategy is given in Figure 7. 
3.4.2 Study selection 
No language restriction was applied. The electronic search was complemented by hand-
searching the reference lists of included studies. All titles and abstracts were examined to 
retrieve potentially relevant studies. I applied inclusion/exclusion criteria and selected the 








Figure 7. Full search strategy for MEDLINE database. 
 
 
1. exp Cohort Studies/   
2. (Cohort analy* or longitudinal or prospective or retrospective or ((cohort or follow up) adj (study or 
studies))).ti,ab. 
3. 1 or 2 
4. Depression/ or exp Depressive Disorder/  
5. depress*.ti,ab. 
6. 4 or 5 
7. adolescent/ or young adult/ or exp child/ or exp infant/  
8. (adolescen* or “young person” or “young people” or child or children or childhood or infant or “early 
adult*” or youth* or teen*).ti,ab. 
9. 7 or 8 
10. exp Cardiovascular Diseases/  
11. cardiovascular.ti,ab. 
12. 10 or 11 
13. exp Risk/  
14. risk.ti,ab. 
15. 13 or 14 
16. 12 and 15 
17. ((cardiovascular or CVD or heart disease or cardiometabolic or coronary artery disease or CAD or 
atherosclerosis) adj3 risk).ti,ab. 
18. 16 or 17 
19. cholesterol/ or cholesterol, dietary/ or lipoproteins/ or exp lipoproteins, hdl/  
20. (“total cholesterol” or cholesterol or “high density lipoprotein*” or hdl).ti,ab. 
21. 15 or 16 
22. exp Smoking/ or Smokers/ or Non-Smokers/ or Ex-Smokers/  
23. smok*.ti,ab. 
24. 18 or 19 
25. body fat distribution/ or adiposity/ or body mass index/ or waist circumference/ or skinfold thickness/ or 
lipid accumulation product/  
26. (BMI or “body mass index” or “body fat distribution” or adiposity or “waist circumference” or WC or 
“skinfold thickness” or “lipid accumulation product” or LAP).ti,ab. 
27. 21 or 22  
28. Blood Pressure/  
29. (“systolic blood pressure” or “systolic BP” or SBP).ti,ab. 
30. 24 or 25 
31. 18 or 21 or 24 or 27 or 30  




3.4.3 Selection criteria 
Studies were included that: (i) had a longitudinal population-based cohort design 
(prospective or retrospective); (ii) included participants with a mean age of 24 years or 
younger at follow-up; (iii) had at least one of the five CVD risk factors (BMI, smoking, SBP, 
total cholesterol, HDL) as the exposure at baseline; (iv) used a validated tool to measure 
depression (binary outcome or symptom score) at follow-up; and (v) reported effect 
estimate(s) for the association between CVD risk and subsequent depression. Studies were 
excluded if they did not have an unexposed group for a particular risk factor (e.g. 
experimental smoking used as the comparison group rather than no smoking), had 
depression as the exposure and the CVD risk factor as the outcome, or measured 
depression comorbid with another mental illness such as bipolar disorder or anxiety.   
3.4.4 Data extraction 
Data extraction was performed independently by me, Natasha Daniels, and Diana Ples. Any 
disagreements were resolved by consensus. For each included study, we extracted the 
following data: (i) details of the cohort (country, name/setting, design, sample size, and 
follow-up length); (ii) assessment of exposure and outcome; (iii) age and sex of the included 
participants; and (iv) results of analysis (number of participants exposed at baseline, number 
of participants with depression at follow-up, adjusted/unadjusted effect estimates). When 
studies reported various methods for assessing the exposure or repeated measures of the 
exposure, we used the most comprehensive measure. For example one study measured 
BMI eight times from birth to age 12 years (306). We chose the measure at age 7 years old 
as the earliest age where BMI may be an appropriate measure of central adiposity to 
maximise the length of follow-up. In cases where there was more than one published report 
from the same population, we included the study with the larger sample size (307–310). 
Some studies reported results where depression at baseline was adjusted for as well as 
analysis where baseline depression cases were removed. To minimise the possibility of 
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reverse causality in such cases, we included results only where baseline depression was 
excluded.  
3.4.5 Data synthesis and meta-analysis 
Separate meta-analyses were performed for BMI (Hypothesis 1, Page 78), smoking 
(Hypothesis 2), and SBP (Hypothesis 3). Results from studies were pooled using the inverse 
variance method meaning that studies with larger sample sizes were given greater weight. 
Results for other CVD risk factors were summarised using a narrative review (Hypothesis 4, 
5). Meta-analyses were performed separately for studies that reported beta estimates i.e. for 
continuous depressive symptom outcomes, and odds ratios (ORs) i.e. for binary depression 
outcomes (Hypothesis 6). I used random-effect meta-analysis, which is appropriate where 
there is heterogeneity between the studies. Heterogeneity between studies was examined 
using the I2 statistic.   
I assessed publication bias by visual inspection of funnel plots, centred on the pooled effect 
estimates, and by Egger’s regression test for funnel plot asymmetry (mixed-effects meta-
regression model). This test indicates the existence of publication bias if the p-value is 
<0.05.   
Study quality was assessed using the Newcastle-Ottawa Scale for cohort studies (311). I 
repeated analyses after (i) removing poor quality studies and (ii) excluding studies with only 
female or male participants. Meta-analyses were carried out using the “meta” package 





3.5.1 Included studies 
Electronic search identified 6,617 publications (Figure 8) from which 1,795 duplicate reports 
were removed to leave 4,822 studies. After title and abstract screening 198 (4%) potentially 
eligible studies were identified, of which 29 met the inclusion criteria and were included in 
the systematic review (92,95–97,306–308,312–333). A total of 23 studies were included in 
meta-analysis. I excluded the remaining studies from meta-analysis because they were not 
comparable with the included studies; four studies measured BMI as a continuous variable 
(92,306,323,325) and three studies assessing smoking did not report comparable effect 
estimates (315,328,329).  
Table 3 shows key characteristics of the 29 included studies. Some of these studies included 
effect estimates for more than one CVD risk factor. In total, there were 17 studies of BMI, 14 
studies of smoking, and one study of SBP. There were no relevant studies of total 
cholesterol or HDL. All included studies were prospective in design, except for one which 
used a retrospective measure of depression at follow-up (324). The age at which CVD risk 
factors were measured or reported ranged from age 7 to 23 years old. The follow-up time for 
included studies ranged from three months to nine years. Studies of both sexes were 
generally well-balanced; the smallest percentage of females in a single study was 46% 
(330). The majority of the 29 included studies (55%) were rated as “good” quality (Table 4, 
Table 5). The five most commonly used confounders in adjusted analyses were: sex, age, 
parental education, race/ethnicity, and baseline depression (Figure 9). Only six studies 
(21%) did not control for or exclude baseline depression cases (Table 5).  
Based on data availability, meta-analysis for BMI included 13 studies (Hypothesis 1) (95–
97,314,316,318,320,321,324,326,330,332,333), and that for smoking included 11 studies 
(Hypothesis 2) (97,307,308,312,313,315,317,319,325,327–329,331,332). Meta-analysis for 
SBP included one study comprising two separate samples (Hypothesis 3) (322). As 
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previously mentioned, there were no studies of total cholesterol or HDL that met our 
inclusion criteria (Hypothesis 4, 5). Depression was the outcome in nine (69%) of the 
included BMI studies, eight (73%) of the smoking studies, and the SBP study (Hypothesis 6). 
Depressive symptoms was the outcome for five (38%) of the included BMI studies, and five 













































Figure 8. PRISMA flow diagram for study selection. 
Records identified through 
databases (N = 6,616) (MEDLINE 
(Ovid) = 3,054; Embase (Ovid) = 
3,219; PsycINFO = 343) 
Additional records identified 
through other sources (N = 1) 
Duplicates removed (N = 1,795) 
Title and abstract screening  
(N = 4,822) 
Records excluded as irrelevant  
(N = 4,624) 
Full-text articles assessed for 
eligibility (N = 198) 
Full-text articles excluded, with 
reasons (N = 169): 
Age >24 years = 68 
Cross sectional design = 36 
Depression as exposure = 20 
Other irrelevant exposure = 21 
Irrelevant outcome = 14 
Unvalidated depression measure = 
5 
No relevant analysis = 3 



































Studies included in qualitative 
synthesis (N = 29) 
Studies included in quantitative 
synthesis (meta-analysis)  
(N = 23) 
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Table 3. Characteristics of studies included in systematic review. 
Study a Country 











baseline – % 






up – mean 
(SD) 
BMI          
Boutelle 2010  USA 495 (100) c  13.5 1 





1.2–3.5  1.3–1.4 (0.4) 
Chang 2017 Taiwan 969 (51.2) 14.7  3 
Obese vs healthy 
weight  
F = 3.5%;  
M = 3.4%  
Self-report (CES-DC) - 
F = 1.8 (0.5);  
M = 1.5 (0.4) 
Clark 2007 UK 776 (51.3) 11–14 2 
Obese vs healthy 
weight 
19.6% Self-report (SMFQ) 15.1 - 
Eitle 2018 USA 
AI = 308 (47.0); 
W = 3,403 
(50.0) 
12-18 1 
Obese vs not 
obese 
AI = 19.0%;  
W = 11.0% 
Self-report (CES-D) - 
AI = 12.4 (0.6); 
W = 10.1 (0.2) 
Frisco 2013 USA 5243 (100) 15.7  4 
Consistently 
obese vs healthy 
weight 
9.8%  Self-report (CES-D) 7.0  - 
Gomes 2019 Brazil NM 18  4 








USA 4718 (48.6)  <20  1 
Obese vs not 
obese 




EPAD = 165 
(57.1); ALSPAC 
= 2,533 (52.1) 
EPAD = 9–17;  
ALSPAC = 11–
14 
EPAD = 1.4;  
ALSPAC = 2 
Standardised 
score  
EPAD = 17.4%;  
ALSPAC = 
23.7% 
EPAD = Semi-structured 
interview (CAPA);  
ALSPAC = Structured 
interview (DAWBA) 
EPAD = 8.3;  
ALSPAC = 1.6 
EPAD F = 2.2 
(NM); EPAD M 
= 1.6 (NM); 
ALSPAC = NM 
Marmorstein 
2014 
USA NM 11–14 6 
Obese vs not 
obese 
F = 14.7%;  
M = 10.7%  
Structured interview 
(SCID) 
F = 12.3;  




Netherlands 820 (53.3) 10–12 4 
Obese vs healthy 
weight 
14.1% 
Structured interview (WHO 
CIDI-3)  
5.6 - 





Italy 178 (78.1) 21.4  1 Raw score 21.1 (2.7)  Self-report (PHQ-2) - 1.1 (0.6) 
Pryor 2016 Canada 661 (54.1) 6–12 1 
Early-onset vs 
never overweight 
11.0% Self-report (Kovacs CDI) - NM 
Rhew 2008 USA 206 (46.2) 12 1 
Overweight vs 
healthy weight 
F = 22.4%;  
M = 30.3%  
Structured interview (MFQ) - NM 
Roberts 2013 USA 2,040 (48.9) c 11–17 1 
Obese vs healthy 
weight 
19.7% 
Structured interview (DISC 
IV-Y) 
1.7 - 
Wang 2014 b Hong Kong 2,793 (48.2) 7 7 
Standardised 
score 
F = -0.03 (1.1); 
M = 0.3 (1.3) 
Self-report (PHQ-9) - 4.0 (NM) 





(Diagnostic Interview for 
Mental Disorders Research 
Version) 
6.5  - 
Smoking          
Albers 2002 USA 259 (49.6) c 12–15 4 
Ever vs never 
smoker 
33.9% 
Self-report (Kandel & 
Davies) 
13.2 - 
Bares 2014 USA 2,486 (53.0) c 16.6  5.5 
Unit increase in 
cigarette use 
31.3% Self-report (CES-D) - 4.9 (3.9) 
Beal 2014 USA 262 (100) 11–20 2 
Ever vs never 
smoker 
2.9 (3.1) Self-report (CDI/BDI) - 46.3 (10.8) 
Chaiton 2015 
b 
Canada 416 (49.7) 12–13 5 
Smoking initiation 









Self-report (Kandel & 
Davies) 
11.5 - 
Clark 2007 UK 776 (51.3) 11–14 2 
Tried/regular vs 
never smoker 
35.2% Self-report (SMFQ) 15.1 - 
Duncan 2005 USA 6,748 (51.6) 11–21 1 
Smoker vs non-
smoker 
F = 25.8%;  
M = 25.3%  
Self-report (CES-D) 
F = 27.0;  
M = 21.4 
F = 13.0 (8.7); 
M = 10.8 (7.5) 
Gage 2015 UK NM 16 2 
Unit increase in 
cigarette use  
9.8% Self-report (CIS-R) 7.2 - 
88 
 
Raffetti 2019 Sweden 1,636 (51.2) 13–14 1 
Current vs non-
smoker 




Finland 2,358 (50.3) c 14  3 
Regular vs never 
smoker 




Finland 2,174 (51.8) c 17.5  5 
Ever vs never 
smoker 
25.3% Self-report (GBI) 4.5 (4.7) - 
Rubio 2008 USA 278 (100) 23  0.25 
Smoker vs non-
smoker 
72.0% Self-report (CES-D) 85.0 - 
Piumatti 2018 Italy 178 (78.1) 21.4  1 
Daily vs non-
smokers 
13.6% Self-report (PHQ-2) - 1.1 (0.6) 





(Diagnostic Interview for 
Mental Disorders Research 
Version) 
6.5 - 








EPAD = 9–17;  
ALSPAC = 11–
14 
EPAD = 2.5;  
ALSPAC = 3 
Standardised 
score 




EPAD = Semi-structured 
interview (CAPA);  
ALSPAC = Structured 
interview (DAWBA) 
EPAD = 8.5;  
ALSPAC = 1.6 
- 
a ALSPAC: Avon Longitudinal Study of Parents and Children; AI: American Indian ethnicity; BDI: Beck’s Depression Inventory; BMI: body mass index; CAPA: Child and Adolescent Psychiatric 
Assessment (Child Version); CDI: Children’s Depression Inventory; CES-D: Centre for Epidemiological Studies Depression; CIS-R: Clinical Interview Schedule Revised; DAWBA: Development 
and Wellbeing Assessment (Child Version); DISC IV-Y: Diagnostic Interview Schedule for Children for direct administration to children or adolescents; DSM: Diagnostic and Statistical Manual of 
Mental Disorders; DSS: depressive symptoms score; EPAD: Early Prediction of Adolescent Depression study; F: female; GBI: General Behaviour Inventory; ICD-10: International Classification of 
Diseases-10; K-SADS: Kiddie Schedule for Affective Disorders and Schizophrenia; M: male; MFQ: Mood and Feelings Questionnaire; MINI-5: Mini International Neuropsychiatric Interview-5; NM: 
not mentioned; NS: not significant; PHQ: Patient Health Questionnaire; SBP: systolic blood pressure; SCID: Structured Clinical Interview for DSM-III-R; SD: standard deviation; SMFQ: Short 
Mood and Feelings Questionnaire; W: White ethnicity; WHO CIDI-3: World Health Organisation Composite International Diagnostic Interview-3.   
b Not included in meta-analysis. The four studies not included in BMI meta-analysis were excluded because they measured BMI as a continuous variable. The three studies not included in 
smoking meta-analysis were excluded because they did not report effect estimates comparable with the other studies.  
c Baseline sample only.  
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(out of 4) 
Comparability  
(out of 2) 
Outcome  
(out of 3) 
Total Rating 
Albers 2002 4 2 2 8 Good 
Bares 2014  3 2 2 7 Good 
Beal 2014  2 2 3 7 Fair 
Boutelle 2010  3 1 3 7 Good 
Chaiton 2015  3 2 2 7 Good 
Chang 2017  2 2 3 7 Fair 
Choi 1997  3 2 3 8 Good 
Clark 2007 3 2 2 7 Good 
Duncan 2005  3 2 1 6 Poor 
Eitle 2018 2 2 3 7 Fair 
Frisco 2013 4 2 3 9 Good 
Gage 2015 3 1 2 6 Good 
Gomes 2019 4 1 2 7 Good 
Goodman 2002 2 2 2 6 Fair 
Hammerton 2014 a 3 / 4 0 3 / 2 6 Poor 
Hammerton 2013 a 3 / 4 0 3 / 2 6 Poor 
Marmorstein 2014 3 0 2 5 Poor 
Monshouwer 2012 3 1 3 7 Good 
Perry 2020  3 1 2 6 Good 
Piumatti 2018  1 2 1 4 Poor 
Pryor 2016  3 1 2 6 Good 
Raffetti 2019  3 1 2 6 Good 
Ranjit, Buchwald 2019  1 2 2 4 Poor 
Ranjit, Korhonen 2019 1 2 1 5 Poor 
Rhew 2008  1 1 3 5 Poor 
Roberts 2013  4 2 2 8 Good 
Rubio 2008  2 2 2 6 Fair 
Wang 2014  3 2 2 7 Good 
Zhang 2018  3 1 2 6 Good 
a Score for EPAD study given first followed by score for ALSPAC study. 
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Cohort type – no. studies (%)  
Prospective  28 (96.6) 
Retrospective 1 (3.4) 
Location – no. studies (%)  
North America 15 (51.7) 
Europe 11 (37.9) 
Asia 2 (6.9) 
South America 1 (3.4) 
Sex – no. studies (%)  
Female and male 24 (82.8) 
Female only 5 (17.2) 
Exposure – no. studies (%) a    
Body mass index 17 (58.6) 
Smoking 14 (48.3) 
Systolic blood pressure 1 (3.4) 
Total cholesterol 0 (0) 
High-density lipoprotein 0 (0) 
Mean (SD)  
Follow-up length (years) 2.9 (2.1) 
Sample size (no. participants) 3,208 (3,004) 
Baseline depression – no. studies (%)   
Controlled for / excluded 23 (79.3) 
No action 6 (20.7) 
Regression type – no. studies (%) a  
Logistic 19 (65.5) 
Linear 14 (48.3) 
NOS quality rating – no. studies (%)  
Good 16 (55.2) 
Fair 5 (17.2) 
Poor 8 (27.6) 




Other confounders used <2 times in included studies: family functioning, availability of social support, family 
economic stress, stressful life events, urban dwelling, birthplace, parenthood/ever pregnant, diet, parental BMI, 
maternal age, maternal mental health, mental health problems other than depression, family history of 
depression, alcoholic parent, cannabis use, peer smoking, impulsivity, rebelliousness, IQ, tiredness/sleep 
problems, interleukin-6 concentration. 
 




3.5.2 Meta-analysis of adjusted and unadjusted effect estimates 
The analyses in this section are relevant to hypotheses 1, 2, 3, and 6 (Section 3.3, Page 78). 
Hypotheses 4 and 5 could not be tested due to a lack of applicable studies.  
3.5.2.1 Longitudinal association between high BMI at baseline and risk of depression 
at follow-up 
Based on seven studies reporting an adjusted OR, comprising a total of 15,753 participants, 
the pooled OR for depression at follow-up associated with high BMI (>25) at baseline was 
1.61 (95% CI = 1.21, 2.14) (Figure 10). There was limited evidence of heterogeneity 
between studies (I2 = 31%; 95% CI = 0%, 71%; Cochran’s Q = 8.7; p = 0.19).  
Based on six studies reporting an unadjusted OR, comprising a total of 21,025 participants, 
the pooled OR for depression at follow-up associated with high BMI at baseline was 1.39 
(95% CI = 0.98, 1.97) (Figure 11). There was evidence of heterogeneity between studies (I2 











 Figure 10. Meta-analysis of longitudinal association between high BMI at baseline 




Figure 11. Meta-analysis of longitudinal association between high BMI at baseline and 




3.5.2.2 Longitudinal association between smoking at baseline and risk of depression 
at follow-up 
Based on eight studies reporting an adjusted OR, comprising a total of 30,539 participants, 
the pooled OR for depression at follow-up associated with smoking at baseline was 1.73 
(95% CI = 1.36, 2.20) (Figure 12). There was evidence of heterogeneity between studies (I2 
= 74%; 95% CI = 52%, 86%; Cochran’s Q = 35.3; p <0.01).  
Based on seven studies reporting an unadjusted OR, comprising a total of 23,398 
participants, the pooled OR for depression at follow-up associated with smoking at baseline 
was 1.88 (95% CI = 1.42, 2.50) (Figure 13). There was evidence of heterogeneity between 
studies (I2 = 84%; 95% CI = 68%, 92%; Cochran’s Q = 36.75; p <0.01).  
 
 
Figure 12. Meta-analysis of longitudinal association between smoking at baseline and 




Figure 13. Meta-analysis of longitudinal association between smoking at baseline and 
subsequent depression in young people (unadjusted models). 
 
3.5.2.3 Longitudinal association between SBP at baseline and risk of depression at 
follow-up 
One study examined associations of both low and high SBP with depression in two separate 
samples comprising a total of 5,111 participants. Meta-analysis of these studies suggest 
depression at follow-up is associated with low SBP at baseline (adjusted OR = 3.32; 95% CI 
= 1.68, 6.55), but not with high SBP at baseline (adjusted OR = 0.82; 95% CI = 0.55, 1.22) 
(Figure 14). There was some evidence of heterogeneity for high SBP (I2 = 66%; 95% CI = 
0%, 92%; Cochran’s Q = 3.0; p = 0.08) and little heterogeneity for low SBP (I2 = 0%; 95% CI 












ALSPAC: Avon Longitudinal Study of Parents and Children; EPAD: Early Prediction of Adolescent Depression 
study; SBP: systolic blood pressure. * Subset of ALSPAC participants with mothers with recurrent depression. † 
EPAD participants have a mother and/or father with recurrent depression. 
 
Figure 14. Meta-analysis of longitudinal association between SBP at baseline and 
subsequent depression in young people (adjusted models). 
 
3.5.2.4 Longitudinal association between high BMI at baseline and depressive 
symptoms at follow-up 
Based on five studies reporting an adjusted beta estimate, comprising a total of 11,516 
participants, the standardised mean difference (SMD) for an increase in depressive 
symptoms at follow-up associated with high BMI at baseline was 0.05 (95% CI = –0.08, 
0.18) (Figure 15). There was evidence of heterogeneity between studies (I2 = 71%; 95% CI = 
34%, 88%; Cochran’s Q = 17.5; p <0.01).  
3.5.2.5 Longitudinal association between smoking at baseline and depressive 
symptoms at follow-up 
Based on five studies reporting an adjusted beta estimate, comprising a total of 21,490 
participants, the SMD for an increase in depressive symptoms at follow-up associated with 
smoking at baseline was 0.37 (95% CI = 0.10, 0.64) (Figure 15). As above, there was 
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evidence of heterogeneity between studies (I2 = 89%; 95% CI = 78%, 94%; Cochran’s Q = 
44.8; p <0.01).  
 
   
Figure 15. Meta-analysis of longitudinal association between high BMI/smoking at 
baseline and subsequent depressive symptoms in young people (adjusted models). 
 
3.5.3 Results for sensitivity analysis  
3.5.3.1 Longitudinal association between high BMI at baseline and risk of depression 
at follow-up 
After excluding three studies containing only female participants (314,318,332), the adjusted 
pooled OR for depression at follow-up for high BMI at baseline was 1.43 (95% CI = 0.94, 
2.18) (Figure 10). There was some heterogeneity between studies (I2 = 47%; 95% CI = 0%, 
83%; Cochran’s Q = 5.7; p = 0.13). The adjusted pooled OR for the three female only 
studies was 1.97 (95% CI = 1.37, 2.83) (Figure 10). There was little heterogeneity between 
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studies (I2 = 0%; 95% CI = 0%, 60%; Cochran’s Q = 0.52; p = 0.77). There were no studies 
excluded based on quality assessment. 
3.5.3.2 Longitudinal association between smoking at baseline and risk of depression 
at follow-up 
After excluding four studies containing only female or male participants (307,317,331,332), 
the pooled adjusted OR for depression at follow-up for smoking at baseline was 1.23 (95% 
CI = 1.02, 1.49) (Figure 12). There was little heterogeneity (I2 = 11%; 95% CI = 0%, 86%; 
Cochran’s Q = 3.4; p = 0.34). The adjusted pooled OR for the four female only studies was 
2.02 (95% CI = 1.69, 2.42) (Figure 12). There was little heterogeneity between studies (I2 = 
0%; 95% CI = 0%, 81%; Cochran’s Q = 2.43; p = 0.49). 
After excluding one study based on quality assessment (307), the pooled adjusted OR for 
depression at follow-up for smoking at baseline was 1.48 (95% CI = 1.21, 1.80) (Figure 16). 
There was some heterogeneity between studies (I2 = 38%; 95% CI = 0%, 73%; Cochran’s Q 
= 11.3; p = 0.12).  
 
 
Figure 16. Meta-analysis, after studies removed based on quality assessment, of 
longitudinal association between smoking at baseline and subsequent depression in 
young people (adjusted models). 
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3.5.3.3 Longitudinal association between high BMI at baseline and depressive 
symptoms at follow-up 
After excluding one study containing only female participants (314), the pooled adjusted 
SMD for an increase in depressive symptoms at follow-up associated with high BMI at 
baseline was –0.03 (95% CI = –0.07, 0.00) (Figure 17). There was no evidence of 
heterogeneity between studies (I2 = 0%; 95% CI = 0%, 72%; Cochran’s Q = 2.92; p = 0.57).  
After excluding one study based on quality assessment (330), the pooled adjusted SMD for 
an increase in depressive symptoms at follow-up associated with high BMI at baseline was 
0.08 (95% CI = –0.08, 0.23) (Figure 18). There was evidence of heterogeneity between 
studies (I2 = 77%; 95% CI = 43%, 90%; Cochran’s Q = 17.16; p <0.01).  
3.5.3.4 Longitudinal association between smoking at baseline and depressive 
symptoms at follow-up 
After excluding two studies containing only female or male participants (307,313), the pooled 
adjusted SMD for an increase in depressive symptoms at follow-up associated with smoking 
at baseline was 0.09 (95% CI = –0.16, 0.34) (Figure 17). There was evidence of 
heterogeneity between studies (I2 = 79%; 95% CI = 32%, 93%; Cochran’s Q = 9.37;              
p <0.01).   
After excluding two studies based on quality assessment (307,325), the pooled adjusted 
SMD for an increase in depressive symptoms at follow-up associated with smoking at 
baseline was 0.11 (95% CI = –0.18, 0.40) (Figure 18). There was evidence of heterogeneity 








Figure 17. Meta-analysis, after female or male only studies removed, of longitudinal 
association between high BMI/smoking at baseline and subsequent depressive 




Figure 18. Meta-analysis, after studies removed based on quality assessment, of 
longitudinal association between high BMI/smoking at baseline and subsequent 
depressive symptoms in young people (adjusted models). 
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3.5.5 Publication bias 
Based on Egger’s test and funnel plots, evidence for publication bias was not present for 
studies reporting adjusted association between high BMI and depression (Egger’s test p = 
0.17 (Figure 19), smoking and depression (Egger’s test p = 0.80) (Figure 20) or high BMI 
and depressive symptoms (Egger’s test p = 0.35) (Figure 21). Evidence for publication bias 
was present for studies reporting the adjusted association between smoking and depressive 














Figure 19. Adjusted OR (SE) of longitudinal association between high BMI at baseline 



















Figure 20. Adjusted OR (SE) of longitudinal association between smoking at baseline 



























Figure 21. Adjusted SMD (SE) of longitudinal association between high BMI at 



























Figure 22. Adjusted SMD (SE) of longitudinal association between smoking at 
baseline and subsequent depressive symptoms in young people.  




Depression and CVD are associated with each other in mid- to late-adulthood. While 
depression is known to arise commonly in young people, the timing of the association with 
CVD risk is unclear and common risk factors for the two conditions raise the prospect of joint 
prevention. To the best of my knowledge, this is the first systematic review to consider the 
association between various CVD risk factors and subsequent depression in young people.  
There are four key findings from this study: (i) BMI and smoking are the most well-studied 
risk factors for depression in this age group; (ii) both BMI and smoking at baseline are 
longitudinally associated with subsequent depression; (iii) smoking but not BMI is 
prospectively associated with depressive symptoms; and (iv) currently there is limited data 
on longitudinal associations of high SBP and cholesterol with subsequent depression in 
young people, which should be examined in future. These findings are consistent with 
hypotheses 1 and 2 (Section 3.3, Page 78) i.e. that high BMI and cigarette smoking are 
independently associated with depression in young people. There was insufficient data to 
test hypotheses 3 to 5 i.e. that high SBP, high total cholesterol, and low HDL are 
independently associated with depression in young people. Hypothesis 6, that CVD risk 
factors are similarly associated with depression and depressive symptoms, requires further 
assessment, since results for high BMI and smoking are difficult to compare in this context.  
Our results suggest that obesity and smoking could be risk factors for depression in young 
people. The pooled OR of 1.61 for the association of high BMI and depression is remarkably 
similar to previous studies in adults. Previous meta-analyses have reported ORs of 1.51 and 
1.70 for the prospective association between childhood high BMI and adult depression 
(94,334). Another meta-analysis reported that obese adolescents had a 40% increased risk 
of being depressed as adults (86). A recent Mendelian randomisation study using data from 
812,000 adult participants also found that fat mass could be a causal factor for depression 
(335). I did not find an association between high BMI and depressive symptoms score, 
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indicating a possibly non-linear association between BMI and depression whereby 
association is restricted to only those with more severe symptoms.  
Our findings also suggest smoking could be a risk factor for depression in young people. The  
pooled OR of 1.73 for the association between smoking and depression is consistent with a 
previous meta-analysis in adults, which reported an OR of 1.62 (336). Similarly, a meta-
analysis of nine cross-sectional and longitudinal studies found that adolescents exposed to 
second-hand smoking had increased odds of depression (103). However, current evidence 
from observational cohort studies and genetic Mendelian randomisation studies reports 
mixed findings regarding the association between smoking and depression, with some 
reporting an association (337) and others no association (338,339). Therefore, residual 
confounding or reverse causality remain viable explanations for the observed association 
between smoking and depression. Further longitudinal studies and genetic Mendelian 
randomisation studies are required to investigate this issue. 
A number of potential mechanisms may be involved in the association of high BMI and 
subsequent depression including low-grade systemic inflammation, HPA axis dysregulation, 
insulin resistance, and psychological distress. Inflammation is evident in around 25% of 
individuals with depression (171) and atypical depression is associated with inflammation 
and metabolic dysregulation (340,341). Adipose tissue also contains abundant inflammatory 
cytokines that are involved in fat metabolism (342). Similarly, the role of insulin in regulating 
adipocyte function contributes to the close link between insulin resistance and obesity (343). 
Furthermore, melancholic depression, higher levels of abdominal fat, HPA axis hyperactivity 
and cortisol dysregulation are inter-related (340,341,344). Adverse childhood experiences 
are also one of the most robust risk factors for depression (345), and are associated with 
increased risk of obesity and metabolic dysregulation (346). Low-grade systemic 
inflammation may be important to the association between smoking and depression (166). 
Studies are required to investigate the complex mechanisms that may underlie the 
association between high BMI and depression. 
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Low SBP, but not high SBP, appeared to be associated with risk of depression in young 
people. However, this meta-analysis was based on only two cohorts at high risk of 
depression and further work is required. Low SBP appears to be associated with depression 
in young people at high-risk of depression but not in the general population (322). Low SBP 
has also been associated with depression in cross-sectional and longitudinal studies of 
middle-aged and elderly adults (347,348). Conversely, higher SBP has been prospectively 
associated with fewer depressive symptoms in older adults with CVD risk factors (349). In 
adult populations, the relationship between SBP and depression may be independent of a 
range of lifestyle factors, age, and sex (347,348).  
The reason why low SBP has a potentially causal role in depression remains unclear. 
Neurons controlling blood pressure could be implicated in the association between SBP and 
depression. Neuropeptide Y, for example, reduces blood pressure and is involved in stress 
responses that have been linked to increased risk of depression, such as the HPA axis 
(347,350). Further research is required to understand the relationship between SBP and 
depression in young people, including potential mechanisms.   
There were no studies assessing the association of either total cholesterol or HDL with the 
risk of subsequent depression in young people. A meta-analysis of 30 cross-sectional 
studies reported that higher total cholesterol was associated with lower levels of depression 
in adults (351). Evidence from adults indicates both higher and lower HDL to be associated 
with increased risk of depression in adults. In a meta-analysis of 16 cross-sectional studies, 
high HDL was related to higher levels of depression, especially in women (351). Conversely, 
a meta-analysis of 11 case-control studies reported that lower HDL levels may be associated 
with first-episode MDD in adults (352). Given that abnormal HDL, LDL and triglyceride levels 
are increasingly common in adolescents (353), effort should be made to study potential 





Strengths of this work include the systematic literature search which identified a large 
number of relevant studies comprising a total of 93,021 participants. I included studies 
considering the effect of various CVD risk factors on either binary or continuous measures of 
depression/depressive symptoms. The studies were assessed using the validated 
Newcastle-Ottawa Scale and sensitivity analyses were conducted to examine the robustness 
of our findings. However, this study is not without limitations.  
First, the majority of studies came from North America and Europe, limiting the 
generalisability of the results to other parts of the world. The number of studies in each of the 
meta-analyses was also relatively small, which resulted in wide confidence intervals for the 
pooled effect estimates, and reduced the statistical power to detect publication bias. There 
was a considerable amount of heterogeneity between studies, particularly studies of 
depressive symptoms. Sensitivity analyses revealed that sex explained heterogeneity in 
some of the meta-analyses. However, stratifying by sex decreased the sample size, and 
consequently, statistical power to detect an association. In future, studies with larger 
samples are required. Finally, the possibility of residual confounding by unidentified factors 
remains high so any conclusion regarding causality should be interpreted with caution. 
Although studies included in this meta-analysis controlled for various potential confounding 
effects, other factors may also explain these associations. Further research is needed to 
examine whether observed associations are likely to be causal. Since randomised controlled 
trials are neither feasible nor ethical for some of the exposures under investigation (e.g. 
smoking, obesity), genetic approaches to dealing with residual confounding, such as 






In summary, I present evidence for a longitudinal association between CVD risk factors, 
namely high BMI and smoking, in childhood/adolescence and subsequent depression in 
young people. These risk factors could be important targets for prevention of depression and 
CVD in young people and subsequently during the life course. Further work is needed to 
understand potential mechanisms for these associations as well as the relationship between 







SECTION C: ANALYSIS OF ALSPAC DATA 
 
Chapter 4: Direction of Association between CVD Risk and 







































Figure 23. Visual summary of Chapter 4.
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4.2 Introduction  
 
Depression and CVD commonly co-occur and are bidirectionally associated in adults. 
Depression is associated with increased risk of CVD after adjusting for smoking and 
hypertension (295). Risk of depression is increased after acute myocardial infarction 
(354,355). It is also a marker of poor prognosis for myocardial infarction (296). Therefore, 
these conditions are likely to share risk factors and pathophysiologic mechanisms (293,294). 
Genome-wide association studies and epidemiological studies have reported relatively small 
genetic correlation between depression and CVD (294,300,356), suggesting that shared 
environmental risk factors are key to this comorbidity. 
Despite a large number of studies testing the links CVD and depression in adults, the 
association between CVD risk factors and depression in young people remains poorly 
understood. Existing studies of CVD risk factors and depression in young people have often 
focused on individual risk factors. Current/past smoking has been linked with increased risk 
of depression in longitudinal studies of adolescents (307,317,357). Longitudinal studies have 
also reported an association between high BMI and subsequent depression in both girls and 
boys (318,320,324,332). One study reported association between SBP and depression only 
in children/adolescents with parental history of depression (322). No obvious link between 
total cholesterol and depression has been found in adolescents (358). However, studies of 
other CVD risk factors, such as HDL, low-density lipoprotein (LDL) and triglycerides, and 
depression in young people are lacking.  
While the concept of a composite CVD risk score for adults is well established in clinical 
practice (359), to my knowledge, no study has considered a variety of CVD risk factors in 
adolescents to determine their combined effect on subsequent mental health outcomes in 
young people. Rarer still are studies testing the direction of association between CVD risk 
and depression in young people. This work is important as this may provide clues regarding 
the origin of the comorbidity between CVD and depression. Studies based on young people 
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are particularly advantageous as this age group is relatively less affected by confounders 
commonly present in older people, such as physical multi-morbidity. 
Childhood determinants of adult CVD risk include a range of physical and social factors. The 
International Childhood Cardiovascular Cohort (i3C) Consortium was established to identify 
early-life risk factors associated with ideal cardiovascular health as defined by the AHA 
(360). A study of three i3C cohorts explored the association of the following factors with adult 
CVD risk: sex, age, ethnicity, family socioeconomic status, smoking, smoking, diet, BMI, 
SBP, HDL, LDL, and triglycerides (361). This study reported that family socioeconomic 
status and smoking in childhood were independently associated with adult cardiovascular 
health (361). Socioeconomic status and smoking are key indicators of social factors related 
to long term health outcomes, so called social determinants of health, which have been 
linked to depression in other studies (362).  
In addition to social factors, which are important determinants of physical and mental health, 
biological processes could represent important shared mechanisms for CVD risk and 
depression. Inflammation could be one such mechanism, which is associated with both 
depression and CVD in adults. Using Mendelian randomisation analysis of data from the UK 
Biobank cohort, members of my lab group recently reported that inflammation and 
triglycerides could be shared risk factors for depression and IHD (294). Circulating markers 
of inflammation such as IL-6 and CRP are associated with depression and CVD in adults 
(63,168,363,364). Demonstrating an association between systemic inflammatory markers in 
childhood and subsequent CVD risk in young people would support the idea that childhood 
inflammation could be a shared mechanism for CVD and depression, but such studies are 
scarce. 
Using prospective data from ALSPAC (272), I investigated the directionality and potential 
mechanism of association between a range of CVD risk factors and depression in young 
people (Figure 24). Regarding direction of association, I have tested: (i) association between 
CVD risk score at age 15 years and depressive symptoms at age 18 years; and (ii) 
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association between depressive symptoms at age 12 years and CVD risk score at age 15 
years. I hypothesised that similar to adults there will be evidence for bidirectional association 
between CVD risk score and depression in young people. Regarding mechanism of 
association, I have tested associations of IL-6 and CRP levels at age 9 years with 
depressive symptoms at age 12 years and with CVD risk score at age 15 years. In addition, I 
tested the mediating effect of CVD risk score at age 15 years on the association between 
inflammatory markers at age 9 years and depressive symptoms at age 18 years. In line with 
the idea that inflammation could be a shared mechanism for depression and CVD, I 
hypothesised that childhood inflammatory markers would be associated with CVD risk score 
subsequently in mid-adolescence, and that childhood inflammatory markers increase 




































Objective 1: Direction of 
association between CVD risk 
and depressive symptoms. 
Objective 2: Childhood 
inflammation as a shared 
mechanism for CVD risk 





4.3 Hypotheses  
 
1. Depressive symptoms at age 12 years are associated with CVD risk at age 15 years. 
2. CVD risk at age 15 years is associated with depressive symptoms at age 18 years. 
3. IL-6 at age 9 years is associated with depressive symptoms at age 12 and 18 years. 
4. CRP at age 9 years is associated with depressive symptoms at age 12 and 18 years. 
5. IL-6 at age 9 years is associated with CVD risk at age 15 years. 
6. CRP at age 9 years is associated with CVD risk at age 15 years. 
7. CVD risk at age 15 years mediates the association between IL-6 at age 9 years and 
depressive symptoms at age 18 years. 
8. CVD risk at age 15 years mediates the association between CRP at age 9 years and 
depressive symptoms at age 18 years.  
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4.4 Methods  
 
4.4.1 Description of sample  
The primary risk set for this study comprised 5,007 unrelated individuals from the ALSPAC 
cohort with CVD risk scores computed after imputation of missing data for individual risk 
factors (Figure 25). Of the risk set 3,462 participants completed assessments at age 18 
years for depressive symptoms. I repeated the analyses based on 1,810 participants with 
complete original data on all CVD risk factors. 
 




4.4.2 Assessment of CVD risk factors at age 15 years  
CVD risk factors were selected based on the AHA criteria for ideal cardiovascular health 
(29). The CVD risk score included: age, ethnicity, maternal SEP, maternal smoking, own 
smoking, physical activity, BMI, SBP, LDL, HDL, and triglycerides. All variables were 
measured at age 15 years, except ethnicity, maternal smoking, and maternal SEP which 
were assessed at birth.  
Age (years) was used as a continuous variable. Self-reported ethnicity was originally coded 
as White, Black African, Black Caribbean, Black Other, Bangladeshi, Chinese, Indian, 
Pakistani, and Other. Ethnicity was recoded as a binary variable (0 = White; 1 = any other 
ethnicity) due to low counts for ethnicities other than White. Self-reported maternal SEP was 
documented using Office of National Statistics categories (365). Maternal SEP was recoded 
as a binary variable (0 = non-manual [I, II or IIIa]; 1 = manual [IIIb, IV or V]). Members of the 
armed forces (N = 4) were excluded because this category was so small.  
Mothers self-reported frequency of smoking during the first three months of pregnancy and 
again during the last two months of pregnancy (no cigarettes per day; 1 to 4 cigarettes per 
day; 5 to 9 cigarettes per day; 10 to 14 cigarettes per day; 5 to 19 cigarettes per day; 20 to 
24 cigarettes per day; 25 to 29 cigarettes per day; ≥30 cigarettes per day). Maternal smoking 
was used as a binary variable (0 = non-smoker at both time points; 1 = smoker at one or 
both time points). Own smoking was self-reported during the child-completed questionnaire 
and coded as an ordered categorical variable (no cigarettes/day; 1 to 5 cigarettes per day; 6 
to 10 cigarettes per day; >10 cigarettes per day). Own smoking was also used as a binary 
variable (0 = non-smokers; 1 = smokers).  
Participants self-reported frequency of physical activity during the past year (5 or more times 
per week; 1 to 4 times per week; 1 to 3 times per month; <1 time per month). A binary 
measure of weekly exercise was created for analysis (0 = exercise at least once per week; 1 
= exercise less than weekly).  
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BMI, SBP, HDL, LDL, and triglycerides were all used as standardised continuous variables. 
To calculate BMI, weight was measured on Tania scales and height was measured using a 
Harpenden stadiometer. SBP was taken twice using a Dinamap 9301 Vital Signs Monitor 
(Morton Medical, London) and the mean of the two measurements was used in analysis. 
HDL, LDL and triglyceride concentrations were measured from fasting blood test as 
previously described (366).  
4.4.3 Assessment of depressive symptoms at age 12 years  
Depressive symptoms were self-reported using the Short Mood and Feelings Questionnaire 
(SMFQ) (367) at age 12 years. The SMFQ is an age-appropriate, widely used and validated 
tool. It comprises 13 items covering core symptoms of depression and anxiety experienced 
in the past two weeks. Each item is scored 0 (not true), 1 (sometimes true) or 2 (true) giving 
a total score of 0 to 26. Depressive symptoms score was used as a standardised continuous 
variable. 
4.4.4 Assessment of depressive symptoms at age 18 years  
Depressive symptoms were measured using a self-administered computerised version of the 
Clinical Interview Schedule Revised (CIS-R) (368,369). The CIS-R is a widely used, fully-
structured assessment for measuring depression in large community samples (369). The 
CIS-R includes questions about a range of symptoms including depression, depressive 
thoughts, fatigue, concentration, and sleep problems. CIS-R sums these symptoms scores 
to provide a total depressive symptoms score (0 to 21), reflecting the severity of depressive 
symptoms in the past week. Depressive symptoms score was used as a standardised 
continuous variable.  
CIS-R also provides diagnosis of depressive episode (mild, moderate, or severe) according 




4.4.5 Assessment of inflammatory markers at age 9 years  
IL-6 and CRP were assayed from the blood samples collected from non-fasting participants. 
The blood samples were spun and frozen at −80°C. After a median of 7.5 years in storage 
with no previous freeze-thaw cycles, IL-6 and CRP levels were measured by enzyme-linked 
immunosorbent assay (R&D Systems), and automated particle-enhanced 
immunoturbidimetric assay (Roche) respectively (168). IL-6 and CRP variables were log-
transformed for analysis. 
4.4.6 Assessment of potential confounders  
Using the modified disjunctive cause criteria (370), I selected the following confounders for 
adjustment: sex, birthweight, maternal education, Strengths and Difficulties Questionnaire 
(SDQ) total difficulties score at age 7 years, and family history of CVD. Variables in the CVD 
risk score were not included as confounders to prevent over-adjustment.  
Sex and birthweight were assessed at birth. Sex was coded as a binary variable. Birthweight 
(grams) was extracted from routine hospital birth records. Maternal education was self-
reported at 32 weeks gestation as a categorical variable reflecting highest educational 
attainment (CSE/none; vocational; O-level; A-level; university degree). Mothers completed 
the parental version of the SDQ when their child was age 7 years. The SDQ is an age-
appropriate, valid, and reliable tool for measuring psychological and behavioural problems in 
young children (371). It measures problems in four domains: emotional, conduct, 
hyperactivity, and social/peer group. Total difficulties score (0 to 40) was used as a 
standardised continuous variable. Family history of CVD (hypertension, diabetes, high 
cholesterol, or vascular disease) was self-reported by participants at the age 18 years clinic 
assessment as a binary variable.  
4.4.7 Statistical analysis   
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All analyses were carried out using R version 3.6.1.  
4.4.7.1 Imputation of CVD risk factors at age 15 years  
At least one CVD risk factor was available for 5,007 participants but complete CVD risk 
scores were available for only 1,810 participants. Analyses were conducted after imputation 
of missing data for CVD risk variables (ethnicity, maternal SEP, maternal smoking, own 
smoking, physical activity, BMI, SBP, LDL, HDL, and triglycerides). Age had no missing 
data. The percentage of missing data across the CVD risk factors varied between 2% and 
36% (Table 6).  
 
Table 6. Missing data in the risk set before imputation (N = 5,007). 
CVD risk factor a Missing data (no. participants) Missing data (%) 
Age (years) 0  0 
BMI (kg/m2) 84  1.7 
Ethnicity (White vs any other ethnicity) 152  3.0 
SBP (mmHg) 176  3.5 
Maternal smoking (no vs yes) 294 5.9 
Maternal SEP  
(non-manual vs manual) 
743  14.8 
Own smoking (no vs yes) 1,540 30.8 
Physical activity (weekly vs less than weekly) 1,588  31.7 
LDL (mmol/L) 1,823  36.4 
HDL (mmol/L) 1,823  36.4 
Triglycerides (mmol/L) 1,823  36.4 
Total missing data - 20.1 
a BMI: body mass index; CVD: cardiovascular disease; CI: confidence intervals; HDL: high-density lipoprotein; 
LDL: low-density lipoprotein; SBP: systolic blood pressure; SEP: socioeconomic position. 
 
I used the fully conditional MCMC method for multiple imputation of the CVD risk variables. I 
included auxiliary variables that were indicators of missingness (financial difficulties, life 




I used the “mice” package version 3.0 to create and analyse the multiply imputed datasets 
(277). Missing data were present in 20% of participants, so I used 20 imputations as 
recommended (372). I used predictive mean matching with 10 donors and type one 
matching. I separately estimated the parameters of interest in each dataset before 
combining using Rubin’s rules. 
4.4.7.2 Calculation of CVD risk score at age 15 years  
CVD risk factors were weighted based on their reported association with AHA ideal 
cardiovascular health from three i3C cohorts (Table 7) (360,361). I summed the weighted 
CVD risk factors and applied z-transformation to create a standardised CVD risk score. 
Seven i3C longitudinal cohort studies examine CVD risk factors in younger adults (360). The 
cohorts present beta estimates reflecting the association between CVD risk factors and AHA 
ideal cardiovascular health (29). One study combined three of these cohorts (Young Finns 
study, Childhood Determinants of Adult Health study, and the Princeton Follow-Up study) to 
give beta estimates for specific risk factors, adjusted for all other risk factors (361). Physical 
activity was adjusted for sex and age only. I used the relevant beta estimate(s) from this 
study as weights for our CVD risk factors (Table 7). I used fixed effects meta-analysis as 
appropriate to combine multiple beta estimates.  
I used BMI instead of waist circumference to match i3C cohort measurements (Figure 26). 
Sex and family history of CVD were excluded from the CVD risk score because they 
independently produced distinct binomial distributions when they were included. Female sex 
is strongly associated with worse mental health outcomes while male sex is associated with 
increased CVD risk score. Fruit and vegetable consumption was also measured in the i3C 




Table 7. Beta coefficients used as weights in the CVD risk score based on the association between risk factors from i3C Consortium 
cohorts and AHA ideal cardiovascular health. 
 
CVD risk factor a 
Beta (p-value) 
Beta coefficient used as weight in 
CVD risk score d YFS (N = 1668) CDAH (N = 1365) PFS (N = 659) 
Age (years) -0.04 (0.67) 0.06 (<0.01) 0.03 (0.09) 0.02 
Sex (female vs male) -1.06 (0.07) -0.99 (0.06) -0.83 (0.09) -0.98 
Ethnicity (White vs African American) b - - -0.16 (0.18) -0.16 
SEP 0.21 (<0.01) 0.13 (<0.01) 0.12 (<0.01) 0.09 e 
Parental smoking (no vs yes) -0.26 (<0.01) -0.10 (0.12) - -0.18 
Own smoking (no vs yes) - -0.38 (0.12) - -0.38 
BMI (kg/m2) -0.08 (0.42) -0.10 (<0.01) -0.07 (<0.01) -0.08 
SBP (per 10 mm/Hg) -0.09 (<0.01) - - -0.09 
LDL (mmol/l) -0.25 (<0.01) - -0.10 (0.09) -0.19 
HDL (mmol/l) - - 0.27 (0.09) 0.27 
Triglycerides (mmol/l) -0.17 (0.16) - -0.09 (0.45) -0.13 
Physical activity  0.01 (0.81) c -0.01 (0.24) c - -0.01 
a BMI: body mass index; CDAH: Childhood Determinants of Adult Health study; CVD: cardiovascular disease; LDL: low-density lipoprotein; HDL: high-density lipoprotein; 
PFS: Princeton Follow-up Study; SBP: systolic blood pressure; SEP: socioeconomic position; YFS: Young Finns Study. 
b Due to a lack of comparable published data from the UK, the i3C Consortium estimate for ethnicity (White vs African American) was interpreted as equivalent to White vs 
any other ethnicity. 
c Estimates adjusted for age and sex only. YFS (N = 1810) measured the variable as physical activity index whereas CDAH (N = 1417) measured the variable as physical 
activity hours per week. 
d Fixed effects meta-analysis used as appropriate to combine multiple estimates.  














All CVD variables refers to age, ethnicity, maternal socioeconomic position, maternal smoking, own smoking, physical activity, BMI/WC, systolic blood pressure, LDL, HDL, 
triglycerides, sex, and family history of CVD. 
 
Figure 26. Distribution of CVD risk score including BMI or waist circumference (WC) under different conditions.
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4.4.7.3 Direction of association between CVD risk and depressive symptoms 
I used linear regression to assess the stability of depressive symptoms at age 12 and 18 
years. Regression models were adjusted for sex, birthweight, maternal education, and SDQ 
total difficulties score at age 7 years.  
I used linear regression to assess the association between depressive symptoms at age 12 
years and CVD risk at age 15 years (Hypothesis 1, Page 116). Regression models were 
adjusted for sex, birthweight, maternal education, and family history of CVD. 
I used linear regression to assess the association between CVD risk at age 15 years 
(composite risk score and individual risk factors) and depressive symptoms at age 18 years 
(Hypothesis 2). Regression models were adjusted for sex, birthweight, maternal education, 
and SDQ total difficulties score at age 7 years. 
For continuous exposures, the beta estimates represent change in outcome (in SD) per one 
SD increase in exposure. For binary exposures, the beta estimates represent change in 
outcome (in SD) for presence of risk factor compared with its absence.  
4.4.7.4 Association of inflammatory markers at age 9 years with depressive symptoms 
at age 12 or 18 years  
Regression models were estimated before and after adjustment for sex, birthweight, 
maternal education, and total difficulties score at age 7 years. I used linear regression to 
assess the association between IL-6/CRP concentration at age 9 years and depressive 
symptoms at age 12 or 18 years (Hypothesis 3, 4). The beta estimates represent change in 
depressive symptoms (in SD) per unit increase in log-transformed IL-6/CRP values.  
4.4.7.5 Association of inflammatory markers at age 9 years with CVD risk score at age 
15 years  
Regression models were estimated before and after adjustment for sex, birthweight, 
maternal education, and family history of CVD. I used linear regression to assess the 
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association between IL-6/CRP concentration at age 9 years and CVD risk score at age 15 
years (Hypothesis 5, 6). The beta estimates represent change in CVD risk score (in SD) per 
unit increase in log-transformed IL-6/CRP values.  
4.4.7.6 Mediation analysis testing mediating effects of CVD risk score at age 15 years 
on the association between inflammatory markers at age 9 years and depressive 
symptoms at age 18 years 
I conducted mediation analysis to test whether CVD risk score at age 15 years mediates the 
relationship between IL-6/CRP at age 9 years and depressive symptoms at age 18 years 
(Hypothesis 7, 8). Mediation models were computed before and after adjustments for sex, 
birthweight, maternal education, and total difficulties score at age 7 years. I analysed 
mediation within a path analysis framework using the “lavaan” R package (283). Lavaan 
uses full information maximum likelihood procedures to handle missing data (283). Non-
parametric bootstrapping, based on 1,000 bootstrap replicates, was used to calculate SE.   
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4.5 Results  
4.5.1 Characteristics of the sample 
Individuals meeting the ICD-10 criteria for depression at age 18 years, compared with those 
without depression, were more likely be female, be smokers, have mothers who smoked, 
have higher SDQ total difficulties score at age 7 years, and have higher BMI and lower SBP 
at age 18 years (Table 8).  
4.5.2 CVD risk score at age 15 years  
Females had slightly higher CVD risk scores than males (Figure 27). In the complete case 
set, the mean CVD risk score for females was 0.02 (SD = 1.04) and for males was –0.02 
(SD = 0.95). After imputation (N = 5,007), the mean CVD risk score for females was 0.03 











Table 8. Characteristics of the participants prior to imputation and using maximum available sample for each variable. 
Characteristics a All participants (N = 5,007) c 
Without depression at 
age 18 (N = 3,208)  
With depression at 
age 18 (N = 254) d 
Difference between groups 
with and without depression 
at age 18 (T-test / X2 p-value) 
Potential confounders     
Sex – no. female (%) 2,639 (52.7) 1,725 (53.8) 189 (74.4) <0.001 
Birthweight (kg) – mean (SD) 3.4 (0.5) 3.4 (0.5) 3.4 (0.6) 0.66 
Total difficulties score at age 7 (SQD) – mean (SD) 7.3 (4.7) 7.1 (4.5) 7.9 (5.1) 0.01 
Maternal education – no. with less than O-level (%)  939 (19.3) 536 (17.1) 44 (17.7) 0.04 
Family history of CVD – no. (%) 1,080 (29.9) 902 (29.3) 80 (32.4) 0.32 
CVD risk factors b     
CVD risk score – mean (SD)   0.0 (1.0) -0.03 (1.0) -0.01 (1.0) 0.84 
Age (years) – mean (SD) 15.5 (0.3) 15.5 (0.3) 15.5 (0.3) 0.39 
BMI (kg/m2) – mean (SD) 21.4 (3.5) 21.3 (3.4) 21.8 (3.7) 0.03 
SBP (mmHg) – mean (SD) 122.9 (10.9) 123.1 (10.7) 121.2 (11.0) 0.01 
LDL (mmol/L) – mean (SD) 2.1 (0.6) 2.1 (0.5) 2.1 (0.6) 0.11 
HDL (mmol/L) – mean (SD) 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) 0.89 
Triglycerides (mmol/L) – mean (SD) 0.8 (0.4) 0.8 (0.4) 0.8 (0.3) 0.82 






Maternal SEP – no. manual (%) 642 (15.1) 404 (14.5) 33 (15.6) 0.67 
Maternal smoking – no. smokers (%) 751 (15.9) 428 (14.0) 56 (23.7) <0.01 
Own smoking – no. smokers (%) 409 (11.8) 250 (9.8) 43 (22.3) <0.001 
Physical activity – no. less than weekly exercise (%) 792 (23.2) 551 (22.0) 50 (26.6) 0.17 
Depressive symptoms     
SMFQ score at age 12 – mean (SD) 4.0 (3.8) 3.8 (3.7) 5.9 (4.9) <0.001 
CIS-R score at age 18 – mean (SD) 3.1 (3.9) 2.4 (2.9) 12.1 (3.3) <0.001 
Inflammatory markers     
IL-6 at age 9 (pg/mL) – mean (SD) 1.3 (1.6) 1.3 (1.5) 1.3 (1.4) 0.87 
CRP at age 9 (mg/L) – mean (SD) 0.8 (2.7) 0.7 (1.9) 1.0 (4.3) 0.38 
CRP at age 15 (mg/L) – mean (SD) 1.2 (3.8) 1.2 (3.6) 1.3 (3.7) 0.92 
a BMI: body mass index; CIS-R: Clinical Interview Schedule-Revised; CRP: C-reactive protein; CVD: cardiovascular disease; DAWBA: Development and Wellbeing Assessment; 
HDL: high-density lipoprotein; IL-6: interleukin-6; LDL: low-density lipoprotein; SBP: systolic blood pressure; SD: standard deviation; SDQ: Strengths and Difficulties 
Questionnaire; SEP: socioeconomic position; SMFQ: Short Mood and Feelings Questionnaire. 
b All CVD risk factors were assessed at age 15 years except ethnicity, maternal smoking, and maternal SEP which were assessed at birth. 
c Not all participants have information about depression at age 18 years. The total number of participants (N = 5004) is therefore greater than the combined number of participants 
with and without depression (N = 3462). 

















Figure 27. CVD risk score distribution at age 15 years (A) after imputation and (B) in complete cases. 
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4.5.3 Stability of depressive symptoms between ages 12 and 18 years  
In the total sample (N = 2,844), depressive symptoms at age 12 years were associated with 
depressive symptoms at age 18 years (adjusted beta = 0.18; SE = 0.01; p <0.001) (Table 9). 
Depressive symptoms at age 12 years were also associated with depressive symptoms in 
sex-stratified analyses. Similarly, depressive symptoms at age 12 and 18 years were 
positively correlated (r = 0.28; 95% CI = 0.24, 0.31; p <0.001).   
 
Table 9. Beta estimates (SE) for the association between depressive symptoms at age 
12 and 18 years. 
 
4.5.4 Direction of association between CVD risk and depressive symptoms 
The analyses in this section are relevant to hypotheses 1 and 2 (Section 4.3, Page 116). 
4.5.4.1 Association between depressive symptoms at age 12 years and CVD risk score 
at age 15 years  
In the total sample (N = 3,226), depressive symptoms at age 12 years were not associated 
with CVD risk score at age 15 years (beta = 0.03; SE = 0.02; p = 0.09). Depressive 
symptoms at age 12 years were also not associated with CVD risk score in sex-stratified 
analyses (Table 10). 
  
Participants Sample (no.) 
Unadjusted Adjusted a 
Beta (SE) P-value Beta (SE) P-value 
All 2,844 0.21 (0.01) <0.001 0.18 (0.01) <0.001 
Female 1,549 0.20 (0.02) <0.001 0.19 (0.02) <0.001 
Male 1,295 0.17 (0.02) <0.001 0.17 (0.02) <0.001 




Table 10. Beta estimates (SE) for the association between depressive symptoms at 
age 12 years and CVD risk score at age 15 years. 
 
4.5.4.2 Association between CVD risk score at age 15 years and depressive symptoms 
at age 18 years  
In the total sample (N = 3,014), CVD risk score at age 15 years was associated with 
depressive symptoms score at age 18 years (beta = 0.07; SE = 0.02; p <0.001) (Table 11). 
Evidence for this association remained after adjusting for confounders (adjusted beta = 0.06; 
SE = 0.02; p <0.001). 
In sex-stratified analysis, CVD risk score was associated with depressive symptoms at age 
18 years in females (beta = 0.09; SE = 0.02; p <0.001) but not in males (beta = 0.03; SE = 
0.02; p = 0.14). In females, evidence for association remained after adjusting for 
confounders (adjusted beta = 0.08; SE = 0.02; p <0.001).  
 
Table 11. Beta estimates (SE) for the association between CVD risk score at age 15 
years and depressive symptoms at age 18 years. 
 
  
Participants Sample (no.) 
Unadjusted Adjusted a 
Beta (SE) P-value Beta (SE) P-value 
All 3,226 0.03 (0.02) 0.09 0.03 (0.02) 0.11 
Female 1,760 0.03 (0.02) 0.21 0.03 (0.02) 0.18 
Male 1,466 0.03 (0.03) 0.35 0.03 (0.03) 0.34 
a Adjusted for sex (if applicable), birthweight, maternal education, and family history of CVD. 
Participants Sample (no.) 
Unadjusted Adjusted a 
Beta (SE) P-value Beta (SE) P-value 
All 3,014 0.07 (0.02) <0.001 0.06 (0.02) <0.001 
Female 1,647 0.09 (0.02) <0.001 0.08 (0.02) <0.001 
Male 1,367 0.03 (0.02) 0.14 0.03 (0.02) 0.21 




4.5.4.3 Association between individual CVD risk factors at age 15 years and 
depressive symptoms at age 18 years  
In the total sample (N = 3,014), depressive symptoms at age 18 years were associated with 
the following CVD risk factors at age 15 years: own smoking (beta = 0.44; SE = 0.05; p 
<0.001); maternal smoking (beta = 0.20; SE = 0.04; p <0.001); physical activity (beta = 0.13; 
SE = 0.04; p <0.001); maternal SEP (beta = 0.11; SE = 0.05; p = 0.03); high LDL (beta = 
0.06; SE = 0.02; p <0.001); and high BMI (beta = 0.05; SE = 0.01; p <0.01) (Table 12). After 
adjusting for confounders, evidence for association remained for own smoking (adjusted 
beta = 0.39; SE = 0.05; p <0.001) and maternal smoking only (adjusted beta = 0.17; SE = 
0.04; p <0.001).  
In sex-stratified analysis, own smoking, maternal smoking, high BMI, and low HDL were 
associated with depressive symptoms in females (Table 12). Evidence for association 
remained for own smoking, maternal smoking, and BMI after adjusting for confounders. In 
males, own smoking was associated with depressive symptoms. Evidence for association 





Table 12. Beta (SE) for the association between CVD risk factors at age 15 years and depressive symptoms at age 18 years. 
CVD risk factor a, b 
All participants (N = 3,014) Females (N = 1,647) Males (N = 1,367) 
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a BMI: body mass index; CVD: cardiovascular disease; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SBP: systolic blood pressure; SE: standard error; SEP: 
socioeconomic position. 
b LDL, BMI, triglycerides, SBP, HDL, and age were used as standardised continuous variables (per SD increase in exposure). Own smoking, maternal smoking, physical 
activity, maternal SEP, and ethnicity were used as binary variables. The outcome for all analyses was standardised depressive symptoms score (per SD increase in 
outcome). 
c Adjusted for sex (if applicable), birthweight, maternal education, and SDQ total difficulties score at age 7 years. 
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4.5.5 Mechanism of association between CVD risk and depressive symptoms 
The analyses in this section are relevant to hypotheses 3 to 8 (Section 4.3, Page 116). 
4.5.5.1 Associations between inflammatory markers at age 9 years and depressive 
symptoms at age 12 or 18 years  
In the total sample (N = 2,574), IL-6 concentration at age 9 years was associated with 
depressive symptoms at age 12 years (beta = 0.13; SE = 0.05; p <0.01) (Table 13). 
Evidence for association did not remain after adjusting for confounders. In the total sample 
(N = 2,574), CRP concentration at age 9 years was not associated with depressive 
symptoms at age 12 years (beta = 0.06; SE = 0.04; p = 0.12) (Table 13).  
In the total sample (N = 2,004), IL-6 concentration at age 9 years was associated with 
depressive symptoms at age 18 years (beta = 0.13; SE =0.05; p <0.01) (Table 13). Evidence 
for association did not remain after adjusting for confounders. In the total sample (N = 
2,004), CRP concentration at age 9 years was not associated with depressive symptom at 












Table 13. Beta estimate (SE) for the association between 1 unit increase in IL-6/CRP 








Unadjusted Adjusted b 
Beta (SE) P-value Beta (SE) P-value 
IL-6 at age 9  DEP at 
age 12 
All 2,574 0.13 (0.05) <0.01 0.08 (0.05) 0.11 
 Female 1,303 0.17 (0.08) 0.03 0.15 (0.08) 0.06 
 Male 1,271 0.03 (0.07) 0.62 0.02 (0.07) 0.76 
IL-6 at age 9  DEP at 
age 18 
All 2,004 0.13 (0.05) <0.01 0.06 (0.05) 0.19 
 Female 1,068 0.14 (0.07) 0.05 0.11 (0.07) 0.14 
 Male 936 0.02 (0.06) 0.66 0.02 (0.06) 0.73 
CRP at age 9  DEP 
at age 12 
All 2,574 0.06 (0.04) 0.12 0.01 (0.04) 0.79 
 Female 1,303 0.08 (0.06) 0.15 0.07 (0.06) 0.21 
 Male 1,271 -0.04 (0.05) 0.44 -0.05 (0.05) 0.31 
CRP at age 9  DEP 
at age 18 
All 2,004 0.03 (0.03) 0.40 -0.04 (0.03) 0.25 
 Female 1,068 0.02 (0.03) 0.75 <0.01 (0.05) 0.96 
 Male 936 -0.07 (0.04) 0.08 -0.08 (0.04) 0.07 
a CRP: C-reactive protein; DEP: depressive symptoms; IL-6: interleukin-6. 




4.5.5.2 Associations between inflammatory markers at age 9 years and CVD risk at 
age 15 years  
In the total sample (N = 2,282), IL-6 concentration at age 9 years was associated with CVD 
risk score at age 15 years (beta = 0.32; SE = 0.05; p <0.001) (Table 14). In the total sample 
(N = 2,282), CRP concentration at age 9 years was also associated with CVD risk score at 
age 15 years (beta = 0.40; SE = 0.04; p <0.001) (Table 14). Evidence for these associations 
remained after adjusting for confounders. 
 
Table 14. Beta estimate (SE) for the association between 1 unit increase in IL-6/CRP 
concentration at age 9 years and CVD risk score at age 15 years. 
 
 
4.5.5.3 Mediating effect of CVD risk at age 15 years on the association between 
inflammatory markers at age 9 years and depressive symptoms at age 18 years  
In the total sample (N = 2,004), there was evidence that CVD risk score at age 15 years 
mediated the association of depressive symptoms at age 18 years with both IL-6 (indirect 
effect: beta = 0.02; SE = 0.01; p = 0.01) and CRP concentration at age 9 years (indirect 
effect: beta = 0.02; SE = 0.01; p <0.01) (Table 15). Evidence for these associations 
remained after adjusting for potential confounders.  
 





Unadjusted Adjusted a 
Beta (SE) P-value Beta (SE) P-value 
IL-6 All 2,282 0.32 (0.05) <0.001 0.30 (0.05) <0.001 
 Female 1,244 0.42 (0.08) <0.001 0.40 (0.08) <0.001 
 Male 1,038 0.20 (0.08) <0.01 0.21 (0.07) <0.01 
CRP All 2,282 0.40 (0.04) <0.001 0.39 (0.04) <0.001 
 Female 1,244 0.42 (0.06) <0.001 0.41 (0.06) <0.001 
 Male 1,038 0.37 (0.06) <0.001 0.36 (0.06) <0.001 
a Adjusted for sex (if applicable), birthweight, maternal education, and family history of CVD. 
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Table 15. Mediating effects of CVD risk score at age 15 years on the association 
between IL-6/CRP at age 9 years and depressive symptoms at age 18 years. 
 
 
4.5.6 Sensitivity analysis 
I repeated analyses testing the direction of association between CVD risk and depressive 
symptoms based on the complete case-set (N = 1,810). The pattern of results was broadly 
similar to the main analyses, although effect sizes were smaller in the complete case-set 
(Table 16).  
Table 16. Beta estimate (SE) for the association between CVD risk score at age 15 
years and depressive symptoms at age 12 or 18 years in the complete case-set. 
Model a Sample (no.) Type of effect 
Unadjusted  Adjusted b 
Beta (SE) p-value Beta (SE) p-value 
IL-6  CVD  DEP 2,004 Direct 0.11 (0.05) 0.02 0.04 (0.05) 0.34 
  Indirect 0.02 (0.01) 0.01 0.02 (0.01) 0.02 
  Total  0.14 (0.05) <0.01 0.06 (0.05) 0.19 
CRP  CVD  DEP 2,004 Direct <0.01 (0.04) 0.90 -0.06 (0.03) 0.07 
  Indirect 0.02 (0.01) <0.01 0.02 (0.01) <0.01 
  Total  0.03 (0.03) 0.40 -0.04 (0.03) 0.25 
a CRP: C-reactive protein at age 9 years; CVD: cardiovascular disease risk score at age 15 years; DEP: 
depressive symptoms at age 18 years; IL-6: interleukin-6 at age 9 years. 
b Adjusted for sex (if applicable), birthweight, maternal education, and SDQ total difficulties score at age 7 years.  
Model a  Sample (no.) Participants 
Unadjusted Adjusted b 
Beta (SE) P-value Beta (SE) P-value 
CVD  DEP  1,390 All 0.03 (0.02) 0.18 0.02 (0.02) 0.43 
 757 Female 0.03 (0.03) 0.28 0.01 (0.03) 0.65 
 633 Male 0.01 (0.03) 0.62 0.01 (0.03) 0.62 
DEP  CVD  1,466 All 0.03 (0.03) 0.31 0.02 (0.03) 0.52 
 804 Female 0.03 (0.03) 0.42 0.02 (0.03) 0.47 
 662 Male 0.01 (0.04) 0.83 <0.01 (0.04) 0.98 
a CVD: cardiovascular disease at age 15 years; DEP: depressive symptoms at age 12 or 18 years. 
b Adjusted for sex (if applicable), birthweight, maternal education, and SDQ total difficulties score at age 7 
years/family history of CVD as appropriate. 
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4.6 Discussion  
This population-based longitudinal study in young people is one of the first to use a 
composite CVD risk score to investigate the associations between CVD risk and depressive 
symptoms in childhood and mid- to late-adolescence. In particular, I tested the direction of 
association between CVD risk and depressive symptoms and the potential role of childhood 
inflammation. I report that higher CVD risk score at age 15 years is associated with 
depressive symptoms subsequently at age 18 years. However, depressive symptoms at age 
12 years were not associated with the CVD risk score at age 15 years. I also report that 
childhood IL-6 and CRP concentration at age 9 years are associated with CVD risk score at 
age 15 years. Furthermore, elevated IL-6/CRP levels at age 9 years appear to influence the 
risk of depressive symptoms at age 18 years via CVD risk score at age 15 years. Thus, the 
findings described above are consistent with hypotheses 2, 5, 6, 7, and 8 but do not support 
hypotheses 1, 3, and 4 (Section 4.3, Page 116).  
The first objective of our analysis was to determine whether CVD risk and depressive 
symptoms are bidirectionally associated in young people. I report that higher CVD risk in 
mid-adolescence was associated with depressive symptoms in late-adolescence. Own 
smoking and maternal smoking were particularly strongly associated with depressive 
symptoms. The lack of association between depressive symptoms in childhood and 
subsequent CVD risk in mid-adolescence may suggest a unidirectional relationship in young 
people, where high CVD risk predicts subsequent depressive symptoms but not the other 
way around. Our findings are consistent with longitudinal studies reporting that high BMI and 
smoking are associated with depressive symptoms in young people (307,317,318,320). 
Other studies have reported an association between depressive symptoms in adolescence 
and subclinical measures of CVD that predict CVD in adulthood (373). Although I found no 
evidence of an association between childhood depressive symptoms at age 12 years and 
subsequent CVD risk in adolescence at age 15 years in this sample, it is possible that 
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childhood depressive symptoms may have a cumulative effect on CVD risk in young people 
which is not yet evident by mid-adolescence. 
Social factors are important determinants of CVD risk and depression in young people. 
Mother’s educational attainment and SEP have been shown to influence the relationship 
between CVD risk and depression in childhood (374,375). Consistent with this literature, I 
found some evidence for an association between low maternal SEP and depressive 
symptoms in early-adulthood. Low SEP is also associated with maternal smoking (374,375); 
I discovered that in the ALSPAC sample maternal smoking is associated with subsequent 
depressive symptoms in the offspring. The idea of programming by early-life factors is 
consistent with the DOHAD hypothesis of the developmental origins of adult disease (2). 
Socioeconomic gradients in adiposity and blood pressure exist in children at age 10 years, 
suggesting that inequalities in CVD risk factors will widen over time, along with depression 
cases (270). Withdrawal symptoms from smoking are also likely to exert psychological 
effects including regular mood fluctuations, which may increase risk of developing 
depression (166,310). In addition, a diet high in trans-fatty acids may contribute to the 
association between CVD risk and depression via increases in plasma LDL-cholesterol 
levels, proinflammatory cytokines, and endothelial dysfunction (376). Diverse psychosocial 
factors therefore influence the development of depression partly through CVD risk factors.   
The second part of our analysis focused on childhood inflammation as a potential 
mechanism for the comorbidity between CVD risk and depression. I report that childhood IL-
6 and CRP levels are associated with higher CVD risk score in mid-adolescence, and that 
adolescent CVD risk score mediates the association between childhood IL-6/CRP levels and 
depressive symptoms in late-adolescence. Infection and inflammation have been implicated 
in the pathogenesis of depression (145,168,377) and there is substantial evidence also 
linking inflammation with CVD risk (196,378,379). Childhood inflammation therefore could be 
a common risk factor for both depression and CVD. This idea is consistent with the idea that 
exposure to risk factors during a critical developmental window may alter certain physiologic 
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system(s) leading to increased risk of chronic illnesses subsequently in adulthood (380). Our 
findings suggest that inflammation could be one such common pathophysiologic mechanism 
because IL-6/CRP levels at age 9 years were associated with CVD risk score at age 15 
years in this study. A previous study from the same cohort reported that childhood IL-6 levels 
were associated with depressive symptoms at age 18 years (168). 
Inflammation may have different effects on different organs. In the brain, inflammation may 
lead to symptoms of depression, while inflammatory processes may contribute to changes in 
the cardiovascular system leading to increased risk of CVD. For instance, human and 
preclinical studies suggest that systemic inflammation may increase risk of depression by 
decreasing synaptic serotonin, and by increasing CNS levels of glutamate, excitotoxicity and 
oxidative stress (119,381). Similarly, inflammation has been reported to be associated with 
atherosclerosis (382) and endothelial dysfunction (383). Our findings are consistent with this 
literature suggesting that childhood inflammatory markers may increase the risk of 
subsequent depressive symptoms in late-adolescence by influencing CVD risk score.  
Inflammation and CVD risk in young people may form a vicious cycle that perpetuates 
pathophysiologic changes and ultimately increase the risk of both CVD and depression in 
adults. For instance, inflammation is linked with insulin resistance (384). On the other hand, 
certain CVD risk factors, such as obesity, can also increase inflammation. Obesity has been 
reported to be associated with increased secretion of inflammatory mediators and low-grade 
inflammation due to progressive accumulation of adipocytes, macrophages and T 
lymphocytes in white adipose tissue, muscles and the liver (385). Overweight individuals 
also have increased gut permeability to bacteria and low bacterial diversity which further 




Our analysis is not without limitations. First, BMI was used in the CVD risk score as a 
measure of central adiposity. BMI is not necessarily the most appropriate measure to use, 
particularly in adolescents. However, using waist circumference instead of BMI made no 
difference to the CVD risk score distribution. In addition, although the AHA cardiovascular 
health guidelines have been shown to be applicable to CVD risk in younger adults, data on 
diet were not available to me and were not included in the CVD risk score. Relatively few 
participants had complete data, reducing statistical power. I attempted to address this issue 
by multiple imputation for missing data. The results appear to show a sex difference in the 
association between CVD risk and subsequent depressive symptoms, but this should be 
interpreted with caution in light of sample attrition and reduced statistical power. Finally, the 
cohort is primarily composed of White individuals, limiting generalisability.  
4.6.2 Conclusion 
The association between CVD risk and depressive symptoms in childhood/adolescence is 
unidirectional, with higher CVD risk increasing the risk of depressive symptoms. Childhood 
inflammation may increase risk of depression by influencing adolescent CVD risk. This 
model where inflammation is a shared, modifiable risk factor for adult CVD and depression 
requires replication in other samples, but may have important implications for the prevention 
of CVD and depression.
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Chapter 5: Association between Common Early-Childhood 
Infection and Subsequent Depressive Symptoms and 































Figure 28. Visual summary of Chapter 5.  
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5.2 Introduction  
Depressive symptoms and psychotic experiences (PEs) may be manifestations of a latent 
continuum of common mental distress, on which PEs measure severity (18). PEs in 
depression are associated with poor response to treatment, increased risk of self-harm, and 
worse outcomes (18). Individuals with PEs are also significantly less likely to reach 
remission of depressive symptoms than those without PEs (18). As such, PEs in depression 
are highly clinically relevant.  
Early-life infections are associated with increased risk of serious mental health disorders in 
adulthood. There is an extensive literature linking prenatal maternal and childhood infections 
with schizophrenia and related psychotic disorders, which are associated with both central 
nervous system (CNS) and non-CNS infections (386–391). Early-life exposure to infection 
may result in activation of an acute inflammatory response potentially affecting 
neurodevelopment (392). Acute inflammation causes reductions in neuroplasticity, an 
important process for brain functioning, which may lead to neuropsychiatric outcomes later 
on (393). Compared with psychosis, longitudinal studies of early-life infection and depression 
are relatively rare, though inflammation is increasingly thought to play a role in pathogenesis 
of the illness (111,381,394). However, most of the existing longitudinal studies of early-life 
infection have focused on psychosis and depression in adults (386,395–399). Longitudinal 
studies of depressive and PEs during childhood/adolescence are scarce (155). 
Childhood/adolescent depressive symptoms are associated with adult depression (66–
68,73). PEs during childhood/early-adolescence may be part of typical development and are 
transient for most individuals. However, population-based longitudinal studies suggest 
associations between early-life PEs with risk of psychotic disorders subsequently in 
adulthood (400,401), and with risk factors for schizophrenia including impaired 
neurodevelopment (402,403). They are also associated with adolescent psychiatric multi-
morbidity (404), and with other psychiatric disorders in adulthood (405). Therefore studying 
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adolescent PEs and depressive symptoms may offer insights into development of adult 
psychotic and mood disorders.  
Some previous longitudinal studies have considered the issue of timing, i.e., whether early-
life infections are associated with psychotic outcomes closer to the time of exposure or 
subsequently after several years (386,406), but such studies of depression are scarce. 
Moreover, previous studies have typically examined effects of severe infections (145,386), 
but studies of common childhood infections and subsequent depressive/ psychotic 
outcomes, or studies of number of childhood infection and subsequent depression are 
scarce. Prospective cohort studies with repeated measures of depressive and psychotic 
experiences over a long period are required to address these issues, but such studies are 
relatively rare. 
Infections are common during childhood, but some children are disproportionately prone to 
high infection burden possibly due to genetic and environmental factors. While childhood 
infection severity, duration, and related hospitalisation have been linked with depression and 
psychosis in adulthood (145,386,406), it is unclear whether the degree of childhood infection 
burden is associated with psychotic/depressive outcomes in childhood/adolescence. A high 
number of childhood infections may be a risk factor for psychiatric disorders, as a dose-
response association between increasing number of childhood infection and adult mood or 
psychotic disorders has been reported (145,386). Early-life infections could also be a marker 
for shared genetic and environmental risk factors for infection and major psychiatric 
disorders (407). It is possible that inflammatory immune response during critical 
developmental window is detrimental for brain development/function (408). A high burden of 
common childhood infections may also reflect underlying familial factors predisposing to 
infection, such as SEP, living conditions, and genetic factors (407). Therefore, studies 
investing the effects of infection burden are required. 
Using data from ALSPAC (272), I have investigated the longitudinal associations of 
childhood infections from age 1.5 to 7.5 years old with depressive symptoms measured six 
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times from age 10 to 19 years and with PEs at age 12 and 18 years. Comorbid depressive 
symptoms and PEs was not included as an outcome due to the small number of cases. I 
have examined not only the number of childhood infections as exposure, but also the effect 
of infection burden, grouped as low, medium, high or very high. I hypothesised that a higher 
overall number of infections and very high infection burden would be associated with higher 




5.3 Hypotheses  
1. Childhood infections are associated with depressive symptoms from age 10 to 19 years. 
2. Childhood infections are associated with PEs at age 12 and 18 years.  
3. Childhood infection burden has a dose-response relationship with depressive symptoms 
from age 10 to 19 years. 







5.4.1 Description of sample 
The risk set for this study comprised 11,786 unrelated individuals from the ALSPAC cohort 
with data on infections during childhood. Out of the risk set, the number of individuals with 
depressive symptoms data decreased from 6,685 at age 10 years to 3,101 at age 19 years 
(Figure 29). From the risk set, PE data were available for 6,176 individuals at age 12 years 
and for 4,253 individuals at age 18 years (Figure 30). These samples formed the basis for 

























Figure 29. Maximum available sample from the risk set with data on depressive 
symptoms at each follow-up from age 10 to 19 years. 
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Figure 30. Maximum available sample from the risk set with data on psychotic 
experiences at age 12 and 18 years.  
 
5.4.2 Assessment of childhood infections from age 1.5 to 7.5 years  
Approximately once per year when the child was aged between age 1.5 and 7.5 years, 
caregivers completed seven postal questionnaires about common childhood infections 
experienced by their child. These included German measles, measles, chicken pox, mumps, 
meningitis, cold sores, whooping cough, urinary infections, eye infections, ear infections, 
chest infections, tonsillitis/laryngitis, scarlet fever, influenza, cold, and other.  
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Overall 11,786 children had fully/partly completed infection questionnaires from the seven 
time-points. In the questionnaire about childhood infections, caregivers could tick the “Yes” 
or “No” boxes for infections that their child has had. Some people simply ticked the “Yes” box 
to indicate that their child has had certain infections, but did not tick the “No” box for 
infections their child did not have. In those instances, the un-ticked boxes were coded as 
“No” that year rather than dropping the subject from analysis for missing data. However, if a 
parent had all boxes unticked they were coded as missing, as this lack of response gave no 
indication of whether their child had any infections that year.   
Childhood infection count was used as a standardised continuous variable. Infection was 
also used as a categorical variable representing the degree of infection burden: low (50 th 
percentile and below; 0 to 4 infections), medium (51-75th percentile; 5 to 6 infections), high 
(76-90th percentile; 7 to 9 infections), and very high burden (above 90th percentile; 10 to 22 
infections). These categories were based on a prior study and were chosen to capture the 
positive skew of childhood infection distribution (409). 
5.4.3 Assessment of depressive symptoms at age 10, 13, 14, 17, 18, and 19 
years   
Depressive symptoms were self-reported by the child/young person using the SMFQ (367). 
Depressive symptoms were measured at age 10 (mean = 10.6; SD = 0.3), 13 (mean = 12.8; 
SD = 0.2), 14 (mean = 13.8; SD = 0.2), 17 (mean = 16.7; SD = 0.2), 18 (mean = 17.8; SD = 
0.4), and 19 years old (mean = 18.6; SD = 0.5). The SMFQ is a widely used, age-
appropriate, and validated tool comprising 13 items that cover core symptoms of depression 
and anxiety experienced in the past two weeks. Each item is scored 0 (not true), 1 
(sometimes true) or 2 (true) giving a total score of 0 to 26. Depressive symptoms was used 





5.4.4 Assessment of psychotic experiences at age 12 and 18 years     
PEs were identified using the face-to-face, semi-structured Psychosis-Like Symptom 
Interview (PLIKSi) (401,410) conducted by trained psychology graduates in assessment 
clinics. PEs were coded according to the definitions and rating rules for the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN), Version 2.0. (411). PLIKSi at age 12 years 
has “fair” inter-rater (kappa = 0.75) and test-retest (kappa = 0.48) reliability (410). PLIKSi at 
age 18 years has “good” inter-rater (kappa = 0.83) and test-retest (kappa = 0.76) reliability 
(401).   
PLIKSi covered the three main domains of positive psychotic experiences: hallucinations 
(visual and auditory), delusions (spied on, persecuted, thoughts read, reference, control, 
grandiosity, and other), and thought interference (insertion, withdrawal, and broadcasting). 
After cross-questioning, interviewers rated PEs as “not present”, “suspected”, or “definitely 
present”. Uncertain responses were always “rated down”, and symptoms were rated as 
definite only if a clear example could be provided. For suspected or definite PEs, 
interviewers also recorded the frequency, affect, effects on social/educational/occupational 
function, help seeking, and attributions including fever, hypnopompic/hypnogogic state, or 
illicit drugs.  
PEs measured at age 12 years refer to experiences from the previous six months while PEs 
measured at age 18 years refer to experiences since age 12 years. In line with previous 
papers originally describing PEs in the ALSPAC birth cohort, I used three increasingly strict 
definitions for this outcome, i.e. any PEs (suspected or definite PEs); definite PEs; and 
definite PEs without attribution. The number of participants meeting each of the outcome 
definitions are different (Figure 30) and the risk of each outcome was analysed separately. 
The comparison group for each outcome included all the individuals who did not meet that 





5.4.5 Assessment of confounders   
Based on previous studies, I included sex, ethnicity, birth weight, maternal SEP, and 
parental history of severe depression or schizophrenia as these are associated with 
exposure and/or outcome and so could be confounders (145,390,412,413).  
Sex (binary) and birth weight (grams, continuous) were assessed at birth. Ethnicity was 
recorded as White, Black African, Black Caribbean, Black Other, Bangladeshi, Chinese, 
Indian, Pakistani, and Other. This variable was recoded as White and any other ethnic group 
due to low counts for non-White ethnic groups.  
Maternal SEP was originally documented using Office of National Statistics categories (365) 
and re-coded as non-manual (I, II and IIIa) and manual (IIIb, IV and V). The armed forces 
was excluded as the sample size for this category was too small (N = 4).  
Mothers and their partners completed separate questionnaires at 12 weeks gestation in 
which they self-reported having severe depression. The categories from the self-reported 
questionnaires were: “Yes, had it recently”, “Yes in past, not now”, “No never”, or “Don’t 
know”. A binary variable for severe depression was created for both the mother and their 
partner where 0 = “No never” and 1 = “Yes, had it recently” or “Yes in past, not now”. 
Individuals who answered “Don’t know” were excluded. Parental history of severe 
depression or schizophrenia were coded as a binary variable, with “yes” being recorded if at 
least one parent reported to having severe depression or schizophrenia. 
5.4.6 Statistical analysis   
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All analyses were carried out using R version 3.6.1. Regression analyses were performed 
before and after adjusting for potential confounders. All main analyses were based on the 
dataset after imputation of missing values for confounders.   
4.4.6.1 Imputation of Missing Confounder Variables 
Regression analyses testing associations between exposure and outcomes were conducted 
after imputation of missing data for confounders (ethnicity, maternal SEP, birthweight, 
parental schizophrenia, and parental severe depression) to increase sample size. Sex had 
no missing data. The percentage of missing values across the relevant confounder variables 
varied between 1.5% and 35% (Table 17). I used the TestMCARNormality function to test 
whether data were missing completely at random (414). The missing completely at random 
hypothesis was to be rejected at 0.05 significance level. Using the missing_compare 
function, each variable returned significance (p <0.05) with at least one other variable, 
suggesting that the data met the missing at random assumption.  
I used multiple imputation using fully conditional MCMC method for the above confounder 
variables plus auxiliary variables that were indicators of missingness. Exposure and outcome 
variables were also included. The selected auxiliary variables included: housing/living 
conditions, parental education/employment status, financial difficulties, life events, and 
maternal characteristics (age, BMI, marital status, anxiety/post-natal depression, and 
smoking status).  
I used the R package “mice” (version 3.0) to create and analyse the multiply imputed 
datasets (277). Since missing data were present in 20% of subjects, I used 20 imputations 
as recommended (372). The parameters of interest were estimated in each dataset 
separately, and combined using Rubin’s rules.   
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Table 17. Characteristics of the imputed confounders. 
 
4.4.6.2 Association of childhood infections with depressive symptoms and psychotic 
experiences 
Linear regression was used to examine the association between the number of childhood 
infections/infection burden and depressive symptoms at age 10 to 19 years (Hypothesis 1, 3, 
Page 149). Low infection burden (0 to 4 infections) was used as the reference group where 
infection burden was used as the exposure. Regression models were adjusted for sex, birth 
weight, maternal SEP, ethnicity, and parental history of severe depression. Beta estimates 
and SEs from regression models are presented.   
Logistic regression was used to calculate ORs and 95% confidence intervals (CI) for PEs at 
age 12 or 18 years associated with the number of childhood infections/infection burden 
(Hypothesis 2, 4). Low burden of infection (0 to 4 infections) was used as the reference 
group for the latter. Regression models were adjusted for sex, birth weight, maternal SEP, 








Value Difference in 
values before and 






Birthweight (kg) – mean (SD) 1.5 11,613 3.4 (0.5) 3.4 (0.5) 0.90 






Maternal SEP – no. manual 
(%) 
22.1 9,183 1752 (19.1) 2621 (22.2) <0.001 
Parental history of severe 
depression – no. (%) 
35.0 7,664 979 (12.8) 1677 (14.2) <0.001 
Parental history of 
schizophrenia – no. (%) 
35.0 7,685 18 (0.2) 40 (0.3) 0.06 
Total missing data 19.9 -- -- -- -- 
a The sample size after imputation was 11,786 participants. 
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For all analyses, I used the maximum available sample for each outcome measure to 
increase statistical power. Holm-Bonferroni P-value correction was performed to correct for 
multiple testing (Table 18, Table 19) (415). 
4.4.6.3 Sensitivity analysis exploring impact of missing data 
To explore the potential impact of missing data I repeated our main analyses based on 
complete case-set, defined as participants with no missing data for exposure, outcome or 
confounder measures. I then carried out a number of comparisons between different 
samples. First, I compared the risk set (i.e. participants with data on childhood infection) with 
the complete case-set for depressive symptoms (i.e., data on childhood infection, all 
confounders, and depressive symptoms at all follow-up time points are available). I did the 
same comparison for PEs. Second, I compared the analytic sample for depressive 
symptoms at age 19 years (i.e. data on both childhood infection and depressive symptoms 
at age 19 years available) with the missing sample (i.e. childhood infection data present but 
depressive symptoms data at age 19 years missing). I performed the same comparison for 












Table 18. Corrected P-value for the association between childhood infections and depressive symptoms using the Holm-Bonferroni 
Method. 
Age at depressive 
symptoms outcome 
(years) 

















10  <0.01 0.02 0.05 0.62 0.47 1.00 0.02 0.24 
13 <0.001 <0.001 0.86 1.00 0.14 1.00 <0.001 <0.001 
14 <0.001 0.01 0.31 1.00 0.28 1.00 <0.01 0.02 
17 0.04 0.48 0.85 1.00 0.53 1.00 0.01 0.12 
18 0.19 1.00 0.95 1.00 0.34 1.00 0.24 1.00 
19 0.31 1.00 0.97 1.00 0.22 1.00 0.25 1.00 
a The P-values correspond to adjusted beta estimates for depressive symptoms. Beta estimates were adjusted for sex, birthweight, maternal SEP, ethnicity and parental 












Table 19. Corrected P-value for the association between childhood infections and psychotic experiences using the Holm-Bonferroni 
Method. 
Outcome 


















age 12  
<0.001 <0.001 0.04 0.48 0.05 0.60 <0.001 <0.01 
Definite PEs age 12 0.01 0.12 0.45 1.00 0.28 1.00 0.07 0.84 
Definite PEs without 
attribution age 12 
0.01 0.12 0.47 1.00 0.34 1.00 0.09 1.00 
Suspected/definite PEs 
age 18 
0.14 1.00 0.97 1.00 0.36 1.00 0.26 1.00 
Definite PEs age 18 0.45 1.00 0.61 1.00 0.65 1.00 0.66 1.00 
Definite PEs without 
attribution age 18 
0.17 1.00 0.65 1.00 0.36 1.00 0.48 1.00 
a The P-values correspond to adjusted odds ratios for psychotic experiences (PEs). Odds ratios were adjusted for sex, birthweight, maternal socioeconomic position, 







5.5.1 Baseline characteristics of the sample 
The risk set (N = 11,786) was predominantly of White ethnicity (98%) (Table 20). The 
average number of childhood infections in the total sample was 4.6 (SD = 3.2), and the 
median was 4 (inter-quartile range (IQR) = 2 to 6). The number of children with very high 
infection burden (≥90th percentile; 10 to 22 infections) was 947 (8%).  
There was a general increase in depressive symptoms between age 10 and 19 years 
(Figure 29); mean SMFQ score at age 10 years was 4.0 (SD = 3.5), and was 6.8 (SD = 5.9) 
at age 19 years (Table 20). The percentage of participants with definite PEs was similar at 
age 12 years (6%) and at age 18 years (5%). 
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Table 20. Characteristics of participants in the risk set (using maximum available sample and after imputation of confounders). 
Characteristics a 
Total participants 
Very high infection 
burden (≥10 infections) 
Lower infection burden  
(<10 infections) 
Difference between groups  
(X2 / t-test p-value) 
Sample Value Sample Value Sample Value 
Confounders        
Birthweight – mean (SD) 11,786 3.4 (0.5) 947 3.4 (0.5) 10,839 3.4 (0.5) 0.39 
Sex – no. female (%) 11,786 5,710 (48.4) 947 483 (51.0) 10,839 5,227 (48.2) 0.10 
Ethnicity – no. White (%) 11,786 11,511 (97.7) 947 922 (97.4) 10,839 10,588 (97.7) 0.63 
Maternal SEP – no. manual (%) 11,786 2,621 (22.2) 947 184 (19.4) 10,839 2,437 (22.5) 0.04 
Parental history of severe depression – no. (%)  11,786 1,677 (14.2) 947 158 (16.7) 10,839 1,519 (14.0) 0.07 
Parental history of schizophrenia – no. (%) 11,786 40 (0.3) 947 3 (0.3) 10,839 37 (0.3) 0.91 
Number of childhood infections        
Mean (SD) 11,786 4.6 (3.2) 947 11.6 (1.8) 10,839 4.0 (2.5) - 
Median (IQR) 11,786 4 (2-6) 947 11 (10-12) 10,839 4 (2-6) - 
Depressive symptoms – mean (SD)        
Age 10  6,685 4.0 (3.5) 697 4.4 (3.9) 5,988 4.0 (3.5) <0.01 
Age 13  6,087 3.9 (3.8) 661 4.6 (4.3) 5,426 3.9 (3.8) <0.01 
Age 14  5,504 4.9 (4.5) 604 5.5 (4.8) 4,900 4.8 (4.4) <0.01 
Age 17  4,645 5.9 (5.6) 506 6.6 (5.8) 4,139 5.8 (5.6) <0.01 
Age 18  4,086 6.6 (5.3) 448 6.9 (5.2) 3,638 6.5 (5.3) 0.17 
Age 19 3,101 6.8 (5.9) 345 7.1 (6.1) 2,756 6.7 (5.8) 0.30 
PEs – no. (%)        
Suspected/definite PEs at age 12 6,176 844 (13.7) 668 117 (17.5) 5,508 727 (13.2) <0.01 
Definite PEs at age 12 6,176 350 (5.7) 668 47 (7.0) 5,508 303 (5.5) 0.14 
Definite PEs without attribution at age 12 6,176 289 (4.7) 668 39 (5.8) 5,508 250 (4.5) 0.17 
Suspected/definite PEs at age 18 4,253 385 (9.1) 469 49 (10.4) 3,784 336 (8.9) 0.29 
163 
 
Definite PEs at age 18 4,253 206 (4.8) 469 22 (4.7) 3,784 184 (4.9) 0.87 
Definite PEs without attribution at age 18 4,253 177 (4.2) 469 18 (3.8) 3,784 159 (4.2) 0.70 






5.5.2 Association between number of childhood infections and depressive 
symptoms 
The analyses in this section are relevant to hypothesis 1 (Section 5.3, Page 149).  
Number of childhood infections from age 1.5 to 7.5 years was associated with subsequent 
depressive symptoms at age 10 (N = 6,685; beta = 0.14; SE = 0.04; p <0.01), 13 (N = 6,087; 
beta = 0.24; SE = 0.05; p <0.001), and 14 years old (N = 5504; beta = 0.23; SE = 0.06; p 
<0.001) (Table 21). Evidence for these associations remained after adjusting for potential 
confounders. Childhood infections were not associated with depressive symptoms at age 17, 
18, or 19 years.   
 
Table 21. Beta estimate (SE) for depressive symptoms from age 10 to 19 years per 1 








Unadjusted Adjusted b 
Beta (SE) P-value Beta (SE) P-value 
10 6,685 14.5 0.14 (0.04)  <0.01 0.14 (0.04)  <0.01 
13 6,087 14.6 0.24 (0.05)  <0.001 0.22 (0.05)  <0.001 
14 5,504 22.2 0.23 (0.06)  <0.001 0.21 (0.06)  <0.001 
17 4,645 28.3 0.14 (0.09) 0.11 0.17 (0.08)  0.04 
18 4,086 34.3 0.11 (0.09) 0.22 0.11 (0.08) 0.19 
19 3,101 34.2 0.11 (0.11) 0.34 0.11 (0.11) 0.31 
a For the purposes of this table, depression is defined as SMFQ score ≥8.  
b Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of severe depression. 
 
After correction for multiple testing, evidence remained for an association between number 
of childhood infections and depressive symptoms at age 10 (p = 0.02), 13 (p <0.001) and 





5.5.3 Association between number of childhood infections and psychotic 
experiences 
The analyses in this section are relevant to hypothesis 2 (Section 5.3, Page 149).  
Number of childhood infections was associated with subsequent PEs at age 12 years (N = 
6,176), including suspected/definite PEs (OR = 1.17; 95% CI = 1.09, 1.26), definite PEs (OR 
= 1.16; 95% CI = 1.04, 1.29), and definite PEs without attribution (OR = 1.17; 95% CI = 1.04, 
1.31) (Table 22). Evidence for these associations remained after adjusting for potential 
confounders. The number of childhood infections was not associated with PEs at age 18 
years.  
 
Table 22. Odds ratio (95% CI) for the association between 1 SD increase in childhood 
infections and PEs at age 12 and 18 years. 
 
 
After correction for multiple testing, evidence remained for an association between number 
of childhood infections and suspected/definite PEs at age 12 years (p <0.001), but not with 













Odds ratio (95% CI)  
Unadjusted Adjusted a 
12 6,176 Suspected/definite 13.7 1.17 (1.09, 1.26)  1.18 (1.09, 1.27)  
  Definite only 5.7 1.16 (1.04, 1.29)  1.16 (1.05, 1.29)  
  Definite without attribution 4.7 1.17 (1.04, 1.31)  1.18 (1.05, 1.32)  
18 4,253 Suspected/definite 9.1 1.07 (0.97, 1.19) 1.08 (0.97, 1.20) 
  Definite only 4.8 0.93 (0.81, 1.08) 0.94 (0.82, 1.10) 
  Definite without attribution 4.2 0.88 (0.75, 1.03) 0.89 (0.76, 1.05) 
a Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of schizophrenia. 
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5.5.4 Association between childhood infection burden and depressive 
symptoms 
The analyses in this section are relevant to hypothesis 3 (Section 5.3, Page 149).  
Compared with low infection burden, very high infection burden was associated with 
depressive symptoms at age 10 (beta = 0.38; SE = 0.16; p = 0.01), 13 (beta = 0.76; SE = 
0.17; p <0.001), 14 (beta = 0.66; SE = 0.21; p <0.01), and 17 years old (beta = 0.68; SE = 
0.30; p = 0.02) (Table 23). Evidence for these associations remained after adjusting for 
potential confounders. Very high infection burden was not associated with depressive 
symptoms at age 18 years (beta = 0.33; SE = 0.29; p = 0.26) or age 19 years (beta = 0.41; 
SE = 0.38; p = 0.27).  
After correction for multiple testing, evidence remained for association between very high 
infection burden and depressive symptoms at age 13 years (p <0.001) and age 14 years (p 
= 0.02) (Table 18). 
5.5.5 Association between childhood infection burden and psychotic 
experiences 
The analyses in this section are relevant to hypothesis 4 (Section 5.3, Page 149).  
Compared with low infection burden, very high infection burden was associated with 
suspected/definite PEs at age 12 years (OR = 1.59; 95% CI = 1.24, 2.04). Evidence for this 
association remained after adjusting for potential confounders. Very high infection burden 
was not associated with PEs at age 18 years (Table 24).  
After correction for multiple testing, evidence remained for an association between very high 
infection burden and suspected/definite PEs at age 12 years (p <0.01) (Table 19). 
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Table 23. Beta estimate (SE) for the association between childhood infection burden and depressive symptoms from age 10 to 19 
years. 
Infection burden between age 
1.5 and 7.5 (no. of infections) 






Unadjusted Adjusted b 
Beta (SE) P-value Beta (SE)  P-value 
Low (0 to 4) 10 2,869 14.6 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  1,703 12.3 -0.23 (0.11)  0.03 -0.20 (0.11) 0.05 
High (7 to 9)  1,416 14.9 0.06 (0.12) 0.65 0.09 (0.12) 0.47 
Very high (10 to 22)  697 18.1 0.38 (0.16)  0.01 0.36 (0.15) 0.02 
Low (0 to 4) 13 2,572 13.5 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  1,538 13.8 -0.03 (0.12) 0.84 -0.02 (0.12) 0.86 
High (7 to 9)  1,316 15.0 0.22 (0.14) 0.11 0.21 (0.14)  0.14 
Very high (10 to 22)  661 20.0 0.76 (0.17)  <0.001 0.72 (0.17)  <0.001 
Low (0 to 4) 14 2,328 21.4 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  1,383 21.0 -0.19 (0.15) 0.20 -0.15 (0.15) 0.31 
High (7 to 9)  1,189 22.9 0.18 (0.17) 0.31 0.18 (0.17)  0.28 
Very high (10 to 22)  604 26.8 0.66 (0.21)  <0.01 0.64 (0.21)  <0.01 
Low (0 to 4) 17 1,917 27.6 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  1,184 28.8 -0.18 (0.21) 0.37 -0.04 (0.20) 0.85 
High (7 to 9)  1,038 26.7 -0.30 (0.24) 0.20 -0.15 (0.23) 0.53 
Very high (10 to 22)  506 33.0 0.68 (0.30)  0.02 0.79 (0.29)  0.01 
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Low (0 to 4) 18 1,708 33.8 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  1,053 33.6 -0.11 (0.20) 0.58 -0.01 (0.20) 0.95 
High (7 to 9)  877 34.7 0.10 (0.24) 0.67 0.22 (0.23) 0.34 
Very high (10 to 22)  448 37.5 0.33 (0.29) 0.26 0.34 (0.29) 0.24 
Low (0 to 4) 19 1,236 34.2 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)  829 32.6 -0.04 (0.26) 0.89 0.01 (0.26) 0.97 
High (7 to 9)  691 35.3 0.26 (0.30) 0.39 0.36 (0.30) 0.22 
Very high (10 to 22)  345 36.2 0.41 (0.38) 0.27 0.43 (0.37) 0.25 
a For the purposes of this table, depression is defined as SMFQ score ≥8.  












Table 24. Odds ratio (95% CI) for the association between childhood infection burden and PEs at age 12 and 18 years.  
Infection burden between age 
1.5 and 7.5 (no. of infections) 
Sample size 
(no.)  




% with PEs 
Odds ratio (95% CI) 
Unadjusted  Adjusted a 
Low (0 to 4) 2,619 12 Suspected/definite  12.3 1.00 [ref] 1.00 [ref] 
Medium (5 to 6) 1,561   14.0 1.20 (1.00, 1.44) 1.21 (1.01, 1.46) 
High (7 to 9) 1,328   14.0 1.22 (0.99, 1.51) 1.24 (1.03, 1.54) 
Very high (10 to 22) 668   17.5 1.59 (1.24, 2.04) 1.60 (1.25, 2.05) 
Low (0 to 4) 2,619  Definite only 5.1 1.00 [ref] 1.00 [ref] 
Medium (5 to 6) 1,561   5.9 1.08 (0.82, 1.42) 1.11 (0.84, 1.46) 
High (7 to 9) 1,328   5.9 1.15 (0.84, 1.57) 1.19 (0.87, 1.63) 
Very high (10 to 22) 668   7.0 1.39 (0.97, 2.01) 1.40 (0.97, 2.02) 
Low (0 to 4) 2,619  Definite without attribution 4.0 1.00 [ref] 1.00 [ref] 
Medium (5 to 6) 1,561   5.1 1.09 (0.81, 1.47) 1.12 (0.83, 1.51) 
High (7 to 9) 1,328   4.8 1.14 (0.81, 1.61) 1.18 (0.84, 1.67) 
Very high (10 to 22) 668   5.8 1.40 (0.94, 2.08) 1.41 (0.95, 2.10) 
Low (0 to 4) 1,783 18 Suspected/definite  8.8 1.00 [ref] 1.00 [ref] 
Medium (5 to 6) 1,089   8.4 0.97 (0.75, 1.26) 1.01 (0.77, 1.31) 
High (7 to 9) 912   9.5 1.09 (0.81, 1.47) 1.15 (0.85, 1.55) 
Very high (10 to 22) 469   10.4 1.21 (0.85, 1.73) 1.23 (0.86, 1.76) 
Low (0 to 4) 1,783  Definite only 5.2 1.00 [ref] 1.00 [ref] 
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Medium (5 to 6) 1,089   4.5 0.87 (0.62, 1.23) 0.91 (0.65, 1.29) 
High (7 to 9) 912   4.6 0.86 (0.58, 1.28) 0.91 (0.61, 1.36) 
Very high (10 to 22) 469   4.7 0.88 (0.53, 1.44) 0.89 (0.54, 1.47) 
Low (0 to 4) 1,783  Definite without attribution 4.6 1.00 [ref] 1.00 [ref] 
Medium (5 to 6) 1,089   4.0 0.87 (0.61, 1.24) 0.92 (0.64, 1.32) 
High (7 to 9) 912   3.6 0.75 (0.49, 1.17) 0.81 (0.52, 1.27) 
Very high (10 to 22) 469   3.8 0.80 (0.47, 1.38) 0.82 (0.48, 1.42) 
a Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of schizophrenia. 
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5.5.6 Results based on complete case-set analyses  
Results from the complete case-sets for depressive symptoms (N = 1,133) and that for PEs 
(N = 2,495) were similar to the main results reported above.   
In the complete case-set for depressive symptoms (N = 1,133), the number of childhood 
infections from age 1.5 to 7.5 years was associated with subsequent depressive symptoms 
at age 13 years (beta = 0.29; SE = 0.12; p = 0.01) and age 14 years (beta = 0.53; SE = 0.14; 
p <0.001) (Table 25). Evidence for these associations remained after adjusting for potential 
confounders. Childhood infections were not associated with depressive symptoms at age 10, 
17, 18 or 19 years old.   
In the complete case-set for PEs (N = 2,495), the number of childhood infections was 
associated with suspected/definite PEs at age 12 years (OR = 1.15; 95% CI = 1.02, 1.30) 
(Table 26). Evidence for this association remained after adjusting for potential confounders. 
Childhood infections were not associated with PEs at age 18 years. 
Compared with low infection burden, very high infection burden in the complete case-set for 
depressive symptoms (N = 1,133) was associated with depressive symptoms at age 13 
years (beta = 0.88; SE = 0.35; p = 0.01) and age 14 years (beta = 1.81; SE = 0.42; p 
<0.001) (Table 27). Evidence for these associations remained after adjusting for potential 
confounders. Very high infection burden was not associated with depressive symptoms at 
age 10, 17, 18 or 19 years old.   
Compared with low infection burden, medium, high, and very high infection burden in the 
complete case-set for PEs (N = 2,495) were not associated with PEs at age 12 or 18 years 






Table 25. Beta estimate (SE) for the association between 1 SD increase in childhood 
infections and depressive symptoms from age 10 to 19 years in the complete case-set 
(N = 1,133). 
 
  
Table 26. Odds ratio (95% CI) for the association between 1 SD increase in childhood 
infections and PEs at age 12 and 18 years in the complete case set (N = 2,495). 
Age at outcome 
(years) 
% with depression a 
Unadjusted Adjusted b 
Beta (SE)  P-value Beta (SE) P-value 
10 11.7 0.09 (0.10) 0.35 0.08 (0.10) 0.39 
13 14.2 0.29 (0.12)  0.01 0.28 (0.11)  0.01 
14 21.4 0.53 (0.14)  <0.001 0.51 (0.13)  <0.001 
17 25.7 0.16 (0.16) 0.32 0.15 (0.16) 0.34 
18 29.2 0.14 (0.15) 0.34 0.14 (0.15) 0.34 
19 29.2 0.04 (0.17) 0.82 0.03 (0.17) 0.86 
a For the purposes of this table, depression is defined as SMFQ score ≥8.  
b Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of severe depression.  
Psychotic experiences (PEs) % with PEs 
Odds ratio (95% CI) 
Unadjusted Adjusted a 
Suspected/definite at age 12 13.1 1.15 (1.02, 1.30) 1.15 (1.03, 1.30) 
Definite only at age 12  5.1 1.13 (0.94, 1.36) 1.13 (0.95, 1.36) 
Definite without attribution at age 12 4.4 1.15 (0.95, 1.39) 1.15 (0.95, 1.40) 
Suspected/definite at age 18 8.1 1.13 (0.97, 1.31) 1.13 (0.98, 1.31) 
Definite only at age 18  4.4 1.01 (0.82, 1.23) 1.01 (0.83, 1.24) 
Definite without attribution at age 18 3.6 0.99 (0.80, 1.24) 1.00 (0.80, 1.25) 
a Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of schizophrenia. 
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Table 27. Beta estimate (SE) for the association between childhood infection burden and depressive symptoms from age 10 to 19 
years in the complete case-set (N = 1,133). 
Infection burden between age 
1.5 and 7.5 (no. of infections) 
Age at outcome 
(years) 
% with depression a 
Unadjusted Adjusted b 
Beta (SE)  P-value Beta (SE)  P-value 
Low (0 to 4)  10 11.8 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)   10.1 -0.10 (0.24) 0.68 -0.08 (0.24) 0.74 
High (7 to 9)  11.5 0.02 (0.25) 0.93 0.04 (0.25) 0.86 
Very high (10 to 22)  15.2 0.31 (0.30) 0.31 0.28 (0.31) 0.37 
Low (0 to 4)  13 11.5 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)   14.2 0.22 (0.27) 0.43 0.18 (0.27) 0.52 
High (7 to 9)  15.1 0.52 (0.28) 0.07 0.55 (0.28) 0.05 
Very high (10 to 22)  20.0 0.88 (0.35) 0.01 0.84 (0.35) 0.02 
Low (0 to 4)  14 17.9 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)   21.7 0.21 (0.32) 0.51 0.12 (0.32) 0.70 
High (7 to 9)  20.8 0.21 (0.34) 0.53 0.27 (0.33) 0.41 
Very high (10 to 22)  31.0 1.81 (0.42) <0.001 1.68 (0.41) <0.001 
Low (0 to 4)  17 22.3 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)   26.1 0.63 (0.38) 0.10 0.52 (0.37) 0.17 
High (7 to 9)  27.6 0.34 (0.40) 0.40 0.49 (0.39) 0.21 
Very high (10 to 22)  30.3 0.65 (0.49) 0.19 0.47 (0.48) 0.33 
Low (0 to 4)  18 28.9 0.00 [ref]  0.00 [ref]  
Medium (5 to 6)   28.0 -0.01 (0.36) 0.98 -0.09 (0.36) 0.80 
High (7 to 9)  27.6 -0.13 (0.37) 0.72 -0.06 (0.37) 0.88 
Very high (10 to 22)  35.9 0.54 (0.46) 0.25 0.46 (0.46) 0.32 



















Medium (5 to 6)   29.6 0.27 (0.41) 0.52 0.19 (0.41) 0.65 
High (7 to 9)  33.3 0.54 (0.43) 0.21 0.61 (0.43) 0.15 
Very high (10 to 22)  30.3 0.11 (0.53) 0.84 <0.01 (0.53) 1.00 
a For the purposes of this table, depression is defined as SMFQ score ≥8.  
b Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of severe depression. 
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Table 28. Odds ratio (95% CI) for the association between childhood infection burden and PEs at age 12 and 18 years (N = 2,495). 
Infection burden between age 1.5 and 
7.5 (no. of infections) 
Psychotic experiences (PEs) % with PEs 
Odds ratio (95% CI) 
Unadjusted  Adjusted a 
Low (0 to 4)  Suspected/definite at age 12 11.8 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   12.1 1.03 (0.76, 1.40) 1.04 (0.77, 1.42) 
High (7 to 9)  15.1 1.33 (0.99, 1.63) 1.35 (1.00, 1.82) 
Very high (10 to 22)  15.5 1.37 (0.94, 2.00) 1.37 (0.94, 1.99) 
Low (0 to 4)  Definite only at age 12 5.0 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   4.0 0.79 (0.48, 1.28) 0.79 (0.49, 1.29) 
High (7 to 9)  6.4 1.30 (0.84, 2.02) 1.33 (0.86, 2.07) 
Very high (10 to 22)  5.2 1.03 (0.57, 1.87) 1.02 (0.56, 1.85) 
Low (0 to 4)  Definite without attribution at age 12 4.3 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   3.5 0.82 (0.49, 1.38) 0.83 (0.49, 1.39) 
High (7 to 9)  5.8 1.37 (0.86, 2.19) 1.39 (0.87, 2.23) 
Very high (10 to 22)  4.5 1.05 (0.55, 1.99) 1.04 (0.55, 1.98) 
Low (0 to 4)  Suspected/definite at age 18 7.3 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   8.1 1.13 (0.78, 1.63) 1.13 (0.78, 1.65) 
High (7 to 9)  8.8 1.23 (0.85, 1.80) 1.25 (0.86, 1.82) 
Very high (10 to 22)  8.9 1.25 (0.78, 2.01) 1.26 (0.78, 2.02) 
Low (0 to 4)  Definite only at age 18 4.5 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   4.1 0.92 (0.56, 1.50) 0.93 (0.57, 1.52) 
High (7 to 9)  4.6 1.02 (0.62, 1.67) 1.04 (0.63, 1.70) 
Very high (10 to 22)  4.5 1.00 (0.53, 1.88) 1.01 (0.53, 1.91) 
Low (0 to 4)  Definite without attribution at age 18 3.7 1.00 [ref] 1.00 [ref] 
Medium (5 to 6)   3.5 0.95 (0.56, 1.61) 0.96 (0.56, 1.63) 
High (7 to 9)  3.6 0.95 (0.55, 1.65) 0.97 (0.56, 1.68) 
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Very high (10 to 22)  3.8 1.01 (0.51, 2.02) 1.02 (0.51, 2.04) 
a Adjusted for sex, birthweight, maternal SEP, ethnicity and parental history of schizophrenia. 
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5.5.7 Comparison between analytic and missing samples for depressive 
symptoms 
Comparison between the risk set (N = 11,786) and the complete case-set (N = 1,133) 
showed that those in the complete case-set were more likely to be female (p <0.001), White 
(p = 0.02), have a higher number of childhood infections (p <0.001), and have lower 
depressive symptoms at age 10 (p <0.001), 17 (p = 0.03), 18 (p <0.001), and 19 years (p 
<0.01) (Table 29). Individuals in the complete case-set were less likely to have a mother of 
manual SEP (p <0.001) or have a parent with a history of severe depression (p <0.001).  
Similarly, comparison between the analytic sample for depressive symptoms (N = 3,101) 
and the missing sample (N = 8,685) showed that those included in analyses were more likely 
to be female (p <0.001), White (p = 0.05), have a higher number of childhood infections (p 
<0.001), and have lower depressive symptoms at age 10 and 18 years (p <0.001) (Table 
30). The analytic sample were less likely to have a mother of manual SEP (p <0.001) or 




Table 29. Missing data: Comparison of the risk set (data for childhood infections) and 
the complete case-set for depressive symptoms (data for childhood infections and 






Risk set  





(N = 1,133) 
Difference 
between groups  
(X2 / t-test p-
value) 
Confounders    
Sex – no. female (%) 5,710 (48.4) 706 (62.3) <0.001 
Ethnicity – no. White (%) 11,511 (97.7) 1,117 (98.6) 0.02 
Maternal SEP – no. manual (%) 2,621 (22.2) 120 (10.6) <0.001 
Birthweight – mean (SD) 3.4 (0.5) 3.4 (0.5) 0.20 
Parental history of severe depression – no. (%) 1,677 (14.2) 90 (7.9) <0.001 
Number of childhood infections    
Mean (SD) 4.6 (3.2) 6.0 (3.0) <0.001 
Median (IQR) 4 (2-6) 6 (4-8) <0.001 
Burden of infection – no. (%)    
Low (0 to 4 infections)  6,371 (54.1) 391 (34.5) <0.001 
Medium (5 to 6 infections)  2,480 (21.0) 318 (28.1) <0.001 
High (7 to 9 infections) 1,988 (16.9) 279 (24.6) <0.001 
Very high (10 to 22 infections) 947 (8.0) 145 (12.8) <0.001 
Depressive symptoms – mean (SD)    
Age 10  4.0 (3.5) 3.7 (3.1) <0.001 
Age 13  3.9 (3.8) 3.9 (3.6) 1.00 
Age 14  4.9 (4.5) 4.8 (4.3) 0.40 
Age 17  5.9 (5.6) 5.5 (5.1) 0.03 
Age 18  6.6 (5.3) 6.0 (4.8) <0.001 
Age 19 6.8 (5.9) 6.2 (5.5) <0.01 
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Table 30. Missing data: Comparison of the analytic sample for depressive symptoms 
(data for childhood infections and depressive symptoms at age 19 years) and the 










sample for  
depressive 
symptoms  
(N = 3,101) 
Missing 
sample for  
depressive 
symptoms  
(N = 8,685) 
Difference 
between groups  
(X2 / t-test p-
value) 
Confounders    
Sex – no. female (%) 1,983 (63.9) 3,727 (42.9) <0.001 
Ethnicity – no. White (%) 3,042 (98.1) 8,469 (97.5) 0.05 
Maternal SEP – no. manual (%) 456 (14.7) 2,164 (24.9) <0.001 
Birthweight – mean (SD) 3.4 (0.5) 3.4 (0.5) 0.13 
Parental history of severe depression – no. (%) 347 (11.2) 1,330 (15.3) <0.001 
Number of childhood infections    
Mean (SD) 5.6 (3.1) 4.3 (3.2) <0.001 
Median (interquartile range) 5 (3-7) 4 (2-6) <0.001 
Burden of infection – no. (%)    
Low (0 to 4 infections)  1,236 (40.0) 5,135 (59.1) <0.001 
Medium (5 to 6 infections)  829 (26.7) 1,651 (19.0) <0.001 
High (7 to 9 infections) 691 (22.3) 1,297 (14.9) <0.001 
Very high (10 to 22 infections) 345 (11.1) 602 (6.9) <0.001 
Depressive symptoms – mean (SD)    
Age 10  3.8 (3.4) 4.2 (3.6) <0.001 
Age 13  4.0 (3.8) 3.9 (3.8) 0.10 
Age 14  5.0 (4.5) 4.8 (4.4) 0.20 
Age 17  5.8 (5.4) 6.0 (5.8) 0.30 
Age 18  6.2 (5.0) 7.0 (5.5) <0.001 
Age 19 6.8 (5.9) -- -- 
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5.5.8 Comparisons between analytic and missing samples for psychotic 
experiences 
Comparison between the risk set (N = 11,786) and the complete case-set (N = 2,495) 
showed that those in the complete case-set were more likely to be female (p <0.001), be of 
White ethnicity (p <0.01), have high number of childhood infections (p <0.001), and less 
likely to have mother of manual SEP (p <0.001) (Table 31). 
Similarly, comparison between the analytic sample for PEs (N = 4,253) compared with the 
missing sample (N = 7,533) showed that those included in analyses were more likely to be 
female (p <0.001), have a higher number of childhood infections (p <0.001), and less likely 




Table 31. Missing data: Comparison of the risk set (data for childhood infections) and 
the complete case-set for psychotic experiences (data for childhood infections and 









Risk set  
(N = 11,786) 
Complete case-
set for PEs  
(N = 2,495) 
Difference 
between groups  
(X2 / t-test p-
value) 
Confounders    
Sex – no. female (%) 5710 (48.4) 1372 (55.0) <0.001 
Ethnicity – no. White (%) 11511 (97.7) 2457 (98.5) <0.01 
Maternal SEP – no. manual (%) 2621 (22.2) 327 (13.1) <0.001 
Birthweight – mean (SD) 3.4 (0.5) 3.4 (0.5) 0.08 
Parental history of schizophrenia – no. (%) 40 (0.3) 9 (0.4) 0.90 
Number of childhood infections    
Mean (SD) 4.6 (3.2) 5.8 (3.0) <0.001 
Median (IQR) 4 (2-6) 5 (4-8) <0.001 
Burden of infection – no. (%)    
Low (0 to 4 infections)  6371 (54.1) 936 (37.5) <0.001 
Medium (5 to 6 infections)  2480 (21.0) 677 (27.1) <0.001 
High (7 to 9 infections) 1988 (16.9) 591 (23.7) <0.001 
Very high (10 to 22 infections) 947 (8.0) 291 (11.7) <0.001 
Psychotic experiences (PEs) – no. (%)    
Suspected/definite PEs age 12  844 (13.7) 326 (13.1) 0.50 
Definite PEs only age 12  350 (5.7) 127 (5.1) 0.30 
Definite PEs without attribution age 12  289 (4.7) 111 (4.4) 0.60 
Suspected/definite PEs age 18 385 (9.1) 201 (8.1) 0.20 
Definite PEs only age 18 206 (4.8) 110 (4.4) 0.40 
Definite PEs without attribution age 18 177 (4.2) 91 (3.6) 0.30 
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Table 32. Missing data: Comparison of the analytic sample for PEs (data for childhood 
infections and PEs at age 18 years) and the missing sample (data for childhood 





sample for PEs 
(N = 4,253) 
Missing sample 
for PEs (N = 
7,533) 
Difference 
between groups  
(X2 / t-test p-
value) 
Confounders    
Sex – no. female (%) 2391 (56.2) 3319 (44.1) <0.001 
Ethnicity – no. White (%) 4164 (97.9) 7348 (97.5) 0.23 
Maternal SEP – no. manual (%) 708 (16.6) 1913 (25.4) <0.001 
Birthweight – mean (SD) 3.4 (0.5) 3.4 (0.5) 0.10 
Parental history of schizophrenia – no. (%) 17 (0.4) 24 (0.3) 0.51 
Number of childhood infections    
Mean (SD) 5.5 (3.1) 4.1 (3.2) <0.001 
Median (IQR) 5 (3-7) 4 (2-6) <0.001 
Burden of infection – no. (%)    
Low (0 to 4 infections)  1783 (41.9) 4588 (60.9) <0.001 
Medium (5 to 6 infections)  1089 (25.6) 1391 (18.5) <0.001 
High (7 to 9 infections) 912 (21.4) 1076 (14.3) <0.001 
Very high (10 to 22 infections) 469 (11.0) 478 (6.4) <0.001 
Psychotic experiences (PEs) – no. (%)    
Suspected/definite PEs age 12  504 (13.4) 340 (14.0) 0.50 
Definite PEs only age 12  203 (5.4) 147 (6.1) 0.30 
Definite PEs without attribution age 12  174 (4.6) 115 (4.8) 0.80 
Suspected/definite PEs age 18 385 (9.1) -- -- 
Definite PEs only age 18 206 (4.8) -- -- 
Definite PEs without attribution age 18 177 (4.2) -- -- 
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5.6 Discussion  
 
Our findings suggest that common early-childhood infections, particularly a very high 
infection burden, are associated with: (i) the risk of depressive symptoms subsequently up to 
age 17 years, and (ii) the risk of suspected/definite PEs subsequently at age 12 years. The 
finding that very high infection burden has the strongest association with mental health 
outcomes is somewhat consistent with hypotheses 3 and 4 (Section 5.3, Page 149), which 
state that childhood infection burden has a dose-response relationship with both depressive 
symptoms and PEs. The associations of infection with depressive symptoms at age 13 and 
14 years and with suspected/definite PEs at age 12 years were robust and persisted after 
correction for multiple testing. Childhood infections were not associated with risk of 
depressive symptoms or PEs at age 18 or 19 years. As such, hypotheses 1 and 2 were not 
supported since childhood infections were not associated with mental heath outcomes at all 
ages. 
Strong links exist between child/adolescent and adult depression (66–68,73). Adolescents 
with recurrent depressive episodes are at particularly high risk of subsequent recurrent 
depression as adults (68). Longitudinal studies suggest that recurrence of depression may 
be similar in clinic and community samples (66). PEs in childhood or adolescence may also 
provide a valid method for studying the development of adult psychotic disorders (403,416). 
PEs in childhood may be transient but population-based studies suggest that PEs in the 
general population and those observed in psychotic disorders may exist on a continuum 
(417). Prospective birth cohort studies have reported that PEs in childhood are associated 
with increased risk of psychotic disorders in adulthood (401). Common underlying 
mechanisms for PEs in healthy individuals and in schizophrenia have also been reported 
(418). Early-life infections could increase psychosis risk by affecting neurodevelopment, 
consistent with the neurodevelopmental hypothesis of schizophrenia (419,420). In many 
cases, PEs in our sample are likely to be part of normal development while for other 
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participants these symptoms may be more pathological (421,422). Childhood PEs are also 
familial and heritable and associated with multiple risk factors for schizophrenia (423–426). 
PEs and depressive symptoms in children and adolescents appear to be markers of mental 
distress and represent useful indicators for subsequent mental health problems.  
In our sample, associations observed between childhood infections and PEs/depressive 
symptoms in childhood and adolescence did not persist for these outcomes in late-
adolescence. There could be a number of explanations for this, including that childhood 
infections do not have a lasting effect on the risk of adult mental health disorders. However, 
findings from other long-term follow-up studies argue against this. For instance, a meta-
analysis of childhood infections reported that children exposed to viral infections of the 
central nervous system were at higher risk of adult psychosis (390). Longitudinal studies of 
childhood infection and subsequent non-affective psychosis found similar results (388,391). 
Furthermore, population-based longitudinal studies suggest that childhood infections and 
autoimmune disease increase risk of adult schizophrenia and mood disorders in a dose-
response fashion (145,386). Benros and colleagues reported that a history of hospitalisation 
for infection increases the risk of mood disorders and schizophrenia by 62% and 60% 
respectively (145,386). One explanation for the null findings could be attrition. At age 19 
years, 86% of the sample with data on childhood infections were missing from follow-up for 
depressive symptoms and at age 18 years, 68% of the sample were missing from follow-up 
for PEs. Another explanation could be choice of exposure and outcome used. For instance, 
previous studies used serious infections requiring hospitalisation as exposure (145,386), and 
diagnosis of schizophrenia or depression as outcome. I have used common childhood 
infections as exposure and depressive symptoms/PEs as outcomes. Nevertheless, I was still 
able to show that relatively common childhood infections are associated with risk of 
depressive symptoms and PEs in adolescence. Sample size for outcomes in late-
adolescence was relatively small and there was attrition over time, a common issue for 
prospective studies. In future, studies with larger sample sizes for cases are required.  
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It is possible that childhood infections contribute indirectly (via inflammatory mechanisms) to 
the risk of mental health disorders. Inflammatory responses to infection, such as elevated 
cytokine levels and fever, may represent the mechanism through which risk of mental 
disorders is increased (427). Sickness behaviour is common in infection and is present in 
some cases of depression. Sickness behaviour is triggered by proinflammatory cytokines in 
response to infectious agents and includes symptoms such as fatigue, anhedonia, 
concentration difficulties, social withdrawal, and appetite changes (381,428). Along with 
sickness behaviour, proinflammatory cytokines may induce depression in physically ill 
individuals with no history of mental health disorders. Depression may be therefore a 
maladaptive form of cytokine-induced sickness in some individuals (381,428). In addition, 
infections in early-life have been associated with adult schizophrenia via inflammation 
(156,157,389,391,429–441). Infection-related inflammation may influence neurodevelopment 
resulting in heightened risk of schizophrenia (442). Inflammation represents a compelling link 
between infection and mental health disorders and requires further investigation. 
The interaction of multiple genetic and environmental factors is likely to contribute to risk of 
psychosis or depression. Genetic susceptibility plays an important role in risk of mental 
health disorders, but there is evidence to suggest that a significant proportion of cases may 
be preventable through modification of the environment (443,444). I attempted to explore the 
effects of environmental factors by controlling for maternal SEP and birth weight. Evidence 
for the association between infection and PEs/depressive symptoms attenuated but did not 
disappear, suggesting that these environmental factors partly explain these associations. 
Some genetic and environmental risk factors for psychosis and depression may be shared 
(444). Childhood maltreatment, social disadvantage, and minority status are independently 
associated with both psychosis and depression (444). By recognising infection and other 
environmental factors that are associated with depression and psychosis, we may be able to 




5.6.1 Limitations   
The strengths of this study include longitudinal design and repeated measures of depressive 
symptoms. A limitation is the method for collection of childhood infection data. The 
questionnaire containing questions on infections were completed by primary caregiver 
throughout childhood with a short period of recall (past 12 months), thus minimising, though 
not completely eliminating, the risk of erroneous recall. The questions on infections also 
require parents to have a good understanding of infectious diseases and may be vulnerable 
to misreporting. For example, 8.2% of parents reported that their children had no infections 
during childhood; a somewhat unlikely scenario. Another limitation is attrition; the number of 
completed mental health assessments decreases over time. This may be indicative of 
selective attrition of mental health cases since mental health problems have been associated 
with non-response and attrition (445). Attrition and subsequent smaller sample size could 
result in underestimation of the true effect of infection on mental health outcomes. Another 
possible explanation for the lack of association with PEs/depression in late-adolescence 
could be that the relative contribution of infection to mental health becomes negligible over 
time due to neuroplasticity and brain development. Finally, statistical power was an issue in 
some of the PE analyses, resulting in wide confidence intervals. 
5.6.2 Conclusion   
Childhood infections are inevitable, but the adverse outcomes of such physical health 
problems may go beyond physical health later in life. Here I present evidence that childhood 
infections, particularly a very high infection burden, can negatively impact mental health well 
into adolescence. Future work is needed (i) to replicate the observed associations between 
common childhood infections and mental health outcomes during adolescence; (ii) to 
examine whether common childhood infections have an effect on depressive symptoms and 




SECTION D: ANALYSIS OF UK BIOBANK DATA 
 
Chapter 6: Systemic Inflammation and Comorbid Lifetime 
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Depression and IHD, both among leading causes of mortality worldwide (1), commonly co-
occur in the population (34). Evidence for a bidirectional association between IHD and 
depression is now well established. For instance, pre-existing IHD is associated with an 
increased risk of subsequent depression (42,44) and vice versa (34). On average, one fifth 
of patients develop depression after IHD (36,37). Similarly, comorbid depression is 
associated with poor prognosis following MI (50,51). This bidirectional relationship points to 
shared risk factors and pathophysiologic mechanisms for depression and IHD, but these 
mechanisms are relatively poorly understood. 
Emerging evidence implicates systemic inflammation in depression (446) and IHD (447). For 
both illnesses, most existing studies are based on assays of acute phase proteins like CRP 
or cytokines like IL-6 (446–448). Meta-analyses of these studies have reported elevated 
CRP levels (>3 mg/L) in a quarter of depressed patients (171). A linear dose-response 
association between CRP levels and severity of depressive symptoms has also been 
reported (449). Similarly, population-based prospective studies have reported an association 
between CRP and CVD (210). However, genetic approaches like Mendelian randomisation 
have suggested that this association may not be causal (294,450,451). WCC, another 
important inflammatory marker, has been reported to be a robust risk factor for fatal and 
non-fatal CVD (198). In contrast, WCC has been studied relatively less extensively in the 
context of depression (159).  
To date, most studies have examined associations of systemic inflammatory markers with 
depression and IHD separately, while studies of comorbid depression and IHD are rare. 
Rarer still are studies of different types of inflammatory markers within the same population. 
Given that the innate immune response comprises protein and cellular components (452), 
studies of different types of inflammatory markers may provide important clues for 




Systemic inflammation is a complex trait, associated with various biologic and environmental 
factors such as obesity, socioeconomic deprivation, and physical activity; some of which are 
well established risk factors for depression and IHD. However, it is unclear to what extent 
confounding from socioeconomic and lifestyle factors contributes to previously reported 
associations of systemic inflammatory markers with depression and IHD. Furthermore, non-
response and selection bias are common methodological issues in observational studies, yet 
most studies have not directly assessed the impact of these issues on observed 
associations. 
In order to examine the potential role of inflammation in the comorbidity between depression 
and IHD, I have used data from the UK Biobank to test whether well-known protein and 
cellular measures of systemic inflammation (i.e., CRP and WCC) are associated with lifetime 
comorbid depression and IHD, and with depression and IHD separately. I have focused on 
IHD because it is one of the more severe CVD subtypes, with extensive evidence suggesting 
a link with depression (42,44,453–456), and with inflammation-related cardiovascular 
changes, namely atherosclerosis (457). I hypothesised that inflammatory markers would be 
more strongly associated with comorbid depression and IHD than either illness alone. In 
addition, to examine commonality verses specificity of association, I jointly modelled 
depression and IHD in relation to CRP and WCC, to test the similarity/difference of the effect 
estimates for the two outcomes. To examine potential confounding from socioeconomic and 
lifestyle factors, I have taken into account effects of age, sex, ethnicity, deprivation (proxy for 
SEP), BMI, smoking, alcohol, and physical activity. I also carried out sensitivity analysis to 
assess the effect of bias from selection of specific UK Biobank participants for respective 









1. CRP is associated with comorbid depression and IHD. 
2. WCC is associated with comorbid depression and IHD. 
3. CRP is more strongly associated with comorbidity than no illness/single illness.  
4. WCC is more strongly associated with comorbidity than no illness/single illness.  
5. CRP shows no specificity of association with either depression or IHD. 


















6.4.1 Description of sample   
The risk set for the analyses comprised 468,553 unrelated participants from the UK Biobank 
with data on CRP concentration at baseline (Figure 32). See Section 2.5 (Page 70) for 
details of the UK Biobank study. Of these individuals, 122,972 had data on lifetime 
depression and 410,252 had data on lifetime IHD. A total of 99,578 individuals had data on 
both lifetime depression and IHD. 
 
 
CRP: C-reactive protein; DEP: depression; IHD: ischaemic heart disease; WCC: white blood cell count. 
 





6.4.2 Assessment of CRP concentration    
During recruitment, blood samples (45 ml) were collected. The blood was collected in a silica 
clot accelerator collection tube and left to clot at room temperature for 30 minutes before the 
serum was separated by centrifugation at 4 oC. The serum was packed and later stored at 
the UK Biobank central facility in either –80 oC or in nitrogen-vapour (458). CRP 
concentration was measured by immunoturbidimetric high sensitivity analysis on a Beckman 
Coulter AU5800. CRP was used as a log-transformed standardised continuous measure in 
analyses. 
6.4.3 Assessment of WCC    
WCC assay was performed on blood samples obtained from UK Biobank assessment centre 
visits. The analyser operating range was 0 to 9x1011 cells/L. WCC was measured as 109 
cells/L. WCC was used as a standardised continuous measure.  
6.4.4 Assessment of lifetime depression 
A binary measure of lifetime probable moderate/severe major depression was derived from 
self-report data collected using a touchscreen questionnaire administered to UK Biobank 
participants at baseline (459). The questionnaire included information on past episodes of 
low mood, loss of interest, duration and number of episodes, help seeking from family 
physician or psychiatrist, which were systematically combined to derive categories of 
probable single episode or recurrent major depression (moderate or severe) (Table 33) 
(459). Probable lifetime depression was used as a binary variable (depression vs no 
depression).  
Lifetime depression diagnosis was defined as ICD-10 code F32 to F33. Depression 
diagnosis was used as a binary variable (depression vs no depression). These data were 
collected from hospital inpatient records. ICD-10 diagnosis of depression was used in 
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sensitivity analysis only, as this is only available for hospital inpatients and are incomplete 
for mental health outcomes resulting in a very small and unrepresentative number of cases. 
 




Definition based on criteria  
1. Ever felt depressed for a whole week 
2. Ever disinterested or unenthusiastic for 
a whole week 
3. Only one episode 
4. ≥2 episodes 
5. Episode lasted ≥2 weeks 
6. Ever seen a GP for nerves, anxiety, 
tension or depression 
7. Ever seen a psychiatrist for nerves, 
anxiety, tension or depression 
Single episode of 
probable major 
depression 
{(1) AND (3) AND (5) AND [(6) OR (7)]}  
OR  








[(1) OR (2)] AND (4) AND (5) AND (7) 
 
6.4.5 Assessment of lifetime IHD 
Lifetime IHD diagnosis was defined as ICD-10 code I20 to I25. IHD was used as a binary 
variable (IHD vs no IHD). These data were collected from hospital inpatient records, which 
were more complete for physical health outcomes than mental health outcomes.  
6.4.6 Assessment of comorbid lifetime depression and IHD 
Comorbidity was defined as the presence of both lifetime depression and IHD.  
6.4.7 Assessment of confounders 
I adjusted for the following covariates: sex, ethnicity, age, TDI, BMI, smoking, alcohol, 
physical activity, mood disorders, metabolic disorders, chronic inflammatory conditions, and 
acute infections. All covariates were recorded at recruitment between 2006 and 2010.  
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Sex and ethnicity were used as binary variables. Sex (female or male) was acquired from 
NHS records. In some cases, recorded sex was updated by the participant. Ethnicity was 
recorded as White, Mixed, Asian/Asian British, Black/Black British, Chinese, and Other. The 
UK Biobank is relatively homogenous in terms of ethnicity, therefore ethnicity was recoded 
as White or any other ethnicity.  
Age, TDI, and BMI were all used as continuous variables. Age (years) was based on self-
reported date of birth and used as a continuous measure. TDI is a measure of material 
deprivation which was used as a proxy for socioeconomic status. TDI covers four 
components: (i) unemployment, (ii) non-car ownership, (iii) non-home ownership, and (iv) 
household overcrowding (460). These components are measured in a specific area, then 
combined and standardised to give an overall score for that area. A higher score represents 
a greater level of deprivation. BMI was calculated as body weight (kilograms) divided by 
height (meters squared).  
Smoking status, alcohol intake, and physical activity were all used as categorical variables. 
Smoking status was categorised into three groups (never; previous; current). Alcohol intake 
was categorised into six groups (never; special occasions only; 1 to 3 times per month; 1 to 
2 times per week; 3 to 4 times per week; daily or almost day). Physical activity in the last four 
weeks was categorised into six groups (none; walking for pleasure [not as a means of 
transport]; light DIY [e.g. pruning, watering the lawn]; heavy DIY [e.g. weeding, lawn mowing, 
carpentry, digging]; strenuous sports; other exercise [e.g. swimming, cycling, keep fit, 
bowling]). Participants could record doing more than one type of physical activity.  
Mood disorders, metabolic disorders, chronic inflammatory conditions, and acute infections 
were all used as binary variables. Mood disorders were defined as diagnosis of bipolar 
disorder (ICD-10 code: F30 to F31), schizophrenia (F20 to F29) or anxiety disorder (F40 to 
F41). Metabolic disorders were defined as diagnosis of diabetes mellitus (E10 to E14) or 
obesity (E65 to E66). Chronic inflammatory conditions were defined as diagnosis of multiple 
sclerosis (G35), irritable bowel syndrome (K50 to K51), rheumatoid arthritis (M05 to M06), or 
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systemic lupus erythematosus (M32). Acute infections were defined as acute viral or 
bacterial infection (A00 to A49, A80, B00 to B19, J00 to J29). These data were collected 
from hospital inpatient records. 
6.4.8 Statistical analysis 
Analyses were carried out using R (version 3.6.1) unless otherwise specified. Regression 
models were estimated before adjustment for potential confounders and using sequential 
adjustment for: (i) age, sex, ethnicity, deprivation; (ii) additional adjustment for alcohol, 
smoking, physical activity; and (iii) additional adjustment for BMI. 
6.4.9 Association of immune markers with lifetime depression and IHD  
Logistic regression was used to calculate ORs with 95% CI for the three outcomes: (i) 
depression; (ii) IHD; and (iii) comorbid depression and IHD (Hypothesis 1 to 4, Page 191). 
Monomorbid depression and IHD outcomes were tested against their respective “no illness” 
control group (e.g. IHD vs no IHD). I used two different control groups for the comorbid 
depression and IHD outcome: (i) “single illness” i.e. either depression or IHD, but not both; 
and (ii) “no illness” i.e. no depression or IHD. I took the decision not to use just one control 
group (i.e. comorbidity vs no comorbidity) because the group with monomorbid depression 
or IHD is likely to be different from the group with neither of these conditions. 
Where CRP concentration was the exposure, the ORs represent the odds of the outcome 
per one SD increase in log-transformed CRP concentration. Where WCC was the exposure, 
the ORs represent the odds of the outcome per one SD increase in WCC.   
6.4.10 Specificity of association of CRP and WCC with lifetime depression and 
IHD 
Bivariate probit regression was performed using Stata/IC 16.0. I jointly modelled depression 
and IHD outcomes with CRP/WCC to compare the effect estimates for the two outcomes 
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(Hypothesis 5, 6, Page 191). Specifically, to test equality of regression parameters for both 
outcomes, I compared a model that allowed exposure estimates to differ between outcomes 
with a model that constrained estimates to be equal for both outcomes using the likelihood 
ratio test (LRT). Probit estimates were converted to ORs by multiplying probit parameters by 
1.6 (461).  
6.4.11 Sensitivity analysis to explore potential influence of selection bias 
I evaluated the influence of potential selection bias for participation in depression and IHD 
data collection using inverse probability weighted regression of the models of depression 
and IHD outcomes on either CRP or WCC (462). This method up-weights participants who 
were less likely to participate in outcome data collection and down-weights participants who 
were more likely to participate. In this way, weighted analyses estimate results as if the full 
UK Biobank dataset were used in analyses. 
To obtain participant weights, I regressed participation in outcome data collection (0 = no 
participation; 1 = participation) on age, sex, ethnicity, BMI, and TDI as well as all possible 
variable interactions and quadratic and cubic effects for continuous variables. I then created 
stabilised inverse probability weights from the above regression model by dividing the mean 
proportion of outcome data collection participation by the fitted values from this regression 
(463).    
I repeated logistic regression analyses of depression and IHD outcomes on CRP/WCC using 
the inverse probability weights as regression weightings.  
6.4.12 Sensitivity analysis using depression diagnosis as the outcome 
I assessed the robustness of the self-reported measure of lifetime depression by repeating 
logistic regression analyses of depression and IHD outcomes on CRP/WCC using ICD-10 





6.4.13 Sensitivity analysis adjusting for additional potential confounders  
I assessed the effect of mood disorders, metabolic disorders, chronic inflammatory 
conditions, and acute infections on associations from main analyses. I repeated logistic 
regression analyses of depression and IHD outcomes on CRP/WCC adjusting for these 
variables. BMI was excluded as a confounder in this sensitivity analysis since metabolic 





6.5 Results  
6.5.1 Baseline characteristics of the sample 
The UK Biobank sample (Figure 32) comprised mainly individuals of White ethnicity (94.6%) 
and low deprivation (TDI mean = –1.3; SD = 3.1) (Table 34). Over half of participants 
(54.4%) were women. The number of participants with lifetime depression, lifetime IHD, and 
comorbid depression and IHD were 24,642 (20%), 32,192 (8%) and 1,661 (2%), 
respectively. 
Individuals with high CRP were more likely to be women (p <0.001), be current smokers 
(p<0.001), have less frequent alcohol intake (p <0.001), have higher BMI (p <0.001), and 



















Table 34. Characteristics of the participants using maximum available sample size. 
Characteristic a 
All participants 
(N = 502,488) 
Low CRP b 
(N = 362,255) 
High CRP b  
(N = 106,298) 
Difference 
between low and 
high CRP  
(X2/T-test p-value) 
Exposure     
WCC (109 cells/L) – mean (SD) 6.9 (2.1) 6.7 (2.1) 7.7 (2.2) <0.001 
Outcomes     
Depression (self-report) – no. (%) 24,642 (20.0) 17,194 (19.2) 5,724 (22.9) <0.001 
Depression (diagnosis) – no. (%) 1,515 (0.4) 995 (0.3) 520 (0.6) <0.001 
IHD (diagnosis) – no. (%) 32,192 (7.8) 21,535 (7.4) 8,372 (9.1) <0.001 
Comorbidity – no. (%)     
Depression (self-report) & IHD 1,661 (1.7) 1,053 (1.5) 491 (2.3) <0.001 
Depression (diagnosis) & IHD 156 (0.0) 97 (0.0) 59 (0.1) <0.001 
Confounders     
Age (years) – mean (SD) 56.5 (8.1) 56.3 (8.1) 57.4 (7.9) <0.001 
Deprivation (TDI) – mean (SD) -1.3 (3.1) -1.4 (3.0) -0.9 (3.3) <0.001 
BMI (kg/m2) – mean (SD) 27.4 (4.8) 26.6 (4.1) 30.3 (5.7) <0.001 
Sex – no. women (%) 273,375 (54.4) 191,387 (52.8) 62,783 (59.1) <0.001 
Ethnicity – no. White (%) 472,679 (94.6) 341,932 (94.8) 99,695 (94.3) <0.001 
Smoking status – no. (%)     
Never  273,513 (54.8) 203,578 (56.5) 51,589 (48.9) <0.001 
Previous 173,050 (34.6) 123,315 (34.2) 38,535 (36.5) <0.001 
Current 52,977 (10.6) 33,694 (9.3) 15,470 (14.7) <0.001 
Alcohol intake – no. (%)     
Never 40,639 (8.2) 26,432 (7.3) 11,174 (10.5) <0.001 
Special occasions only 58,006 (11.6) 37,881 (10.5) 15,927 (15.0) <0.001 
1 to 3 times per month 55,853 (11.1) 38,899 (10.8) 13,144 (12.4) <0.001 
1 or 2 times per week 129,288 (25.8) 93,888 (26.0) 26,809 (25.3) <0.001 
3 or 4 times per week 115,434 (23.0) 87,610 (24.2) 20,450 (19.3) <0.001 
Daily or almost daily  191,767 (20.3) 76,840 (21.3) 18,466 (17.4) <0.001 
Physical activity – no. (%)     
None 32,844 (6.6) 18,677 (5.2) 11,667 (11.1) <0.001 
Walking 350,932 (70.8) 263,322 (73.0) 67,253 (64.0) <0.001 
Light DIY 33,819 (6.8) 22,034 (6.1) 9,754 (9.3) <0.001 
Heavy DIY 12,707 (2.6) 8,810 (2.4) 3,191 (3.0) <0.001 
Strenuous sports 3,871 (0.8) 3,035 (0.8) 628 (0.6) <0.001 
Other 61,165 (12.3) 44,826 (12.4) 12,635 (12.0) <0.001 
Related conditions – no. (%)     
Mood disorders 1,973 (0.5) 1,331 (0.5) 642 (0.7) <0.001 
Metabolic disorders 3,056 (0.8) 1,743 (0.6) 1,313 (1.4) <0.001 
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Chronic inflammatory conditions 5,723 (1.5) 3,442 (1.2) 2,281 (2.5) <0.001 
Acute infections 28,345 (7.4) 18,680 (6.4) 9,665 (10.5) <0.001 
a BMI: body mass index; IHD: ischemic heart disease; SD: standard deviation; TDI: Townsend deprivation index; 
WCC: white blood cell count.  
b For the purposes of this table, low CRP defined as ≤3mg/L and high CRP defined as >3mg/L. 
 
6.5.2 Associations of CRP with depression, IHD, and comorbid depression and 
IHD  
The analyses in this section are relevant to hypotheses 1 and 3 (Section 6.3, Page 191). 
There was consistent association of CRP with comorbid depression and IHD after fully 
adjusting for potential confounders, using the group with neither depression nor IHD as 
reference (adjusted OR = 1.07; 95% CI = 1.01, 1.13) or using the group with either 
depression or IHD alone as reference (adjusted OR = 1.07; 95% CI = 1.01, 1.14) (Table 35). 
CRP was also associated with depression (adjusted OR = 1.03; 95% CI = 1.01, 1.05) but not 
with IHD (adjusted OR = 0.98; 95% CI = 0.97, 1.00) after adjusting for potential confounders 
including BMI.  
6.5.3 Associations of WCC with depression, IHD, and comorbid depression 
and IHD  
The analyses in this section are relevant to hypotheses 2 and 4 (Section 6.3, Page 191). 
There was consistent association of WCC with comorbid depression and IHD after adjusting 
for potential confounders, using the group with neither depression nor IHD as reference 
(adjusted OR = 1.10; 95% CI = 1.06, 1.13) or using the group with either depression or IHD 
alone as reference (adjusted OR = 1.11; 95% CI = 1.06, 1.17) (Table 35). WCC was also 
associated with IHD (adjusted OR = 1.09; 95% CI = 1.08, 1.10), but not with depression 




Table 35. Odds ratio (95% CI) for the association between 1 SD increase in CRP or WCC and depression/IHD outcomes.
Exposure a Outcome  Sample size  
No. with outcome 
(%)  
Odds ratio (95% CI) for depression/IHD outcomes 
Unadjusted  Adjusted 1 b Adjusted 2 c  Adjusted 3 d 
CRP Depression 112,522 22,522 (20.0) 1.10 (1.09, 1.12) 1.11 (1.10, 1.13) 1.08 (1.07, 1.10) 1.03 (1.01, 1.05) 
 IHD 374,811 29,023 (7.7) 1.16 (1.15, 1.18) 1.12 (1.10, 1.13) 1.07 (1.06, 1.08) 0.98 (0.97, 1.00) 
 Comorbidity [ref: no illness] 67,579 1,491 (2.2) 1.34 (1.27, 1.41) 1.28 (1.22, 1.35) 1.20 (1.13, 1.26) 1.07 (1.01, 1.13) 
 Comorbidity [ref: single illness]   24,896 1,491 (6.0) 1.21 (1.15, 1.27) 1.19 (1.13, 1.26) 1.15 (1.09, 1.21) 1.07 (1.01, 1.14) 
WCC Depression 115,391 23,085 (20.0) 1.09 (1.07, 1.10) 1.08 (1.06, 1.10) 1.04 (1.02, 1.05) 1.02 (1.00, 1.03) 
 IHD 382,469 29,693 (7.8) 1.19 (1.18, 1.21) 1.15 (1.14, 1.16) 1.11 (1.10, 1.12) 1.09 (1.08, 1.10) 
 Comorbidity [ref: no illness] 69,298 1,537 (2.2) 1.18 (1.13, 1.22) 1.15 (1.11, 1.20) 1.11 (1.08, 1.15) 1.10 (1.06, 1.13) 
 Comorbidity [ref: single illness]   25,523 1,537 (6.0) 1.21 (1.15, 1.27) 1.18 (1.12, 1.24) 1.14 (1.08, 1.19) 1.11 (1.06, 1.17) 
a  CI: confidence interval; Comorbidity: presence of both lifetime depression and IHD; CRP: C-reactive protein; IHD: ischaemic heart disease; No illness: absence of both 
lifetime depression and IHD; Single illness: presence of either lifetime depression or IHD but not both; WCC: white blood cell count. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + BMI. 
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6.5.4 Specificity of association of CRP and WCC with depression and IHD 
The analyses in this section are relevant to hypotheses 5 and 6 (Section 6.3, Page 191). 
In bivariate probit regression analysis, I demonstrated minimal evidence that adjusted ORs 
representing outcome-specific associations of CRP with depression and IHD differed from 
the adjusted OR representing a common effect of CRP on both outcomes (p-value for LRT 
<0.01 to 0.71), suggesting that CRP is not specifically associated with depression or IHD 
(Table 36).  
 
Table 36. Odds ratio (95% CI) for association between 1 SD increase in CRP 
concentration and depression/IHD outcomes (N = 92,658). 
Adjustment a 
Odds ratio (95% CI) for depression/IHD outcomes LRT comparing 
specific vs common 
effect (P-value)  
Specific effect on 
depression   
Specific effect on 
IHD 
Common effect on 
both outcomes 
Unadjusted 1.09 (1.08, 1.11) 1.12 (1.10, 1.28) 1.23 (1.16, 1.31) 0.04 
Adjusted 1 b 1.10 (1.09, 1.12) 1.10 (1.08, 1.12) 1.10 (1.09, 1.12) 0.71 
Adjusted 2 c 1.08 (1.06, 1.09) 1.06 (1.04, 1.08) 1.07 (1.06, 1.09) 0.22 
Adjusted 3 d 1.03 (1.01, 1.05) 0.98 (0.96, 1.01) 1.02 (1.00, 1.03) <0.01 
a CI: confidence interval; CRP: C-reactive protein; IHD: ischaemic heart disease; LRT: likelihood ratio test. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + BMI. 
 
 
I also revealed evidence that adjusted ORs representing outcome-specific associations of 
WCC with depression and IHD differed from the adjusted OR representing a common effect 
of WCC on both outcomes (p-value for LRT <0.001), suggesting that WCC is specifically 
associated with IHD (Table 37).  
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Table 37. Odds ratio (95% CI) for association between 1 SD increase in WCC and 
depression/IHD outcomes (N = 93,795). 
Adjustment a 
Odds ratio (95% CI) for depression/IHD outcomes LRT comparing 
specific vs common 
effect (P-value)  
Specific effect on 
depression   
Specific effect on 
IHD 
Common effect on 
both outcomes 
Unadjusted 1.08 (1.07, 1.10) 1.16 (1.14, 1.18) 1.11 (1.10, 1.12) <0.001 
Adjusted 1 b 1.08 (1.06, 1.09) 1.14 (1.12, 1.16) 1.10 (1.09, 1.11) <0.001 
Adjusted 2 c 1.04 (1.02, 1.05) 1.11 (1.09, 1.13) 1.07 (1.06, 1.08) <0.001 
Adjusted 3 d 1.02 (1.00, 1.03) 1.09 (1.07, 1.11) 1.05 (1.04, 1.06) <0.001 
a CI: confidence interval; IHD: ischaemic heart disease; LRT: likelihood ratio test; WCC: white blood cell count. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + BMI. 
 
6.5.4 Sensitivity analysis exploring potential influence of selection bias 
Results mimicking main analyses in the full UK Biobank sample were largely unchanged for 
both CRP concentration and WCC (Table 38). 
6.5.5 Sensitivity analysis using depression diagnosis as the outcome 
The effect sizes were slightly larger for both CRP concentration and WCC when depression 
diagnosis was used as the outcome (Table 39). 
6.5.6 Sensitivity analysis adjusting for additional potential confounders 
Adjustment for mood disorders, metabolic disorders, chronic inflammatory conditions, and 
acute infections did not dramatically alter the results for either CRP concentration or WCC 






Table 38. Sensitivity analysis exploring selection bias: Odds ratio (95% CI) for the association between 1 SD increase in CRP or WCC 







Exposure a Outcome  Sample size  
No. with outcome 
(%)  
Odds ratio (95% CI) for depression/IHD outcomes 
Unadjusted  Adjusted 1 b Adjusted 2 c  Adjusted 3 d 
CRP Depression 112,522 22,522 (20.0) 1.10 (1.09, 1.12) 1.11 (1.10, 1.13) 1.09 (1.07, 1.10) 1.03 (1.02, 1.05) 
 IHD 374,811 29,023 (7.7) 1.17 (1.16, 1.18) 1.12 (1.11, 1.14) 1.07 (1.06, 1.09) 0.99 (0.97, 1.00) 
 Comorbidity [ref: no illness] 67,579 1,491 (2.2) 1.35 (1.28, 1.42) 1.29 (1.22, 1.36) 1.20 (1.14, 1.27) 1.07 (1.01, 1.14) 
 Comorbidity [ref: single illness]   24,896 1,491 (6.0) 1.22 (1.15, 1.28) 1.20 (1.13, 1.26) 1.15 (1.09, 1.21) 1.08 (1.01, 1.14) 
WCC Depression 115,391 23,085 (20.0) 1.09 (1.07, 1.11) 1.08 (1.07, 1.10) 1.04 (1.02, 1.05) 1.02 (1.00, 1.03) 
 IHD 382,469 29,693 (7.8) 1.19 (1.18, 1.21) 1.15 (1.14, 1.16) 1.11 (1.10, 1.12) 1.09 (1.08, 1.10) 
 Comorbidity [ref: no illness] 69,298 1,537 (2.2) 1.18 (1.14, 1.23) 1.16 (1.11, 1.20) 1.11 (1.08, 1.15) 1.10 (1.06, 1.13) 
 Comorbidity [ref: single illness]   25,523 1,537 (6.0) 1.21 (1.15, 1.27) 1.18 (1.13, 1.24) 1.14 (1.09, 1.19) 1.11 (1.06, 1.17) 
a  CI: confidence interval; Comorbidity: presence of both lifetime depression and IHD; CRP: C-reactive protein; IHD: ischaemic heart disease; No illness: absence of both 
lifetime depression and IHD; Single illness: presence of either lifetime depression or IHD but not both; WCC: white blood cell count. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + BMI. 
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Table 39. Sensitivity analysis using ICD-10 depression diagnosis: Odds ratio (95% CI) for the association between 1 SD increase in 








Exposure a Outcome  Sample size  
No. with outcome 
(%)  
Odds ratio (95% CI) for depression/IHD outcomes 
Unadjusted  Adjusted 1 b Adjusted 2 c  Adjusted 3 d 
CRP Depression diagnosis 374,811 1,453 (0.4) 1.26 (1.20, 1.32) 1.24 (1.18, 1.30) 1.15 (1.10, 1.21) 1.12 (1.06, 1.19) 
 IHD 374,811 29,023 (7.7) 1.35 (1.31, 1.38) 1.23 (1.20, 1.27) 1.15 (1.12, 1.19) 0.96 (0.93, 1.00) 
 Comorbidity [ref: no illness] 344,633 149 (0.04) 1.48 (1.27, 1.72) 1.37 (1.18, 1.60) 1.26 (1.08, 1.48) 1.12 (0.94, 1.33) 
 Comorbidity [ref: single illness]   30,327 149 (0.5) 1.29 (1.10, 1.51) 1.18 (1.01, 1.38) 1.14 (0.97, 1.34) 1.09 (0.92, 1.30) 
WCC Depression diagnosis 382,469 1,477 (0.4) 1.05 (1.03, 1.08) 1.04 (1.02, 1.07) 1.02 (1.00, 1.04) 1.02 (1.00, 1.04) 
 IHD 382,469 29,693 (7.8) 1.18 (1.16, 1.19) 1.13 (1.12, 1.15) 1.11 (1.09, 1.12) 1.09 (1.07, 1.10) 
 Comorbidity [ref: no illness] 351,603 152 (0.04) 1.04 (1.01, 1.06) 1.04 (1.01, 1.07) 1.03 (1.00, 1.07) 1.03 (0.99, 1.08) 
 Comorbidity [ref: single illness]   31,018 152 (0.5) 1.09 (0.99, 1.19) 1.05 (0.92, 1.19) 1.00 (0.85, 1.18) 0.97 (0.82, 1.16) 
a  CI: confidence interval; Comorbidity: presence of both lifetime depression and IHD; CRP: C-reactive protein; IHD: ischaemic heart disease; No illness: absence of both 
lifetime depression and IHD; Single illness: presence of either lifetime depression or IHD but not both; WCC: white blood cell count. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + BMI. 
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Table 40. Sensitivity analysis adjusting for additional potential confounders.  
Exposure a Outcome  Sample size  
No. with outcome 
(%)  
Odds ratio (95% CI) for depression/IHD outcomes 
Unadjusted  Adjusted 1 b Adjusted 2 c  Adjusted 3 d 
CRP Depression 90,984 19,385 (21.3) 1.10 (1.09, 1.12) 1.12 (1.10, 1.13) 1.08 (1.07, 1.10) 1.08 (1.06, 1.10) 
 IHD 374,811 29,023 (7.7) 1.16 (1.15, 1.18) 1.12 (1.10, 1.13) 1.07 (1.06, 1.08) 1.06 (1.05, 1.07) 
 Comorbidity [ref: no illness] 67,579 1,491 (2.2) 1.34 (1.27, 1.41) 1.28 (1.22, 1.35) 1.20 (1.13, 1.26) 1.17 (1.11, 1.23) 
 Comorbidity [ref: single illness]   24,896 1,491 (0.6) 1.21 (1.15, 1.27) 1.19 (1.13, 1.26) 1.15 (1.09, 1.21) 1.13 (1.07, 1.19) 
WCC Depression 93,284 19,876 (21.3) 1.09 (1.07, 1.10) 1.08 (1.06, 1.10) 1.04 (1.02, 1.06) 1.03 (1.02, 1.05) 
 IHD 382,469 29,693 (7.8) 1.19 (1.18, 1.21) 1.15 (1.14, 1.16) 1.11 (1.10, 1.12) 1.10 (1.09, 1.11) 
 Comorbidity [ref: no illness] 69,298 1,537 (2.2) 1.18 (1.13, 1.22) 1.15 (1.11, 1.20) 1.11 (1.08, 1.15) 1.10 (1.07, 1.13) 
 Comorbidity [ref: single illness]   25,523 1,537 (0.6) 1.21 (1.15, 1.27) 1.18 (1.12, 1.24) 1.14 (1.08, 1.19) 1.13 (1.07, 1.18) 
a CI: confidence interval; Comorbidity: presence of both lifetime depression and IHD; CRP: C-reactive protein; IHD: ischaemic heart disease; Single illness: presence of 
either lifetime depression or IHD but not both; WCC: white blood cell count. 
b Adjusted for age, sex, ethnicity, deprivation (TDI).  
c Adjusted 1 + alcohol use, smoking, physical activity.  
d Adjusted 2 + mood disorders, metabolic disorders, chronic inflammatory conditions, acute infections. 
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6.6 Discussion  
 
In this large, population-based sample, I examined associations of protein and cellular 
measures of inflammation with comorbid depression and IHD, elucidating a number of key 
findings. First, both CRP and WCC are associated with comorbid depression and IHD, even 
after controlling for a number of potential confounders including BMI. These associations 
remain using either no illness or single illness as the reference category, which is consistent 
with hypotheses 1 to 4 (Section 6.3, Page 191). These associations also remain in sensitivity 
analyses, supporting the robustness of the findings. Second, concerning risk of single 
outcome, CRP is associated with depression while WCC is associated with IHD specifically. 
The specific association of WCC with IHD is replicated using bivariate probit regression. This 
suggests that while systemic inflammation is likely to be a shared mechanism for depression 
and IHD, the risk of individual outcomes could be underpinned by distinct inflammatory 
pathways. The findings regarding specificity of association support hypothesis 5 but 
contradict hypothesis 6 (Section 6.3, Page 191). Finally, these findings are not fully 
explained by selection bias or by adjustment for relevant mood, metabolic, and inflammatory 
conditions indicating that associations between inflammation, depression and IHD are likely 
to be robust within the UK Biobank sample.  
The results are consistent with systemic inflammation increasing the risk of comorbid 
depression and IHD. Animal models and epidemiological studies support the idea that 
systemic inflammation plays a role in the link between depression and CVD (464,465). The 
increased risk of this comorbidity appears to be similar whether compared to individuals with 
neither outcome or with depression/IHD only and without comorbidity. In addition, the risk of 
comorbid depression and IHD seems to be similarly increased whether CRP or WCC is the 
exposure. There is some evidence to suggest that comorbidity between depression and 
CVD arises largely from shared environmental factors (294). For example, chronic exposure 
to social stress can lead to dysregulation of the immune system (466). Physical activity, 
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another environmental factor, can exert cardioprotective and antidepressant effects (466). 
Conversely, genetic factors may partly explain why women are disproportionately affected by 
this comorbidity (467,468). Despite these potential sex differences, systemic inflammation 
appears to contribute to depression and IHD via endothelial dysfunction, oxidative damage, 
and altered serotonin metabolism in both women and men (63,469). Therefore, the 
association between systemic inflammation and comorbid depression and CVD appears to 
be robust. Taken together, this suggests that inflammation could particularly predispose to 
comorbidity of these disorders, therefore constituting a crucial link. Further research is 
required to understand the role of other inflammatory markers on comorbid depression and 
IHD.  
BMI may offer some explanation for how comorbidity can arise between depression and 
IHD. In my analysis adjusting for BMI attenuated, but did not fully explain, the associations of 
CRP/WCC with comorbid depression and IHD. It is possible that BMI acts as a (partial) 
mediator in the relationship between inflammation and subsequent comorbidity. For 
example, early-life factors such as childhood adversity, may programme immunometabolic 
pathways leading to inflammation and obesity which then contribute to risk of depression 
and IHD in adulthood. Previous studies report that childhood adversity is associated with 
increased circulating inflammatory markers (470) and BMI (471) as well as increased risk for 
adult depression (472) and cardiometabolic illness (473). Work from other members of my 
lab group who also used the ALSPAC birth cohort, suggests that increased BMI during 
puberty is associated with depression in early-adulthood, particularly in females (474). 
Childhood inflammation is also associated with adult psychiatric (168) and cardiometabolic 
risk (475,476). Studies are required to test whether inflammation mediates the effects of 
early-life factors operating during childhood and fetal development on the risk of adult 
psychiatric and cardiometabolic illness. 
I showed that different markers of systemic inflammation show distinct associations with 
depression and IHD. Associations of CRP with depression and IHD were similar until 
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adjustment for BMI, with BMI explaining the former to some extent and fully explaining the 
latter. This is consistent with a meta-analysis reporting that adjustment for BMI did not fully 
explain the association between CRP and depression (446). This result is also supported by 
other observational studies reporting that CRP is more strongly associated with depression 
than IHD (477,478). However, bivariate probit analysis indicated that CRP is not specifically 
associated with depression, suggesting a common effect of CRP on both depression and 
IHD. Genetic evidence for a causal relationship between CRP and depression is mixed and 
may be due to upstream activity in proteins such as IL-6 (294,449,479–481). Similarly, 
Mendelian randomisation studies have suggested that IL-6 is a causal determinant of IHD 
(206,450), but that this is not the case for CRP (294,450,451). Thus, IL-6 may be a key 
driver in the comorbidity between depression and IHD (294).  
Furthermore, I showed that associations of WCC with depression and IHD were also similar 
until adjustment for BMI. BMI fully explained the association between WCC and depression 
but only partly explained the association between WCC and IHD. Bivariate probit analysis 
indicated that WCC is specifically associated with IHD. WCC may contribute to IHD by 
playing a direct role in the destabilisation of atherosclerotic plaques (482,483). Relevant 
Mendelian randomisation studies of these factors are lacking. I did not find association 
between CRP and IHD, or WCC and depression. One possible explanation for this 
divergence is that BMI is strongly correlated with CRP. Mendelian randomisation provides 
evidence that BMI causally influences CRP but not the other way around (484). Adjusting for 
BMI may therefore represent overadjustment. However, BMI appears to attenuate the effect 
of CRP and WCC to a similar extent. BMI does not provide the full explanation for distinct 
association of CRP/WCC with depression and IHD. Therefore, it is possible that distinct 
inflammatory pathways underpin the risks for depression and IHD.  
6.6.1 Limitations   
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There are a number of limitations to this study. A key limitation is the cross-sectional study 
design, though the results lay the foundation for longitudinal approaches that would establish 
the temporality of association between inflammatory markers and outcomes. Furthermore, 
the depression outcome used in main analysis was derived from various self-reported 
information on past low mood and help seeking, and not ICD-10 diagnosis of depression, 
since it only captures the most extreme cases of depression from hospital linkage data. 
However, sensitivity analysis using ICD-10 depression diagnosis as the outcome showed 
comparable results. Another limitation is that reverse causality and residual confounding 
may still explain the associations between systemic inflammation and depression/IHD. 
Moreover, medication use may influence these relationships but I did not include it as a 
confounder due to a lack of access to relevant measures. Finally, I explored the influence of 
selection bias and found that it had little impact on the results, but non-White groups are 
underrepresented in the UK Biobank (485), limiting generalisability of the findings to the 
larger UK population. 
6.6.2 Conclusion  
To conclude, systemic inflammation could be a shared mechanism for depression and IHD, 
but the mechanistic basis of each outcome is likely to be underpinned by distinct 
inflammatory pathways. Further research is required to test causality, potential for targeting 
inflammation for treatment and prevention of these illnesses, and to elucidate possible 





SECTION E: CONCLUSION  


























7.1 Main Findings  
 
In this thesis, I have investigated the relationship between depression and CVD across the 
lifespan and the potential role of systemic inflammation in the pathogenesis of these 
conditions. The aims of this thesis were: (i) to determine the direction of association between 
CVD risk and depressive symptoms in young people; (ii) to test the convergence of evidence 
for systemic inflammation as a shared mechanism for depression and CVD across the 
lifespan; and (iii) to determine the influence that demographic factors have on associations 
between systemic inflammation, depression and CVD. 
Given that CVD and depression are bidirectionally associated in adults, I hypothesised that 
the same relationship would be present in younger age groups. This was not supported; the 
evidence supported only a unidirectional relationship between CVD risk and subsequent 
depressive symptoms in young people (Chapter 4, Page 110). Mid-adolescent CVD risk was 
associated with depressive symptoms in late-adolescence but childhood depressive 
symptoms were not associated with mid-adolescent CVD risk. Both the meta-analysis of 
longitudinal studies and ALSPAC analysis suggested that obesity and cigarette smoking 
contribute to this association (Chapter 3, Page 74; Chapter 4, Page 110). 
Regarding the second aim, I hypothesised that different markers of systemic inflammation 
would be similarly associated with depression and CVD across the lifespan. Results from 
ALSPAC and UK Biobank analysis indicated that different inflammatory markers may have 
distinct associations with these conditions. CRP was associated with outcomes in both 
adolescence and adulthood. Childhood IL-6 and CRP were both associated with adolescent 
CVD risk (Chapter 4, Page 110). CVD risk appeared to mediate the association between 
childhood IL-6/CRP and depressive symptoms in late-adolescence. Childhood infections 
were associated with depressive symptoms in late-adolescence but it was not possible to 
test association with CVD risk (Chapter 5, Page 144). In middle-aged and older adults, 
specific associations were present, particularly between WCC and IHD (Chapter 6, Page 
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187). Both CRP and WCC were associated with comorbid depression and IHD. BMI may 
play a role in these associations; see Section 7.3.2 (Page 225) for further discussion. 
Finally, I demonstrated evidence of sex differences in the association between systemic 
inflammation and depression/CVD outcomes across the lifespan. Female ALSPAC 
participants were more likely to have high levels of depressive symptoms and CVD risk than 
male participants (Chapter 4, Page 110). Similarly, women participating in the UK Biobank 
had higher CRP concentration than men (Chapter 6, Page 187). Associations between 
inflammation, CVD risk, and subsequent depressive symptoms may be particularly relevant 
in child/adolescent females. In addition, sex, ethnicity, and SEP had the greatest attenuating 
influence on associations in older adults, suggesting complex, age-dependent interactions of 
multiple environmental and genetic factors.  












Table 41. Summary of hypotheses tested in the analytic chapters. 
Chapter  Hypotheses Supported by findings? 
3 1. High BMI is associated with depression in young people.   Yes 
 2. Cigarette smoking is associated with depression in young people. Yes 
 3. High SBP is associated with depression in young people. -- 
 4. High total cholesterol is associated with depression in young people. -- 
 5. Low HDL is associated with depression in young people. -- 
 6. CVD risk factors are similarly associated with depression and depressive symptoms. Somewhat 
4 1. Depressive symptoms at age 12 years are associated with CVD risk at age 15 years. No 
 2. CVD risk at age 15 years is associated with depressive symptoms at age 18 years. Yes  
 3. IL-6 at age 9 years is associated with depressive symptoms at age 12 and 18 years. No 
 4. CRP at age 9 years is associated with depressive symptoms at age 12 and 18 years. No 
 5. IL-6 at age 9 years is associated with CVD risk at age 15 years. Yes 
 6. CRP at age 9 years is associated with CVD risk at age 15 years. Yes 
 7. CVD risk at age 15 years mediates the association between IL-6 at age 9 years and depressive symptoms at age 18 years. Yes 
 8. CVD risk at age 15 years mediates the association between CRP at age 9 years and depressive symptoms at age 18 years. Yes 
5 1. Childhood infections are associated with depressive symptoms from age 10 to 19 years.  No 
 2. Childhood infections are associated with PEs at age 12 and 18 years.  No 
 3. Childhood infection burden has a dose-response relationship with depressive symptoms from age 10 to 19 years. Somewhat 
 4. Childhood infection burden has a dose-response relationship with PEs at age 12 and 18 years. Somewhat 
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6 1. CRP is associated with comorbid depression and IHD. Yes 
 2. WCC is associated with comorbid depression and IHD. Yes 
 3. CRP is more strongly associated with comorbidity than monomorbid depression or IHD.  Yes 
 4. WCC is more strongly associated with comorbidity than monomorbid depression or IHD.  Yes 
 5. CRP shows no specificity of association with either depression or IHD. Yes 





7.2 Methodological Limitations 
The main findings should be considered in light of the limitations of the observational 
methodological approach. Key limitations include study design, selection bias, sample size, 
measurement bias, and residual confounding.  
7.2.1 Study design  
The results presented in this thesis are based on data from observational studies. I used 
both cohort and cross-sectional study designs depending on the availability of data. Both of 
these study designs have strengths and limitations which may affect the interpretation of the 
findings. The decision to use the ALSPAC and UK Biobank datasets also has an impact on 
the interpretation of the results. 
The studies selected for inclusion in the systematic review and meta-analysis were all 
longitudinal cohort studies. The studies using data from the ALSPAC cohort were also 
longitudinal by design. Longitudinal cohort studies can be used to determine the temporality 
of association between an exposure and outcome; however, this type of study is vulnerable 
to a range of issues including attrition (see below) and acquisition of data at multiple time 
points. Repeated measures allow potential changes in the temporal association between an 
exposure and outcome to be scrutinised, contributing to more robust conclusions.  
The UK Biobank study of systemic inflammation and comorbid depression and IHD is cross-
sectional by design. Although the results lay the foundation for longitudinal approaches that 
would establish the temporality of association between inflammatory markers and outcomes, 
the possibility of reverse causality is a major limitation in cross-sectional studies.  
In this thesis I aimed to cover associations between systemic inflammation, depression, and 
CVD across the lifespan. The study populations I used in analyses were young people in 
both the ALSPAC cohort and meta-analysis, and middle-aged and older adults in the UK 
Biobank study. I presented the definitions for these age groups in Section 2.3 (Page 63). The 
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decision to include these particular datasets led to two issues: (i) younger adults age 25 to 
39 years were not included in any analyses; and (ii) relevant measures and data collection 
methods differed between the two datasets. These issues were the result of a trade-off 
between using datasets with longer follow-up times and using good quality studies 
containing the appropriate exposure, outcome, and confounder measures. 
7.2.2 Selection bias  
Selection bias occurs when the study participants are not representative of the target 
population. Criteria for selecting the risk set from the study population can lead to differences 
in key variables between the included and excluded participants. Incomplete responses to 
surveys and missing data due to attrition are further sources of bias. In addition, study 
participants may be different to the individuals who did not take enrol in the study.  
The UK Biobank and ALSPAC cohort are primarily composed of White British individuals, 
which limits the generalisability of the results in this thesis to other parts of the population. 
Similarly, the majority of studies included in the systematic review and meta-analysis came 
from North America and Europe. Therefore, the results from these analyses may not be 
relevant to individuals from other ethnic groups or geographic locations. Moreover, the UK 
Biobank and ALSPAC slightly oversampled individuals from higher socioeconomic 
backgrounds, leading to further reduction in generalisability.  
The results in this thesis suggest that there may be sex differences in the associations 
between systemic inflammation, depression and CVD (risk). Sensitivity analyses revealed 
that sex explained the heterogeneity in some of the meta-analyses. Similarly, the association 
between CVD risk and subsequent depressive symptoms appeared to be stronger in 
females than in males. These potential sex differences must be interpreted with caution 
given the role of selection bias, particularly attrition, may play in these stratified analyses. 
For example, female participants in the ALSPAC cohort were more likely to complete all 
assessments than male participants. Therefore, the relatively smaller male sample size may 
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not have sufficient power to detect associations raising the possibility of spurious sex 
differences.  
Attrition was an issue in my longitudinal analyses, particularly where measures of exposure 
or outcome were required. For example, investigating associations of childhood infection 
with subsequent depressive symptoms and PEs across an 18 year period included 
measures of childhood infection at seven time points, depressive symptoms at six time 
points, and PEs at two time points. The individuals who completed all of these assessments 
were more likely to be female, of White ethnicity, and have a mother from the non-manual 
socioeconomic group, than those missed at least one assessment.   
Furthermore, missing data due to attrition prevented any investigation into the association 
between childhood infections and subsequent CVD risk in young people. This analysis could 
not be performed because the exposure, outcome, and confounders would have had to be 
imputed to achieve a sufficiently large sample size.  
7.2.3 Sample size  
Both too small and very large samples have limitations that can alter the interpretation of 
findings. A small sample size may hinder statistical interpretation and prevent the results 
from being extrapolated, whereas a very large sample size may emphasise small statistical 
differences that are not biologically or clinically relevant (486). The number of required cases 
increases as the difference to be identified decreases. Larger sample sizes increase the 
statistical power to detect these differences and reduce the likelihood of type I and type II 
errors. However, too large samples may be problematic since statistical tests were 
developed to interpret difference in samples rather than within whole populations.  
Several analyses were affected by small sample size. The number of studies in each of the 
meta-analyses in the systematic review was relatively small, restricting statistical precision. 
This was reflected by wide confidence intervals and reduced statistical power to exclude the 
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null hypothesis of no difference between groups (i.e. type II errors). There was also 
considerable heterogeneity between studies in the meta-analyses. In addition, relatively few 
participants had complete data to create the composite CVD risk score at age 15 years. 
Multiple imputation somewhat addressed the issue of missing data and helped to increase 
statistical power (Section 2.4.3, Page 68), but has its own problems. For example, multiple 
imputation is based on the assumption that data are missing at random and that the 
imputation model is appropriately specified (277). Moreover, small sample size and reduced 
statistical power was an issue in the analyses assessing relationship of infection and PE, 
resulting in wide confidence intervals. Attrition was an issue in analyses where depressive 
symptoms was an outcome. The number of completed mental health assessments 
decreased over time, leading to subsequently smaller sample size, which could result in 
underestimation of the true effect size.  
7.2.4 Measurement bias  
Measurement bias, also called misclassification or information bias, refers to the difference 
between the true and observed, measured value. This type of bias is potentially relevant to 
all of the analyses presented in this thesis.  
Underreporting by participants on specific measures may have led to measurement bias. For 
example, parents involved in the ALSPAC study were asked to retrospectively report 
childhood infections over a number of years. Some parents reported that their children never 
had any infections during childhood. This unlikely scenario could be the result of 
underreporting of childhood infections by parents. Parents may underreport for many 
reasons including a lack of understanding of infectious disease terminology, recall issues, 
fear of potential scrutiny, etc.  
Reliable and valid measurements are key to observational research and can influence the 
interpretation of results. Despite this, many of the measures used in analysis have not been 
221 
 
validated. Assessing the validity of measures for diagnosing conditions is not always 
possible or may have to be performed indirectly. The depression outcome I used in the UK 
Biobank analysis was derived from various self-reported information on past low mood and 
help seeking. Although this measure was not validated, I used this measure of depression 
rather than ICD-10 diagnosis, since the ICD-10 diagnosis measure only captures the most 
extreme cases of depression from clinical service linkage data. In contrast, the reliability of 
some ALSPAC measures has been performed. Within or between observer variation and 
random subject variation can limit the reliability of questionnaires and other measurements. 
For example, the semi-structured interview measuring PEs during childhood/adolescence in 
the ALSPAC cohort had good reliability at age 18 years but only fair reliability at age 12 
years. The test-retest reliability at age 12 years was limited, suggesting that participants may 
give different answers over time. Issues with reliability and validity may lead to 
misclassification of cases and subsequent alteration to the effect sizes.  
The way that variables are created can also introduce measurement bias. Dichotomisation of 
variables can lead to information losses and may also alter our understanding of how that 
particular variable affects other variables in analysis. For example, ethnicity was 
dichotomised in all ALSPAC and UK Biobank analyses due to low counts for groups other 
than White ethnicity. This decision meant it was not possible to investigate the role of 
ethnicity in associations beyond being a member of a minority ethnic group in the UK, which 
is not necessarily capturing the same information as an individual’s specific ethnicity that 
may encompass a multiplicity of relevant factors. In addition, the way the composite CVD 
risk score was created using ALSPAC cohort data may have introduced bias. First, the 
variables included in the CVD risk score were imputed. Imputation requires selection of 
auxiliary variables to support the prediction of missing data. Auxiliary variables therefore 
influence the final CVD risk score values. Second, the CVD risk score was a combination of 
binary and continuous variables which were designed to reflect measures created in i3C 
consortium datasets. Ideally, the measures would all be continuous although this was not 
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possible given the data available. Certain measures such as diet were not available and 
other measures may not have been the most suitable for the target population. For example, 
waist circumference may be a better measure of central adiposity in young people than BMI, 
but I used BMI to reflect the i3C consortium datasets. Performing the same analysis without 
including i3C consortium-based weights in the CVD risk score may have produced different 
results.  
Given the length of follow-up and volume of information collected from participants, human 
error during data collection in the ALSPAC and UK Biobank datasets is likely. Similarly, a 
number of steps in the systematic review and meta-analysis process were subject to human 
error, despite steps being taken to minimise this type of measurement bias. Study selection 
and data extraction is a long, manual process involving multiple individuals, meaning that 
errors in data collection are probable.   
7.2.5 Residual confounding  
Residual confounding refers to the bias by confounding that remains after controlling for 
potential confounders in analysis. While these factors can be balanced between comparison 
groups in randomised trials, they are endemic in research using observational designs. 
Residual confounding is difficult to measure or take into account in such studies so it is likely 
to affect all analyses presented in this thesis. 
There may be additional confounders that were not considered in analysis due to the lack of 
data collected on these factors. For example, in the systematic review and meta-analysis, 
the possibility of residual confounding by unidentified factors remains high. This is partly 
because the studies included in the meta-analysis controlled for various confounders but 
these varied considerably between studies, meaning that other factors may also explain 
associations between CVD risk factors and subsequent depression/depressive symptoms. 
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Residual confounding could also occur due to a lack of precise data on the confounding 
variables. In the UK Biobank study of associations between systemic inflammation and 
depression/IHD, many confounders were categorical variables with somewhat arbitrary 
groups. For example, the alcohol measure was categorised based on frequency of alcohol 
consumption per day/month but did not account for volume of alcohol consumed during this 
time. As such, this measure may fail to capture precise enough information about alcohol 
use to fully control for this variable in analysis.  
Finally, there may be measurement errors in the way that participants were classified with 
respect to potential confounders. Many of the variables used in ALSPAC and UK Biobank 
analyses were self-reported by participants. Participants may not give accurate answers for 
a number of reasons, but the result is the introduction of residual confounding. For example, 
in the ALSPAC study of association between childhood infections and subsequent 
depressive symptoms/PEs, many parents reported that their children experienced no 
childhood infections from age 1.5 to 7.5 years old. It is very unlikely that these children had 
no common infections during this time, however it is difficult to determine from this self-
reported measure what the “true” values should be. Linkage with primary and secondary 
care electronic health record data may be useful to address residual confounding arising due 
to this type of measurement bias. 
7.2.6 Personal time constraints  
Time constraints meant that the systematic review and meta-analysis could only focus on 
associations between selected CVD risk factors and depression in one direction. I decided to 
investigate the association of CVD risk factors with subsequent depression/depressive 
symptoms in young people because some systematic reviews of the reverse relationship 
(e.g. depression as the exposure and obesity as the outcome) already existed. 
Unfortunately, this exclusion criterion left an analytical gap in this thesis.   
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7.3 Future Directions 
The results presented in this thesis could lead to a variety of further research investigations. 
First, the findings require replication in other samples since the participants in the ALSPAC 
and UK Biobank samples are relatively homogenous. Second, there is some evidence that 
different inflammatory markers may exert their effect on mental and physical health 
conditions via distinct pathways. Further longitudinal studies and genetic analysis are 
needed to investigate potential mechanisms. Finally, a non-exhaustive list of specific 
research questions arising from the work in this thesis is given in the relevant subsection 
below. 
7.3.1 Replication of findings in other samples 
A number of results require replication in other samples with a different study design or 
larger sample size. For example, the results from the UK Biobank study require replication in 
a prospective sample. The study using UK Biobank data (Chapter 6) was cross-sectional by 
design and the extent to which systemic inflammation may predict comorbid depression and 
IHD (versus monomorbid illness) should be investigated in a longitudinal cohort and/or using 
genetic techniques such as Mendelian randomisation. A longitudinal study would allow 
direction of associations to be determined while reducing the risk of reverse causality. 
Moreover, the systematic review highlighted the lack of longitudinal studies investigating 
associations between CVD risk factors other than high BMI or smoking with subsequent 
depression in young people. Although I found no relationship between cholesterol, blood 
pressure, or triglycerides with depressive symptoms in the ALSPAC cohort, these results 
require replication in other larger samples to ensure the lack of association is not due to 
sample size issues. In addition, future work is required to replicate the observed associations 
between common childhood infections and depression outcomes in young people, given that 
this is another relatively understudied area of research.  
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Replication of findings is also required in more diverse study populations. Although the UK 
Biobank and ALSPAC contain relatively large study populations, there is little diversity in 
ethnic group or SEP measures in these datasets. As previously mentioned, selection bias  
means that the results presented in this thesis may not be generalisable to all ethnic groups 
(populations living in or outside the UK) or individuals of lower SEP. The reasons for low 
diversity in the UK Biobank and ALSPAC samples are likely to be multifaceted but continued 
effort is required to address such issues in future observational studies. Systemic 
inflammation, depression, and CVD may have distinct relationships depending on 
environmental factors related to ethnicity or SEP that cannot be adequately assessed in 
homogenous populations (487,488). As such, exploring the influence of related 
environmental factors may add a new layer of understanding (and complexity) to 
associations between systemic inflammation, depression, and CVD.  
More generally, greater effort is required to understand how to increase participation of 
under-represented groups in observational studies containing measures of systemic 
inflammation, depression and CVD. Study recruitment, attrition, help-seeking behaviour, and 
disease diagnoses may differ according to characteristics such as age, sex, ethnicity, and 
SEP. Despite this, much of our clinical understanding is not based on findings from 
heterogenous datasets. Continued work is needed to increase representation of historically 
under-represented groups such as women, non-binary genders, diverse ethnic groups, low 
SEP groups etc in observational studies. This is important because findings based on 
homogenous datasets are likely to be biased and, if extrapolated to unrepresented groups, 
may lead to adverse outcomes. Translating non-generalisable results into clinical practice 
may result in misinterpretation or misdiagnosis of symptoms in different populations and 
prescription of inappropriate treatment options.  
7.3.2 Investigating potential mechanisms and other inflammatory markers  
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In this thesis I have shown that various inflammatory markers (infections, WCC, IL-6, and 
CRP) are associated with depression and/or CVD across the lifespan, suggesting that 
systemic inflammation is a robust shared mechanism for these two conditions. There is 
some evidence that specific inflammatory markers have distinct associations with 
depression/CVD. Below, I discuss plausible mechanisms to explain the different effects of IL-
6, CRP, and WCC in the pathogenesis of these two conditions. Further work, using 
longitudinal studies and genetic analysis, is required to confirm the existence of these 
distinct mechanisms and to better understand the pathophysiological mechanisms 
underlying these relationships.  
The IL-6 trans-signalling pathway (Section 1.3.3, Page 41) has been directly implicated in 
the development of both depression (480) and CVD (206,207) (Figure 33). Much of the 
interaction between IL-6 and the brain occurs via trans-signalling (489). Increased trans-
signalling (as indicated by increased sIL-6R) appears to have a causal effect on depression 
(480), perhaps via its role in neuroinflammation (490) and sickness behaviour (491). 
Subtypes of depression may be specifically associated with increased IL-6 trans-signalling 
(492). Moreover, the IL-6 trans-signalling pathway appears to be causally related to CVD 
(206,207). Trans-signalling contributes to the pathogenesis of atherosclerosis by initiating 
recruitment and infiltration of immune cells (493,494), which may increase the risk of future 
cardiovascular events (495). High levels of soluble glycoprotein-130 may protect against 
CVD by inhibiting IL-6 trans-signalling (495). Thus, IL-6 may have a causal role in the 







Figure 33. Summary of IL-6 signalling pathways and depression/CVD outcomes. 
 
IL-6 activity may be key to understanding the distinct associations of CRP with depression 
and CVD. I have shown that CRP is specifically associated with elevated CVD risk in 
adolescents and depression in adults. CRP is unlikely to have a causal role in the 
pathogenesis of depression (294,449,480,481) or CVD (294,450,451) but the intrinsic link 
between IL-6 and CRP could explain the associations between CRP and CVD 
risk/depression. Although CRP is a marker of classic IL-6 signalling (480,495), it can 
promote shedding of sIL-6R by neutrophils, resulting in stimulation of resident tissue cells 
(139,496,497). Thus, is plausible that CRP amplifies IL-6 trans-signalling activity, thereby 
indirectly affecting the causal pathway between IL-6 and depression/CVD (Figure 34). The 
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precise role of CRP isoforms (Section 1.3.3, Page 41) in depression and CVD also remains 
unknown and requires investigation.  
 
Figure 34. Possible links between CRP, IL-6 signalling, and depression/CVD 
outcomes. 
 
Mechanisms regarding WCC and depression/CVD outcomes are less clear. I have 
demonstrated that WCC is specifically associated with IHD but not depression in adults. 
Elevated WCC may have a causal direct effect on CVD by contributing to atherosclerotic 
plaque development and destabilisation (482,483). Alternatively, WCC may be associated 
with but not causally related to CVD. As mentioned above, shedding of sIL-6R by neutrophils 
could play a role (139,496,497) since elevated IL-6 trans-signalling has been implicated in 
CVD (206,207). The lack of association between WCC and depression may simply indicate 
that total WCC as an inflammatory biomarker is too general. NLR (498) and platelet to 




The associations described above are likely to be heavily influenced by a variety of factors 
across the lifespan (see Section 1.4, Page 50 for discussion of social and demographic 
factors). In particular, I discovered that BMI is a particularly important confounder. I found no 
association between CRP and CVD in adults after controlling for BMI, perhaps due to 
overadjustment since BMI has a causal effect on CRP concentration (484). WCC was also 
no longer associated with depression after controlling for BMI. Indeed, unhealthy lifestyle 
factors such as high BMI and smoking have a strong contributing role to systemic 
inflammation in individuals with depression (500). Furthermore, high BMI reflects external 
eating habits and internal metabolic dysregulations, which are both potentially involved in 
depression (501) and CVD (502).  
Although I used a number of different inflammatory markers in this thesis, the role of other 
inflammatory markers in the development of depression and/or CVD also requires 
investigation. For example, GlycA is a relatively new nuclear magnetic resonance biomarker 
for systemic inflammation and CVD risk (503), and potentially also for depression (504). The 
GlycA test is a composite measure of changes in both the number and complexity of N-
glycan side chains attached to acute phase proteins such as CRP (505,506). Compared with 
high-sensitivity CRP, GlycA is more stable with considerably lower biological variability 
(506,507) and has comparable predictive value for future CVD-related events (503). 
Understanding the mechanisms through which different inflammatory markers exert their 
effect on the body may contribute to a better understanding of the biological underpinnings 
of depression, in particular. It may also support the development of novel biotherapeutics 
that can target depression and/or CVD.   
7.3.3 Specific questions arising from the work in this thesis 
The findings presented in this thesis raise an array of additional questions, which could form 
the basis of future research projects. Below is a selection of such questions: 
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1. What can be done to increase the number of studies focusing on young people in 
relation to systemic inflammation, depression, and CVD risk? 
2. Do e-cigarettes pose same risk as traditional cigarettes to development of subsequent 
depression and/or CVD? 
3. Is high BMI a risk factor for depression in all settings, including in different ethnic and 
socioeconomic groups? 
4. Is it possible to create clinically relevant CVD risk score for young people, which is 
comparable to the Framingham risk score in adults? 
5. What are the underlying mechanisms for observed sex differences in associations 
between systemic inflammation, depression and CVD?  
6. Why does the relationship between CVD risk and depression differ in young people and 
adults? 
7. Is CVD risk linearly associated with depression severity across the lifespan? 
8. How are CVD risk and depression trajectories related across the lifespan? 
9. What are the mechanisms underlying the distinct associations of specific markers of 
systemic inflammation with depression, CVD, and comorbidity? 
10. To what extent does IL-6 explain the distinct associations between CRP and WCC and 
depression/CVD outcomes?  
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7.4 Conclusion  
To conclude, I showed that there is evidence of an inflammatory component to both 
depression and CVD. This is evident in both young people and adults, suggesting that 
associations between systemic inflammation, depression, and CVD (risk) are robust across 
the lifespan.  
The prospective relationship between CVD risk and subsequent depression in young people 
differs to the bidirectional relationship present in adults. The bidirectional relationship 
between depression and CVD found in adults appears to take time to develop and may be 
influenced by other environmental and/or social factors. As such, finding from adult studies 
should not be extrapolated to young people. 
Systemic inflammation appears to play a role in the development of depression and CVD, 
and comorbidity between these conditions. However, specific inflammatory markers may 
increase risk of these outcomes through distinct mechanisms in adults and young people. 
Female sex, high BMI and smoking appear to play important roles in the associations 
between systemic inflammation, depression, and CVD across the lifespan. It may be 
important to target these higher risk groups for early-intervention or prevention strategies for 
depression and CVD in young people and subsequently across the lifespan. Moreover, 
greater understanding of the relationship between systemic inflammation, depression, and 
CVD is required in clinical and pharmaceutical context, as well as knowledge of key 
demographic influences. 
Taken together, these findings suggest new avenues for research and the prospect of new 
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